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The adrenal gland can be divided in the adrenal medulla (inner part of the adrenal gland) and the 
adrenal cortex (outer part of the adrenal gland)1. Pheochromocytomas (PCCs) are rare neuroendocrine 
tumors, derived from chromaffin cells of the adrenal medulla1 (Figure 1). The average annual 
incidence of PCCs in the United States is 1.35 per 100.000 adults per year2. The incidence in The 
Netherlands is not known. If these tumors are located outside the adrenal medulla, they are called 
paragangliomas (PGLs). PGLs can arise from either sympathetic paraganglia or parasympathetic 
paraganglia1. Sympathetic PGLs are mostly located in the thorax and abdomen and consist of 
chromaffin cells, whereas parasympathetic PGLs are located in the head and neck region (HNPGLs)1. 
Sympathetic PGLs and parasympathetic PGLs have the same embryological origin. Both derive 
from the neuronal plate which later develops into the neuronal crest3. Sympathetic PGL consist 
of chromaffin cells, whereas parasympathetic PGLs do not contain chromaffin (nonchromaffin 
cells). PCCs and PGLs both contain type 1 cells and type 2 cells. Type 1 cells have neurosecretory 
granules, with catecholamines that can be released upon stimulation. Sympathetic PGLs secrete 
catecholamines, whereas secretion of catecholamines has only been observed in 19-28% of 
parasympathetic PGLs4,5.
Figure 1. Schematic representation of the adrenal gland.
(color image see page 185)
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In the normal adrenal medulla, secretion of catecholamines is stimulated in response to stress, also 
called the ‘fight or flight’ response. The release of catecholamines ensures that heart rate, blood 
pressure and blood glucose levels are increased by acting on alpha (α1 and α2) - and beta (β1, β2 and 
β3) - adrenergic receptors6. In patients with PCCs, there is a non-physiological continuous leakage of 
metanephrines out of the tumor cells. Clinical presentation of PCCs/PGLs can vary greatly and can be 
very similar to signs and symptoms produced by other clinical conditions. PCCs are therefore often 
referred to as the great mimic7. Most of the clinical signs and symptoms are due to the direct actions 
of paroxysmal secretion of catecholamines. Signs and symptoms most often seen in these patients 
are palpitations, hypertension, headache, perspiration, pallor and feelings of panic or anxiety8,9. 
Metabolic effects include hyperglycemia, lactic acidosis and weight loss9. The high rate of diabetes 
mellitus in patients with PCCs/PGLs is caused by the β-adrenoreceptor-mediated gluconeogenesis 
and glycogenolysis by catecholamines and by their α-adrenoreceptor-mediated inhibitory effect 
on insulin secretion10. Massive release of catecholamines can be provoked by exercise, increased 
abdominal pressure, (intraoperative) manipulation of the tumor, ingestion of foods containing 
tyramine and certain drugs8. Patients with PCCs/PGLs have a higher rate of cardiovascular events 
than patients with essential hypertension11. The most likely explanation for the increased rate in 
cardiovascular events is the prolonged exposure to the effects of catecholamine secretion by the 
tumor11. Cardiovascular emergencies that can occur due to the massive release of catecholamines are 
sudden death, heart failure, due to cardiomyopathy, hypertensive encephalopathy, cerebrovascular 
accidents, or neurogenic pulmonary edema9. 
Genetic mutations and screening
PCCs can occur sporadically or as part of a hereditary tumor syndrome. Approximately 40% of patients 
with PCCs/PGLs carry a germline mutation in one of since this year 21 known genes37,38. Historically, 
PCCs/PGLs were know to be part of some hereditary tumor syndromes, such as multiple endocrine 
neoplasia type 2 (MEN type 2), van Hippel-Lindau (vHL) syndrome, and von Recklinghausen’s 
disease, with mutations in rearranged during transfection (RET), vHL and neurofibromatosis (NF) type 
1 gene, respectively39. Since 2000, additional genes have been discovered that are involved in the 
development of PCCs/PGLs, including mutations in the succinate dehydrogenase (SDH) subunit A 
(SDHA), subunit B (SDHB), subunit C (SDHC) or subunit D (SDHD) genes40, succinate dehydrogenase 
complex assembly factor 2 (SDHAF2)41, transmembrane protein 127 (TMEM127)42, Myc-associated factor 
X (MAX)43, Harvey rat sarcoma viral oncogene (H-RAS)44, Kirsten rat sarcoma viral oncogene (K-RAS)45, 
kinesin family member 1B transcript variant β (KIF1Bβ)46, isocitrate dehydrogenase 1 (IDH1)47, fumarate 
hydratase (FH)48,49, prolyl hydroxylase  type 1 (PHD1), PHD type 250, hypoxia-inducible factor (HIF)-2α51, 
and BRCA1-associated protein-1 (BAP1)52. In 2015, germline mutations in the malate dehydrogenase 
2 (MDH2)53 and somatic mutations in alpha thalassemia/mental retardation syndrome X-lined (ATRX) 
genes54 were identified in PCC/PGLs. All together, these mutations are associated with transcriptome 
changes that are subdivided into 2 main clusters. Cluster 1 contains tumors with mutations in the 
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vHL, components of the SDH complex (SDHA, SDHB, SDHC, SDHD) and its flavination factor (SDHAF2), 
HIF2α, FH, PHD1 and PHD2 genes, that are associated with impaired degradation and accumulation 
of HIF-1α/HIF-2α, which lead to changes in cell metabolism causing pseudohypoxia55. Cluster 2 
gene mutations include mutations in the RET, the NF1, TMEM127, MAX, and KIF1Bβ genes, and are 
connected by kinase signaling and protein translation pathway activation as well as combined HIF-
1α and HIF-2α signaling pathways55-57.
Diagnosis and biochemical analysis 
The biochemical diagnosis of a PCC/PGL is made by demonstrating an increased concentration of the 
metabolites of epinephrine, norepinephrine and dopamine, metanephrine (MN), normetanephrine 
(NMN) and 3-methoxytyramine (3-MT), in plasma or urine12 (Figure 2). Catecholamines methylated 
by the catechol-O-methyltransferase (COMT) can be measured as free metanephrines in plasma. 
In addition, catecholamines and metanephrines can be converted to sulfate conjugates by a 
sulfotranfersase isoenzyme (SULT1A3), located in the gastro-intestinal tract. This enzyme inactivates 
both endogenous and dietary-derived (exogenous) catecholamines. Free and deconjugated (sum 
of free and sulfate-conjugated) metanephrines can both be measured in urine and plasma. The 
deconjugated concentrations are commonly used for measurement of urinary metabolites13 (Figure 
2). Measurement of plasma free metanephrines is currently considered to be the most accurate 
method for diagnosing these tumors, with a sensitivity of 98.6% and a specificity of 89.3%12,14,15. It 
should be realized, however, that plasma metanephrines can be affected by several pre-analytical 
and analytical factors such as position8, age16, coffee17,18, diet19, salt intake20, certain drugs (e.g. 
mesalamine, sulfasalazine, and tricyclic antidepressants, depending on the analytical method 
used)15,21,22, and even the season of the year23. Among all these factors, posture during blood 
sampling and diet are the most important once. Plasma NMN and MN concentrations in samples 
collected in seated position are 30% and 27% higher, respectively, compared to samples drawn after 
30 minutes of supine rest8. A catecholamine rich diet had substantial effects (up to 3-fold increase) 
on plasma and urine free and deconjugated 3-MT concentrations and (up to 2-fold increases) on 
deconjugated NMN concentrations in plasma and urine13. Therefore, the United States Endocrine 
Society recommends overnight fasting when measurements include 3-MT and supine rest for 20-30 
minutes before blood sampling15. 
Metanephrines can be measured by liquid chromatography with electrochemical or fluorometric 
detection (LC-ECD), liquid chromatography with tandem mass spectrometry (LC-MS/MS), or 
immunoassay methods. Results from comparison studies suggest the use of LC-MS/MS or LC-ECD 
rather than other laboratory methods to measure metanephrines and establish a biochemical 
diagnosis of PCCs/PGLs12,15,24.
When the diagnosis of a PCC has been suggested by elevated metanephrines in plasma/urine, 
anatomical (CT, MRI) and functional (123I-metaiodobenzylguanidine (MIBG), positron emission 
tomography (PET)) imaging studies are performed to localize the tumor25. Lesions detected by 
13
Introduction  and aims of the thesis
1
anatomical imaging can be visualized by functional imaging techniques using specific tracers 
that target catecholamine synthesis, storage and secretion pathways of chromaffin cells. Several 
tracer are currently available such as 123I-metaiodobenzylguanidine (MIBG), [111In]-Pentetreotide, 
6-18F-fluorodopamine (FDA), 2-[18F]fluoro-2-deoxy-D-glucose (FDG), and 18F-dihydroxyphenylalanine 
(DOPA)25-27. MIBG is structurally similar to norepinephrine, and has the same transport pathway 
as norepinephrine via the cell membrane norepinephrine transporter (NET)28. MIBG is stored in 
the neurosecretory granules via the vesicular monoamine transporters 1 and 2 (VMAT 1 and 2). 
[111In]-Pentetreotide specifically binds to the somatostatin receptors (SSTR) expressed on cell 
membranes, especially subtypes 2 and 5. SSTR are expressed on many cells of neuroendocrine 
origin, and therefore in tumors derived from these cell types28. 18F-FDA is a substrate for the 
dopamine transporter (DAT) and NET. Thereafter, 18F-FDA is stored in the cytoplasmatic secretory 
vesicles through the VMAT system29. Its sensitivity is higher than that of MIBG in detecting both 
Figure 2. Schematic representation of catecholamine synthesis and metabolism pathway inside the 
adrenal gland. Dopamine, norepinephrine and epinephrine are synthesized inside the adrenal medulla. 
Dihydroxyphenylalanine (DOPA) is converted to dopamine by the aromatic L-amino acid decarboxylase (AADC: 
EC 4.1.1.28) enzyme. Dopamine is converted by the dopamine beta hydroxylase (DBH: EC1.14.17.1) enzyme to 
norepinephrine, which is finally converted to epinephrine by the phenylethanolamine-N-methyltransferase 
(PNMT) enzyme. PNMT is stimulated by cortisol from the adrenal cortex. The catecholamines are metabolized 
by the catechol-O-methyltransferase (COMT: EC 2.1.1.6) enzyme and can be measured as 3-methoxytyramine 
(3-MT), normetanephrine (NMN) and metanephrine (MN) in plasma. The metanephrines are sulfated by the 
sulfotransferase isoenzyme 1A3 (SULT1A3: EC 2.8.2.1) enzyme. The sulfated (conjugated) metanephrines and 
the free (unconjugated) metanephrines are measured in urine. PAH: phenylalanine hydroxylase (EC 1.14.16.1); 
TH: tyrosine hydroxylase (EC 1.14.16.2).
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primary and metastatic PGLs, however, reported data regarding its usefulness in patients with a 
germline mutation in one of the SDHx  genes are very limited30,31. 18F-FDG is taken up via the glucose 
membrane transporter (GLUT). Inactivation of vHL and SDHx genes upregulate HIF-α and specific 
downstream target genes including GLUT resulting in increased 18F-FDG uptake in PCC/PGLs. 
18F-FDOPA enters the chromaffin cells via the L-type amino acid transporter (LAT) system and was 
considered the most sensitive overall imaging modality for PCCs/PGLs, especially in the detection of 
HNPGLs tumors (>90% sensitivity)32,33,34. Recently, PET/CT using [68Ga]-labeled somatostatin analogs 
such as DOTA-TATE was shown to have a lesion based detection rate of 98.6% (Confident Interval 
(CI) 96.5-99.5%) in patients with malignant PCCs/PGLs and a SDHB mutation35. The optimal imaging 
algorithm in metastatic PCCs/PGLs is widely dependent on genetic status (Table 1)28,36.
In clinical practice, mutations in the SDHx genes are most often seen in PCC/PGL patients. The 
penetrance of PCCs/PGLs in SDHB mutation carriers ranges from 8-55% at the age of 4058-61. This wide 
range can be explained by the inclusion or exclusion of index patients, or by variation in genotypes. 
In addition to PCCs/PGLs, mutations coding for SDHx genes have been identified in Carney-Stratakis 
syndrome (a combination of PGLs, gastrointestinal stromal tumors (GISTs)), in Cowden syndrome 
(consists of benign and malignant breast, follicular thyroid and endometrial cancer in addition to 
cutaneous findings and macrocephaly), in renal and papillary thyroid cell carcinoma, and pituitary 
adenoma62-65. A SDHB mutation is an independent risk factor for the development of a malignant 
PGLs. Malignancy is defined as local invasion or the presence of metastases of chromaffin tissue at 
sites where no chromaffin tissue is expected9. In general, the risk of malignancy is higher in tumors 
with a diameter larger than 5 cm and an extra-adrenal location compared to smaller, intra-adrenal 
tumors66-68. 
Guidelines for the follow-up germline mutation carriers with a MEN2a, vHL and SDHx mutation 
include annual screening for PCCs/PGL. This includes annual measurement of blood pressure, 
biochemical testing (plasma and/or urine metanephrine levels). For SDHB/SDHC mutation carriers 
and paternally inherited SDHD/SDHAF2 mutation carriers, the Dutch national guideline advices to 
complement biochemical screening with MRI scans of the head/neck (every 3 years) and thorax/
abdominal region (every 2 years) starting from the age of 1869. Some international studies advocate 
the use of 18F-DOPA PET in the screening of SDHx mutation carriers59,70. Especially the detection of 
HNPGLs could be improved by screening with 18F-DOPA PET32,33.  
Treatment and follow-up
Resection of PCCs through adrenalectomy is necessary to prevent complications and morbidity 
associated with catecholamine excess. Perioperative pharmacological blockade of α- and 
β-adrenergic receptors is recommended for prevention of a PCC crises due to massive release of 
catecholamines. This can result in severe cardiovascular complications such as a hypertensive crisis, 
cardiac arrhythmia, respiratory edema, and ischemic heart disease6. During surgery, several stimuli 
can provoke the uncontrolled release of catecholamines by a PCC, like intubation, administration of 
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anaesthetic agents, pneumoperitonea and manipulation of the tumor. 
In addition to total adrenalectomy, adrenal-sparing surgery can be an option in patients with a 
high risk for the development of bilateral PCCs, such as patients with MEN type 2. After total bilateral 
adrenalectomy, patients lifelong depend on steroids and can develop Addison crises in stressful 
events. Approximately 60% of patients with bilateral PCCs who underwent adrenal-sparing surgery 
did not become steroid dependent. PCCs reoccurred in 3% of the operated glands after adrenal-
sparing surgery after 6-13 years follow-up, compared to 2% glands operated by adrenalectomy71. 
The long-term survival of patients after surgery for PCCs is very good. After tumor removal, rates of 
cardiovascular morbidity drop to the general population risk and life expectancy is not reduced in 
long-term follow-up studies67,72-74. Biochemical evaluation should be done postoperatively in order 
to check for recurrent disease, one month after surgery and annually up to 5 years after operation67,75. 
On long-term follow-up, about 17% of tumors recur within 10 years postoperatively, but even after 
15 years tumor recurrences have been described76. Follow-up consists of physical examination and 
measurement of metanephrines in plasma and/or urine in patients identified with mutations of 
disease causing genes. There is currently no method to predict potential malignant recurrence.
AIM OF THE THESIS
The aim of this thesis is to address different strategies in the biochemical diagnosis of PCC. In part 
1 the clinical evaluation and optimalization of current diagnostics for PCC/PGLs is discussed. Part 2 
focuses on new tools in PCCs/PGL research with a focus on dopamine.
OUTLINE OF THE THESIS
Part 1  Clinical evaluation and optimalization of current diagnostics for PCCs/PGLs
Pre-analytical factors can influence the MN and NMN concentrations in plasma. As stated above, 
follow-up of patients after surgical resection of a PCC/PGL is recommended, because of the risk 
for recurrence of the tumor. Plasma and/or urinary metanephrines of patients after adrenalectomy 
are normally interpreted using reference intervals obtained in healthy subjects with two adrenal 
glands. However, unilateral or bilateral adrenalectomy is expected to be followed by a decrease 
of epinephrine and, consequently, lower plasma and urinary MN concentrations. In chapter 
2 we describe the retrospective results of a cohort of 108 patients who underwent unilateral 
adrenalectomy and 24 patients who underwent bilateral adrenalectomy because of a PCC, to obtain 
an estimate of the reference intervals for patients with one or no adrenal glands. 
Next to adrenalectomy, retrospective studies suggest that plasma metanephrine concentrations 
could be influenced by medication-related interferences, because medication can interfere with 
the release, reuptake or metabolization of catecholamines. This is known from sympathomimetic 
agents, that increase the release and inhibit the reuptake of catecholamines, but the effect of anti-
hypertensive medication on plasma metanephrine levels has not been studied yet. This is of clinical 
importance because patients suspicious for PCCs/PGLs often use antihypertensive medication, due 
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to (paroxysmal) hypertension which is seen in a majority of patients with a PCC/PGL. In chapter 3 
we prospectively studied the effects of antihypertensive agents on the free plasma MN and NMN 
concentrations in a cohort of 39 patients with newly diagnosed hypertension.
Germline mutations occur in up to 30-40% of patients with PCCs/PGLs, with mutations in the 
SDHB and SDHD genes being the most common. Blood samples are favored for obtaining high 
quality DNA, however leucocytes can also be obtained by collecting saliva. The aim of the study in 
chapter 4 was to determine whether SDHB and SDHD gene mutations in patients with PCCs/PGLs 
could be determined using a salivary sample. Paired blood and salivary samples were collected from 
30 patients: nine with a SDHB mutation, 13 with a SDHD mutation, and eight without any SDHx 
mutations.
Chapter 5 gives an example of the wide variety of symptoms caused by catecholamines that 
can be encountered in patients with PCCs/PGLs. We describe a patient with an intestinal pseudo-
obstruction due to extensive secretion of catecholamines by a malignant PGL. Intestinal pseudo-
obstruction is a rare and poorly recognized complication of catecholamine secretion, and is directly 
related to the inhibition of acetylcholine release from the parasympathetic nervous system and 
activation of α1-, α2-, β2- adrenergic receptors of the intestinal smooth muscle cells. We performed a 
comprehensive literature search for other cases of intestinal pseudo-obstruction caused by either 
benign or malignant PCCs/PGLs.
In addition to determination in plasma and urine, measurement of MN, NMN and 3-MT in 
saliva could be of diagnostic value in patients with PCCs. We conducted a pilot study in 11 healthy 
subjects in order to compare the concentration of metanephrines in saliva with the simultaneously 
measured concentrations in plasma. Furthermore, we studied the possible influence of pre-
analytical conditions such as the use of a collection device, awakening, position, and eating on the 
salivary metanephrine levels. The results of this study are described in chapter 6. 
Part 2  New tools in PCC/PGL research with a focus on dopamine
In chapter 7 we describe the role of dopamine in angiogenesis and hypoxic conditions in normal 
tissues physiology as well as its potential contributory role in oncogenesis. In particular, we explore 
the counterintuitive relationship between dopamine production by PCCs and malignant tumor 
behavior. Dopamine functions both as a hormone and neurotransmitter. As a hormone, it plays a role 
in normoxic and hypoxic conditions. In vitro and in vivo studies have shown that dopamine impairs 
angiogenesis by inhibiting the activation of vascular endothelial factor (VEGF) 2–receptors. This 
underexposed feature of dopamine is especially intriguing in PCCs/PGLs. PCCs/PGLs are (pseudo-) 
hypoxia sensitive tumors involved in catecholamine secretion. Mutations in oxygen concentration 
regulating genes such as SDHx, hypoxia inducible factor 2 (HIF2) alpha and prolyl hydroxylase domain 
(PHD) genes increases the risk of the development of these tumors. The dopamine production in 
these specific tumors is considered an independent risk factor for malignancy in malignant PCCs 
which is seemingly in contrast to the tumor inhibiting effect of dopamine. 
18
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The 18F-DOPA PET scan is a highly sensitive functional imaging modality for the detection 
of HNPGLs. These observations strongly indicate that HNPGLs have the capacity for L-3,4-
dihydroxyphenylalanine (L-DOPA) uptake and conversion towards dopamine. In chapter 8 
we examine the presence of catecholamine-synthesizing enzymes in 19 HNPGL tissues by 
immunohistochemical staining for tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase 
(AADC) and dopamine β-hydroxylase (DBH). 
In contrast to PCCs, catecholamine excess is rarely demonstrated in patients with HNPGLs. 
Therefore, we conducted a study to document the prevalence of catecholamine excess with 
emphasis on elevated dopamine secretion in relation to clinical signs and symptoms in 36 
consecutive patients with HNPGLs. We evaluated the dopamine excess, measured as elevated 3-MT 
and/or dopamine concentrations in urine or plasma in chapter 9. 
We showed that dopamine plasma and/or urine concentrations are elevated in patients with 
HNGPLs and it is known that free dopamine is incorporated in the dense granules of circulating 
platelets, we aimed in chapter 10 to assess the dopamine concentration in blood platelets in 36 
patients with a HNPGL and in a healthy control group with 68 subjects for the dopamine in platelets 
and 120 subjects for the plasma metanephrines. We compared the dopamine in blood platelet 
concentration with the plasma 3-MT concentration. 
Chapter 11 provides a summary of the main findings in this thesis and addresses future 
perspectives. In chapter 12 a summary of this thesis in Dutch is given.
19
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Context: Follow-up after adrenalectomy for pheochromocytoma is recommended because of a 
recurrence risk. During follow-up, plasma and/or urinary metanephrine (MN) and normetanephrine 
(NMN) are interpreted using reference ranges obtained in healthy subjects.
Objective: Because adrenalectomy may decrease epinephrine production, we compared MN and 
NMN concentrations in patients after adrenalectomy to concentrations in a healthy reference 
population.
Design: A single-center cohort study was performed in pheochromocytoma patients after 
adrenalectomy between 1980 and 2011. 
Subjects: Seventy patients after unilateral and 24 after bilateral adrenalectomy were included. 
Main outcome measures:  Plasma-free and urinary-deconjugated MN and NMN determined at 3 
to 6 months and annually until 5 years after adrenalectomy, were compared to concentrations in a 
reference population. Data are presented in median [interquartile range].
Results: Urinary and plasma MN concentrations 3 to 6 months after unilateral adrenalectomy were 
lower compared to the reference population (39 [31-53] µmol/mol creatinine and 0.14 [0.09-0.18] 
nmol/L vs. 61 [49-74] µmol/mol creatinine and 0.18 [0.13-0.23] nmol/L respectively, both P<.05). 
Urinary MN after bilateral adrenalectomy was reduced even further (7 [1-22] µmol/mol creatinine; 
P<.05). Urinary and plasma NMN were higher after unilateral adrenalectomy (151 [117-189] µmol/
mol creatinine and 0.78 [0.59-1.00] nmol/L vs. 114 [98-176] µmol/mol creatinine and 0.53 [0.41-0.70] 
nmol/l; both P<.05). Urinary NMN after bilateral adrenalectomy was higher (177 [106-238] µmol/
mol creatinine; P<.05). Changes in urinary and plasma metanephrines persisted during follow-up.
Conclusion: Concentrations of MN are decreased, whereas NMN concentrations are increased after 
unilateral and bilateral adrenalectomy. Adjusted reference values for MN and NMN are needed in 





Pheochromocytomas are rare catecholamine-producing tumors, derived from adrenal chromaffin 
tissue1. Pheochromocytomas occur sporadically or as part of several hereditary tumor syndromes, 
such as multiple endocrine neoplasia (MEN) type 2, von Hippel-Lindau syndrome, neurofibromatosis 
type 1 and in the context of succinate dehydrogenase (SDH) mutations2. In pheochromocytoma 
patients, the demonstration of excessive production of catecholamines and their 3-O-methylated 
metabolites, metanephrine (MN) and normetanephrine (NMN), constitutes the cornerstone of 
biochemical diagnosis3-5. In healthy individuals, the adrenal medulla together with the sympathetic 
nervous system represent the main sources of catecholamine production and metabolism6 (Figure 1). 
Cortisol from the adrenal cortex enhances the activity of phenylethanolamine-N-methyltransferase 
(PNMT: EC 2.1.1.28)7,8. Because the enzymatic conversion of norepinephrine to epinephrine by PNMT 
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Figure 1. Schematic representation of catecholamine synthesis and metabolism pathway inside the adrenal 
gland. 
Dopamine, norepinephrine and epinephrine are synthesized inside the adrenal medulla. Dihydroxyphenylalanine 
(DOPA) is converted to dopamine by the aromatic L-amino acid decarboxylase (AADC: EC 4.1.1.28) enzyme. 
Dopamine is converted by the dopamineβ-hydroxylase (DBH: EC1.14.17.1) enzyme to norepinephrine, 
which is finally converted to epinephrine by the phenylethanolamine-N-methyltransferase (PNMT) enzyme. 
PNMT is stimulated by cortisol from the adrenal cortex. The catecholamines are metabolized by the 
catechol-O-methyltransferase (COMT: EC 2.1.1.6) enzyme and can be measured as 3-methoxytyramine (3-
MT), normetanephrine (NMN) and metanephrine (MN) in plasma. The metanephrines are sulfated by the 
sulfotransferase isoenzyme 1A3 (SULT1A3: EC 2.8.2.1) enzyme. The sulfated (conjugated) metanephrines and 
the free (unconjugated) metanephrines are measured in urine. Abbreviations: PAH,  phenylalanine hydroxylase 
(EC 1.14.16.1); TH, tyrosine hydroxylase (EC 1.14.16.2).
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is cortisol-dependent, the adrenal medulla is main source of MN measured in urine and/or plasma6,9. 
 Resection of a pheochromocytoma through adrenalectomy is indicated to prevent potentially 
fatal complications due to catecholamine excess10,11. Postoperatively, periodic measurement 
of plasma and/or urinary MN and NMN is performed in order to monitor for recurrent disease. 
Follow-up is recommended 2 to 3 months postoperatively, annually during the first 5 years, and 
once every 2 years thereafter12. During long-term follow-up, 6-16% of tumors recur within 10 years 
postoperatively, but tumor recurrences have been described even after 15 years13-15. Follow-up is 
especially important for patients with hereditary tumor syndromes, as these individuals have an 
increased risk for developing a pheochromocytoma in the contralateral adrenal gland13,14. 
In routine clinical practice, the concentrations of urinary and/or plasma MN and NMN found 
in patients after adrenalectomy are interpreted by using reference intervals established in healthy 
subjects. However, unilateral or bilateral adrenalectomy is expected to be followed by a decrease 
of epinephrine and, consequently, lower plasma and urinary MN concentrations. Use of incorrect 
reference intervals may interfere with early detection of tumor recurrence, e.g. when the associated 
rise in MN concentration occurs within the reference range applicable to healthy individuals with 
normally functioning adrenal glands. Currently, there is no detailed information on the influence of 
adrenalectomy on epinephrine and norepinephrine concentrations.
Therefore, the aim of this cohort study was to compare the urinary and plasma MN and 
NMN concentrations in patients who underwent unilateral or bilateral adrenalectomy for a 
pheochromocytoma with those determined in a healthy reference population. 
MATERIALS AND METHODS  
Study population
We retrospectively studied patients above 20 years of age at the time of diagnosis who had 
undergone either bilateral or unilateral adrenalectomy for pheochromocytoma at the University 
Medical Center of Groningen between January 1980 and August 2011. This period was chosen 
because assays of fractionated total metanephrines in urine with gas chromatography-mass 
spectrometry and plasma fractionated free metanephrines with liquid chromatography tandem 
mass spectrometry (LC-MS/MS) have been available at our institution since 1979 and 2005, 
respectively. The diagnosis of a pheochromocytoma was histologically confirmed in all patients. 
Postoperative concentrations of metanephrines had to be available for at least one follow-up visit 
after adrenalectomy. Exclusion criteria were a recurrent tumor within five years of surgery, a partial 
(i.e. cortical-sparing) adrenalectomy and incomplete resection of the tumor. Patients who presented 
with a concurrent extra-adrenal paraganglioma were also excluded. Preferably, tumor recurrence 
had to be confirmed by histology. In cases lacking this information, a diagnosis of tumor recurrence 
was based on the combined results of anatomical and functional imaging. 
The initial clinical diagnosis of a pheochromocytoma was based on elevated urinary and/




of both adrenal glands (computed tomography (CT)/ magnetic resonance imaging (MRI)) as well 
as whole body functional imaging with ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy or 
18F-dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) (available at our institution 
since 2003). Long-term follow-up was performed by measurement of urinary and/or plasma 
metanephrines. Anatomical and/or functional imaging was repeated in patients with persistently 
elevated metanephrines, in order to localize recurrent disease. In accordance with international 
guidelines, patients below 50 years of age were tested for germline mutations16-19. In patients above 
50 years of age, the family history was checked to evaluate the risk for hereditary syndromes.
For all patients, the following data were retrieved from their medical files: symptoms (headache, 
abdominal complaints, palpitations, paleness, flushes, vertigo, nausea and anxiety), signs related to 
a pheochromocytoma (blood pressure (BP) and pulse rate) at presentation, pre- and postoperative 
use of medication, and  results of germline mutation analysis. Hypertension was defined as a systolic 
BP of ≥ 140 mmHg and/or a diastolic BP of ≥ 90 mmHg or the use of antihypertensive medication. 
Additionally, we evaluated surgical and pathology reports of all the patients included in the study to 
confirm complete resection of the adrenal medulla. Because of the retrospective nature of this study 
and the use of clinical data, no further Institutional Review Board approval was required, according 
to the Dutch Medical Research Involving Human Subjects act. 
The concentrations of urinary and/or plasma MN and NMN were collected pre- and 
postoperatively, at 3 to 6 months and annually up to five years. The main outcome measure was 
the concentration of urinary or plasma MN and NMN concentration at 3 to 6 months after unilateral 
or bilateral adrenalectomy. Blood samples were collected by venipuncture, with patients in seated 
position, in 10-mL Vacutainer Tubes (Becton Dickinson) containing K2EDTA solution as anticoagulant. 
Reference values for deconjugated urinary MN and NMN concentrations were established in a 
group of 60 healthy subjects (30 men, 30 women, range 20-70 years of age), as reported previously 
by Willemsen et al.20. Reference values for plasma free MN and NMN concentrations were determined 
in a group of 120 healthy subjects (63 men, 57 women, range 36-81 years of age) participating 
in the Prevention of Renal and Vascular End Stage Disease (PREVEND) study21,22. Healthy subjects 
taking antihypertensive medication were not included. Measurement of plasma and urinary 
metanephrine concentrations in both healthy subjects and patients was performed without prior 
dietary restrictions.
Analytical Methods
Isotope-dilution mass spectrometry-based measurements of urinary and/or plasma metanephrines 
were used. Urinary deconjugated metanephrine concentrations were determined by isotope-
diluting gas chromatography-mass spectrometry, as described by Muskiet et al.23,24. Urinary 
deconjugated metanephrine concentrations were normalized to the urinary excretion of creatinine, 
measured using a picric acid-based method (before 2005) or an enzymatic method (Roche 
Diagnostics, Almere, the Netherlands) (after 2005), and expressed in units of µmol/mol creatinine. 
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The intra-assay variation coefficient was 1.7-4.2% and the inter-assay variation coefficient was 
3.3-15.4%. Reference intervals for urinary metanephrines were as follows: MN 33-99 µmol/mol 
creatinine, NMN 64-260 µmol/mol creatinine.
Plasma free metanephrine assays were performed with a HPLC tandem mass spectrometric 
technique (LC-MS/MS) with automated solid phase extraction sample preparation, as described by 
de Jong et al.22. Established reference intervals for plasma free metanephrines were: MN 0.07-0.33 
nmol/L, NMN 0.23-1.07 nmol/L. The intra-assay and inter-assay variation coefficients were 2.5-4.8% 
and 3.4-5.6% for the free plasma MN measurement, and 5.1-6.2% and 4.2-7.1% for the free plasma 
NMN measurements.
Statistics
Data are presented as mean (+ standard deviation (SD)) or as median [interquartile ranges (IQR)] 
where appropriate. Differences between urinary metanephrines in healthy subjects and patients 
after unilateral or bilateral adrenalectomy were evaluated using the Mann–Whitney U  test with 
Bonferroni correction. A Mann–Whitney U  test was performed to calculate the differences 
between the reference population and patients after unilateral adrenalectomy for the plasma 
metanephrines. Baseline was defined as 3 to 6 months after adrenalectomy. For each individual, a 
Spearman correlation coefficient was calculated regarding the relationship of the respective plasma 
and urinary metanephrines concentrations with follow-up time (i.e. baseline and the various follow-
up time points). Subsequently, averaged correlation coefficients were calculated after Fisher’s 
Z-transformation using the correlation coefficients per patient. We also calculated the percentage 
changes in plasma and urinary metanephrines at the various follow-up moments compared to 
baseline. A two sided P-value of P<.05 was considered statistically significant. Statistical analyses 
were performed with PASW statistics (version 18.0; IBM/SPSS, Armonk, New York).
RESULTS
Patient characteristics
Between January 1980 and August 2011, 108 pheochromocytoma patients underwent a unilateral 
or bilateral adrenalectomy at our institution. Of these, 14 patients (13.0%) were excluded. Reasons 
for exclusion were missing laboratory data (n=4), subtotal adrenalectomy (n=1) and recurrent 
disease (n=9) within five years after adrenalectomy. Table 1 shows the preoperative characteristics 
of all patients included in the study. In two patients (2.1%) with a sporadic pheochromocytoma no 
functional imaging was performed.
Seventy patients (74.5%) underwent a unilateral adrenalectomy. Median follow-up time for 
these patients was 39.2 [14.9-86.2] months. During follow-up, 4 patients (5.7%) died (cardiovascular 
disease n=1; malignancy n=2; unknown cause n=1) after a median follow-up of 17.0 [3.9-30.5] 
months. Twelve patients (17.1%) were referred to other centers for continuation of follow-up after a 




Twenty-four patients (25.5%) underwent a bilateral adrenalectomy. The median follow-up 
time was 169.5 [56.8-235.4] months. During follow-up 4 patients (16.7%) died (malignancy n=1; 
gastrointestinal bleeding n=1; suicide n=1; unknown cause n=1) after a median period of 42.6 [3.3-
132.1] months and in 1 patient (4.2%) follow-up was continued at another center after 128.4 months. 
Preoperatively, all patients were treated with adrenergic receptor antagonists to prevent 
potentially fatal complications of surgery. At 3 to 6 months after adrenalectomy, 24 patients (25.5%) 
used anti-hypertensive medication, of whom 13 used beta-adrenergic receptor antagonists (13.8%). 




Age, y (mean±SD) 47±16
Adrenalectomy, n (%)
  Unilateral, left 33 (35)
  Unilateral, right 37 (39)
  Bilateral 24 (26)
Functional Imaging, n (%)
  Whole body [¹²³I]MIBG 75 (80)
  Whole body [18F]DOPA PET 48 (51)
Pathology, median (IQR)
  Adrenal volume, cm³ 54 (30-224)
  Weight, g 38.8 (21.2-121.5)
Germline mutations, n (%)
  None (sporadic) 60 (64)
  Familiar syndrome 34 (36)
MEN 2a   22 (65)
MEN 2b 2 (6)
VHL  5 (15)
Neurofibromatosis type 1 3 (9)
SDHB 1 (3)
SDHD 1 (3)
Main reason for referral
  Tumor on anatomical imaging 22 (23)
  Analysis hypertension 23 (24)
  Symptoms related to pheochromocytoma 25 (27)
  Known mutation carrier 23 (24)
  Unknown 1 (1)
Hemodynamic control
  Mean BP ±SD, mmHg 139 ±31/ 85 ±17
  Mean pulse ±SD, beats/min 81 ±13
  Hypertension, n % 66 (70)
Antihypertensive medication, n (%) 39 (43)
  β-adrenergic receptor antagonists 25 (26)
  α-adrenergic receptor antagonists 14 (15)
  Angiotensin-II-receptor antagonists 5 (5)
  Calcium channel blockers 4 (4)
  ACE inhibitors 9 (9)
  Diuretics 11 (12)
Pre-operative biochemistry, median [IQR]a
  Urinary MN, µmol/mol creatinine 898 [178 – 3286]
  Urinary NMN, µmol/mol creatinine 1160 [333 – 2499]
  Plasma MN, nmol/L 1.03 [0.28 – 4.35]
  Plasma NMN, nmol/L 4.31 [1.26 – 13.36]
Abbreviations: ACE, angiotensin-converting enzyme; SDH, succinate dehydrogenase; VHL, von Hippel-Lindau; 
IQR, interquartile range. 
aReference ranges for urinary metanephrines were: MN 33-99 µmol/mol creatinine, NMN 64-260 µmol/mol 
creatinine. Reference ranges for plasma metanephrines were: MN 0.07-0.33 nmol/L, NMN 0.23-1.07 nmol/L.
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Postoperative deconjugated urinary and plasma free MN concentrations
In patients who underwent a unilateral adrenalectomy, the median urinary and plasma MN 
concentration were significantly lower 3 to 6 months after unilateral adrenalectomy compared with 
the reference population (both P<.05), as shown in Table 2. The median urinary MN concentration 3 
to 6 months after unilateral adrenalectomy was 36.1% [13.1-49.2] lower, whereas the median plasma 
MN concentration was 22.3% [0.0-50.0] lower compared to the median values in the reference 
population. In 19 patients (33.9%), the urinary MN concentration was below the lower reference 
limit (LRL) 3 to 6 months after unilateral adrenalectomy. The plasma MN concentration was below 







Urinary MN, µmol/mol creatinine 39 [31-53]b 7 [1-22]b 61 [49-74]
n 58 18 60
Plasma MN, nmol/L 0.14 [0.09-0.18]c 0.01 and 0.03 0.18 [0.13-0.23]
n 30 2 120
Urinary NMN, µmol/mol creatinine 151 [117-189]b 177 [106-238]b 114 [98-176]
n 58 18 60
Plasma NMN, nmol/L 0.78 [0.59-1.00]c 0.52 and 0.67 0.53 [0.41-0.70]
n 30 2 120
a Data are shown as median [interquartile range]. 
b P<.05, both calculated for urinary metanephrines between the reference population and patients after 
unilateral or bilateral adrenalectomy and with Bonferroni correction. 
c P<.05, calculated for plasma metanephrines between the reference population and patients after unilateral 
adrenalectomy. Because of the low number of patients, no comparison was made between plasma metanephrines 
after bilateral adrenalectomy and the reference population. 
the LRL in 2 patients (6.7%) 3 to 6 months after adrenalectomy. During the 5-year follow-up, there 
was a median increase of the urinary MN concentration of 11.1% [-8.5 to 36.9] compared with 
baseline values (defined as 3 to 6 months after adrenalectomy) (averaged correlation coefficient: 
0.37; P<.05). This correlates to a small absolute increase of the median urinary MN concentration 
from 39 to 43 μmol/mol creatinine. There were no changes over the 5-year time-frame in plasma 
MN (averaged correlation coefficient: 0.19; P=.058) (Figure 2). In patients who underwent a bilateral 
adrenalectomy, the median urinary MN concentration 3 to 6 months after adrenalectomy was 
88.5% [63.9-98.4] lower compared to the reference population (P<.05) (Table 2). Fifteen patients 
(83.3%) had a urinary MN concentration below the LRL 3 to 6 months after bilateral adrenalectomy. 
There was a decrease of 55.3% [-77.0 to 44.6] in urinary MN after bilateral adrenalectomy during 
the 5 years of follow-up (averaged correlation coefficient: -0.28; P<.05) (Figure 3). The plasma MN 
concentration was available for only 2 patients, and was 0.01 and 0.03 nmol/L, at 3 to 6 months, 
-respectively; therefore, no statistical comparison was made (Table 2). The urinary MN concentration 
of 17 patients with MEN type 2A 3 to 6 months after bilateral adrenalectomy was 4 (1-11.8) µmol/




Postoperative deconjugated urinary and plasma free NMN concentrations
Median urinary and plasma NMN concentrations in patients after unilateral adrenalectomy were 
higher compared with the reference population 3 to 6 months after unilateral adrenalectomy 
(both P<.05) (Table 2). The median urinary NMN concentration 3 to 6 months after unilateral 
adrenalectomy was 32.5% [2.6- 65.8] higher compared with the median value in the reference 
population, whereas the median plasma NMN concentration was 47.2% [11.3-88.7] higher. The 
urinary NMN concentration 3 to 6 months after unilateral adrenalectomy was above the upper 
reference limit (URL), in 6 patients (10.7%), with concentrations ranging from 268 to 537 µmol/mol 
creatinine. Four patients (13.3%) had a plasma NMN concentration above the URL 3 to 6 months 
after unilateral adrenalectomy. In the five years of follow-up, there was a median increase in urinary 
NMN concentration of 11.2% [-21.6 - 22.4] compared with the baseline values (averaged correlation 
coefficient: 0.14; P<.05). There was no change in plasma NMN after unilateral adrenalectomy over 





























































































































Figure 2. Percent changes from baseline (3 to 6 months after adrenalectomy) of urinary and plasma 
metanephrines after unilateral adrenalectomy. Baseline measures are set at 100%. Graphs depicting the percent 
changes with interquartile ranges of urinary and plasma metanephrines from baseline. In deconjugated urinary 
MN (A) and deconjugated urinary NMN (B), there was a change of 11.1% and 11.2% during 5-year follow-up 
compared with baseline values (3 to 6 months after adrenalectomy). In plasma free MN (C) and plasma free NMN 
(D), there is no significant change in a 5-year time frame.
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In patients who underwent a bilateral adrenalectomy, the median urinary NMN concentration 
significantly increased compared to the reference population (P<.05). Three patients (16.7%) had 
a urinary NMN concentration above the URL 3 to 6 months after bilateral adrenalectomy with 
concentrations ranging from 382 to 430 µmol/mol creatinine. There were no changes during 
the 5 years of follow-up in the urinary NMN after bilateral adrenalectomy (averaged correlation 
coefficient: -0.00; P=.972) (Figure 3). The plasma NMN concentration was 0.52 and 0.67 nmol/L 3 to 6 
months after bilateral adrenalectomy in the 2 patients in whom this was available. The urinary NMN 
concentration of 17 patients with MEN type 2A 3 to 6 months after bilateral adrenalectomy was 
higher compared to the reference population, 177 (102-232) µmol/mol creatinine (P=.09).
In 17 patients (18.1%) an increased urinary and/or plasma NMN concentration was found during 
one or more follow-up moments in the 5-year follow-up period.  In seven out of these 17 patients, 
additional imaging with CT (n= 2), MRI (n=2), ¹²³I –MIBG (n=5), 18F-DOPA PET (n=2), 111In-Octreoscan 
(n=1) or a clonidine suppression test (n=1) was performed with no evidence of recurrent disease. 




















































































Figure 3. Percent changes from baseline (3 
to 6 months after adrenalectomy) of urinary 
and plasma metanephrines after unilateral 
adrenalectomy. Baseline measures are set at 100%. 
Graphs depicting the percentage change with 
interquartile ranges of urinary metanephrines 
after bilateral adrenalectomy from baseline. 
Deconjugated urinary MN (A) and deconjugated 
urinary NMN (B) show no significant change of 
urinary MN and urinary NMN in a 5 year time frame. 
Plasma MN and NMN concentrations after bilateral 
adrenalectomy are not shown because of the low 





In the present study, we found that MN concentrations in both plasma and urine after unilateral 
and bilateral adrenalectomy were persistently lower compared with the values obtained in a 
reference population consisting of healthy subjects. As expected, this difference was most profound 
in patients after bilateral adrenalectomy. In contrast, we found that NMN concentrations in both 
plasma and urine in patients after adrenalectomy were higher than in healthy subjects.  
Two previous studies have described the catecholamine and  metanephrine concentration after 
bilateral adrenalectomy. Shah et al.25 demonstrated that plasma epinephrine and norepinephrine 
were still detectable after bilateral adrenalectomy in a small group of five patients with Cushing’s 
syndrome. Eisenhofer et al.26 studied 12 patients after bilateral adrenalectomy, of whom 11 patients 
had Cushing’s syndrome, and one patient had a pheochromocytoma. In concordance with our 
study, they found that the plasma epinephrine concentration was below the limit of detection, and 
plasma concentrations of free and conjugated MN were decreased compared with healthy control 
subjects. Plasma NMN concentrations, however, were unaffected in that study26. It should be noted 
that the present study is considerably larger, includes patients after unilateral adrenalectomy and 
contains long-term follow-up data. Furthermore, the liquid chromatography with electrochemical 
detection used in the latter study is more susceptible to interference and has a higher detection 
limit and is therefore not as accurate as the LC-MS/MS technique we applied27.
Although we observed a small statistically significant increase of 4 μmol/mol creatinine in the 
urinary MN concentration during the five-year follow-up, the urinary MN concentration in persistently 
lower after unilateral adrenalectomy. This implies that the contralateral adrenal gland cannot fully 
compensate for the loss of production and secretion of epinephrine. The detection of MN in patients 
after bilateral adrenalectomy, suggests that epinephrine production might take place outside the 
adrenal gland. This is supported by the demonstration of positive immunohistochemical staining 
for PNMT in adrenergic cells present in fetal rat hearts and in rat adipocytes28-30. 
There might be several explanations for the observed increase in postsurgical NMN concentrations. 
Most likely, this increase is explained by an augmented production of norepinephrine in sympathetic 
nerves, thereby compensating for the loss of epinephrine activity in maintaining vascular tone. 
Alternatively, this phenomenon could also result from desensitization of α- and β-receptors due 
to the high amount of circulating catecholamines before adrenalectomy, but this phenomenon is 
temporary and therefore expected to resolve after adrenalectomy31. Because patients with tumor 
recurrence within five years after surgery were excluded, the increase can not be attributed to a 
recurrent pheochromocytoma. This is additionally supported by the observation that the increase in 
NMN concentrations had already occurred 3 to 6 months postoperatively and the increase thereafter 
was only marginal. False-positive results caused by analytical interference are not likely because we 
used mass spectrometric detection, which is known for its very high analytical specificity22. It could 
be argued that our results might be confounded by preanalytical factors such as pharmacological 
interference by antihypertensive drugs, the lack of dietary restrictions, or patient positioning during 
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blood sampling. However, analyzing patients without antihypertensive medication did not change 
the results (data not shown). In the present study, blood was collected while healthy subjects 
and patients were seated. It has been demonstrated that plasma metanephrines are moderately 
elevated in the seated compared to the supine position32. Our conclusions, however, will not be 
affected by the position during sampling, because the postoperative concentrations of plasma 
were compared with the reference population in whom blood sampling had also been performed 
in the seated position. In addition, the concomitant increase in 24-hour urinary NMN concentrations 
argues against a possible influence of body position during blood collection. Dietary restrictions 
of catecholamine-rich food supplies are considered to minimize the possibility of false-positive 
results for urinary deconjugated NMN concentrations. We found decreased concentrations of both 
urinary deconjugated and plasma free NMN concentrations. Therefore, it seems unlikely that diet is 
a confounding factor21.  
Our results strongly suggest that the diagnostic yield of the measurement of metanephrines 
in plasma or urine is negatively affected by adrenalectomy. The decrease in MN levels is expected 
to reduce the sensitivity, whereas the increase in NMN levels after adrenalectomy is likely to lower 
the specificity of this assay. Consequently, adjusted reference intervals are needed for patients with 
pheochromocytoma after unilateral or bilateral adrenalectomy. Downward adjustment of the MN 
reference ranges in these patients could thus contribute to an earlier detection of tumor recurrence, 
whereas upward adjustment of the NMN reference ranges could prevent unnecessary diagnostic 
tests. The latter might be particular relevant for patients with von Hippel-Lindau syndrome, which 
is accompanied by an increased secretion of NMN33. According to current knowledge, additional 
imaging could have been prevented during follow-up in 7 out of 94 patients (7.5%) seen in our 
hospital after adrenalectomy because of a pheochromocytoma. Because imaging was not 
performed in patients with MN concentrations within the reference intervals, we cannot give an 
indication about how much sooner tumor recurrence would have been detected with adjusted 
reference intervals for MN. Specific reference intervals for urine and/or plasma MN and NMN need 
to be established in patients after adrenalectomy in order to improve both sensitivity and specificity 
for this patient group. Partial adrenalectomy is an emerging alternative procedure reducing the 
risk of adrenal insufficiency when performed by an experienced surgeon. Because the adrenal 
medulla is complete resected in partial adrenalectomy, the effects on the catecholamine secretion 
after successful resection of the pheochromocytoma are comparable with patients after complete 
adrenalectomy34,35.  We, therefore, believe that our results are also applicable in patients after partial 
adrenalectomy.
Our study has some limitations. Because of the retrospective nature of this study, not all data are 
complete. Plasma metanephrine concentrations after bilateral adrenalectomy were available in only 
a few patients, as this particular assay was only introduced in our laboratory after 2005. Patients with 
tumor recurrence after adrenalectomy within the observation period were excluded, but follow-




tumor syndromes, tumor recurrence could not always be completely excluded even in the absence 
of detectable tumor on imaging. Furthermore, the number of patients was too small to perform 
statistical tests on the different hereditary groups. However, analyzing patients with MEN type 2a 
after bilateral adrenalectomy gave comparable with the results.
From these data, it can be concluded that adrenalectomy in pheochromocytoma patients 
results in a new set point in catecholamine production, with lower epinephrine and higher 
norepinephrine secretion. We therefore recommend the use of adapted reference intervals in the 
follow-up of pheochromocytoma patients after adrenalectomy. These reference intervals need to 
be established prospectively in a large population of patients who have underwent surgery for a 
sporadic or hereditary pheochromocytoma. These adapted reference intervals for metanephrines 
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Background: hypertension can be the predominant sign of pheochromocytoma (PCC) and 
sympathetic paraganglioma (sPGL) and screening for PCC/sPGL is often performed in patients who 
are already being treated with antihypertensive agents. There is very little information about the 
influence of antihypertensive drugs on plasma free metanephrines. The aim of this study was to 
determine whether commonly prescribed antihypertensive drugs can falsely elevate plasma free 
metanephrines concentrations measured by LC-MS/MS analysis. 
Methods: in a prospective study we included patients with newly diagnosed hypertension, who 
started monotherapy with an antihypertensive agent (i.e. β-blocker, thiazide diuretic or angiotensin-
converting enzyme (ACE) inhibitor). Plasma free metanephrine (MN) and normetanephrine (NMN) 
levels were measured before and one month after the start of the medication quantified by LC-MS/
MS.
Results: between 2009-2014, 39 patients were included (β-blocker n=13, thiazide diuretic n=14 
and ACE inhibitor n=12). In the whole group, the median plasma free MN and NMN concentrations 
at baseline were 0.19 [0.17-0.26] nmol/L and 0.56 [0.38-0.95] nmol/L. One month after the start of 
antihypertensive treatment, the median plasma free MN and NMN concentrations were comparable; 
0.20 [0-16-0.20] nmol/L and 0.63 [0.39-0.63] nmol/L, respectively (P=.43 and P=.39). Separate analysis 
for each of the three antihypertensive agents examined did not reveal any significant changes in the 
median plasma free MN and NMN concentrations. 
Conclusions: The measurement of plasma free MN and NMN with LC-MS/MS is not affected by use 
of β-blockers, diuretics and ACE inhibitors. Withdrawal of these drugs prior to the quantification of 
plasma metanephrines is therefore not necessary. 
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INTRODUCTION
Pheochromocytoma (PCC) and sympathetic paraganglioma (sPGL) are rare neuroendocrine 
tumors known for their uncontrolled catecholamine secretion. Measurement of the O-methylated 
metabolites of catecholamines, metanephrine (MN) and normetanephrine (NMN), is the preferred 
biochemical method for diagnosing these tumors1,2. Measurement of plasma free metanephrines is 
currently considered to be the most accurate test1-3. Increased catecholamine secretion may produce 
a highly variable clinical picture with cardiovascular, neurologic, respiratory and metabolic signs and 
symptoms4. This variable clinical presentation combined with the rarity of the disease contributes 
to a diagnostic delay of approximately one to three years5,6. Hypertension may be the predominant 
sign in a patient with a PCC/sPGL, present in nearly all patients, either sustained or paroxysmal4. On 
the other hand, only an estimated 0.3-0.5% of patients with hypertension in the general population 
harbor a PCC/sPGL7,8. Screening for a PCC/sPGL is recommended in young patients, patients with an 
acute hypertensive crisis and in patients with therapy resistant hypertension9. Therefore, in clinical 
practice, screening for a PCC/sPGL is often performed in patients who are already being treated with 
antihypertensive agents. 
It has been demonstrated that measurement of plasma free metanephrines may be affected 
by several factors such as position during blood collection (seated vs. supine)10, age11, coffee 
consumption12,13 and salt intake14, catecholamine-rich diet15, previous adrenalectomy16 and the 
season of the year17. Furthermore, in one retrospective study, it has been suggested that plasma free 
MN concentrations could be falsely elevated by the use of β-blockers18. As a result, according to the 
recently published guideline, confirmatory testing after exclusion of false-positives sources, such as 
β-blockers, can be useful2. 
Currently, information is very limited with respect to the clinical relevant question whether 
measurement of plasma free metanephrines is influenced by the use of antihypertensive agents. 
Theoretically, antihypertensive agents might affect this measurement either in vitro through 
direct interference with the laboratory assay (analytical interference) or in vivo by an effect on 
catecholamine secretion or metabolism (physiological interference). Determination of plasma 
free metanephrines with liquid chromatography with electrochemical detection (LC-ECD) was 
shown to be prone to analytical interference by several drugs (i.e. acetaminophen, mesalamine 
and sulfasalazine)19-22. Analytical interference can be reduced by using liquid chromatography with 
tandem mass-spectrometry (LC-MS/MS)23,24. Physiological interference with the metabolism of 
catecholamines can occur with the use of drugs that block the neuronal reuptake and enzymatic 
degradation of catecholamines such as sympathomimetic agents, monoamine oxidase (MAO) 
inhibitors, serotonin norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake 
inhibitors (SSRIs) and tricyclic antidepressants (TCAs)18,25-28. 
The aim of this study was to determine with LC-MS/MS analysis whether commonly prescribed 
antihypertensive drugs (i.e. β-blockers, thiazide diuretics and angiotensin-converting enzyme (ACE) 





Patients ≥18 years of age with newly diagnosed hypertension (defined as a repeatedly recorded 
systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg, according 
to JNC 8 guidelines29), who started monotherapy with an antihypertensive agent (i.e. β-blocker, 
thiazide diuretic or ACE inhibitor) were included. Exclusion criteria were the use of additional 
antihypertensive agents or concomitant use of drugs known to interfere with catecholamine 
metabolism such as MAO inhibitors, TCAs, SSRIs, SNRIs, opiates or methyldopa. Patients who were 
prescribed additional antihypertensive agents on their second visit were also excluded.
Patients were recruited by local general practitioners or by internists at the outpatient clinic of 
the Department of Endocrinology at the University Medical Center of Groningen. Medical history and 
the use of additional medication were recorded before the start of the antihypertensive medication. 
Blood pressure and pulse rate were measured with a sphygmomanometer while in seated position, 
before and one month after the start of the antihypertensive medication. A blood sample for the 
measurement of plasma free MN and NMN was collected in seated position without prior dietary 
restrictions before and one month after the start of the antihypertensive medication. The study 
was approved by the Medical Ethics committee of the University Medical Center of Groningen. All 
patients gave written informed consent.
Reference population
The upper reference limits (URLs) for plasma free MN and NMN concentrations were established in 
120 healthy controls (63 men and 57 woman, 36-81 years of age) participating in the Prevention 
of Renal and Vascular End Stage Disease (PREVEND) study in seated position without prior dietary 
restrictions30. 
Analytical methods
Blood samples were collected by venipuncture in a 10 mL Vacutainer Tube (Becton Dickinson®) 
containing K2EDTA solution as anticoagulant. Blood samples were centrifuged at 2500 g for 11 
minutes and stored at -80 °C until processing. In order to decrease analytical variation, all samples 
were measured in one analysis batch after the inclusion of all subjects. 
Plasma free MN and NMN assays were performed with a High-Performance Liquid 
Chromatography tandem mass spectrometric technique (LC-MS/MS) with automated solid phase 
extraction sample preparation, essentially as described by de Jong et al.30. In order to prevent 
influence of ionic cross talk between MN and 3-MT, chromatographic conditions were optimized 
by applying a longer analytical column (Atlantis HILIC Silica column (particle size 3 µm, 2.1 mm 
internal diameter by 100 mm). Established reference intervals in seated position for plasma free 
metanephrines were: MN 0.07-0.33 nmol/L and NMN 0.23-1.07 nmol/L30. The intra-assay and inter-
assay analytical variation coefficients were 2.5% to 4.8% and 3.4% to 5.6% for plasma free MN, 5.1 
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to 6.2% and 4.2% to 7.1% for plasma free NMN, respectively. Biological intra- and interday analytical 
variation were 9.4% and 8.4% for plasma free MN and 15% and 13% for plasma free NMN30.
Sample size calculation
We used the reference intervals and distribution of plasma free MN and NMN to calculate the sample 
size. We assumed a total difference (analytical and/or physiological) of 10%. This implied that the 
URL would change to 0.36 nmol/L for plasma free MN and 1.18 nmol/L for plasma free NMN. This 
would be a clinically relevant difference. The sample size that would be required to provide more 
than 80% power with a two-sided alpha level of 0.05 was calculated to be 8 patients per medication 
group. 
Statistical analysis
Data are presented as mean ± (standard deviation (SD)) or as median [interquartile ranges (IQR)] 
where appropriate. Differences in plasma free MN and NMN concentrations before and after therapy 
were calculated with the Wilcoxon signed rank test for related samples. Differences between 
medication groups were calculated with the Kruskal-Wallis test. Two-sided P values <.05 were 
considered significant. Statistical analysis was performed with PASM statistics (version 22; IBM/SPSS, 
Armonk, New York). 
RESULTS
Patient characteristics 
Between 2009 and 2014, a total of 50 patients were eligible for inclusion. Eleven patients were 
excluded because they were either using a TCA or SSRI or more than one antihypertensive drug 
at their second visit. Fourteen patients (8 males, age 57±13 years) were given a thiazide diuretic 
(hydrochlorothiazide n=13, chlorotalidone n=1), 12 patients (6 males, age 55±13 years) were started 
on an ACE inhibitor (enalapril n=5, perindopril n=2, lisinopril n=4, ramipril n=1) and in 13 patients 
(4 males, age 41±13 years) a β-blocker was prescribed (metoprolol n= 9, propranolol n=3, labetalol 
n=1). 
Median systolic and diastolic blood pressure before and one month after the start of the 
antihypertensive treatment were 150 [140-160]/ 93 [82-100] mmHg and 130 [120-149]/ 85 [80-90] 
mmHg, respectively (both P<.001). Median pulse rate did not significantly change one month after 
the start of the medication (73 [61-82] vs. 76 [62-84] /minute, P=.72).
Plasma concentration of metanephrines before and after hypertensive treatment
In the whole group, the median plasma free MN and NMN concentrations at baseline were 0.19 
[0.17-0.26] nmol/L and 0.56 [0.38-0.95] nmol/L, respectively. One month after antihypertensive 
treatment, the median plasma free MN and NMN concentrations did not differ from the baseline 
values; 0.20 [0.16-0.20] nmol/L and 0.63 [0.39-0.63] nmol/L, respectively (P=.43 and P=.39). 
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There were also no significant differences in the median plasma free MN and NMN concentrations 
before and after treatment in the separate groups receiving β-blockers, diuretics or ACE inhibitors 
(Table 1, Figure 1). 
Three patients had a plasma free MN or NMN concentration >10% above URL. One patient 
had a plasma free MN after treatment with a thiazide diuretic of 0.37 nmol/L and one patient after 
treatment with a β-blocker of 0.45 nmol/L (Figure 1). The latter patient also had a slightly elevated 
plasma free MN level before the start of the medication of 0.36 nmol/L. In addition, there was one 














































Values are reported as median [interquartile range]. Reference ranges for plasma metanephrines were: MN 0.07-
0.33 nmol/L and NMN 0.23-1.07 nmol/L. MN: metanephrine, NMN: normetanephrine. 
Table 1. Plasma metanephrine concentrations before and after antihypertensive treatment
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Figure 1. Scatter plot with median showing the plasma free metanephrine and free normetanephrine 
concentrations before and after the use of β-blockers, diuretics and ACE inhibitors. The dashed line represents a 
plasma free MN or NMN concentration 10% above the upper reference limit (URL). 
DISCUSSION
In this study among hypertensive patients, we did not find a significant effect of frequently 
prescribed blood pressure lowering drugs on the measurement of plasma free metanephrines. This 
is the first prospective study investigating the influence of antihypertensive drugs on the plasma 
metanephrine concentration with a state of the art LC-MS/MS assay. Until now, the influence of 
antihypertensive drugs on the plasma free metanephrine levels has been described in only one 
retrospective study described the influence of antihypertensive drugs on the plasma free MN or 
NMN levels, determined with LC-ECD18. In this study, β-blockers were associated with 60% (9 out 
of 15 patients) of all false-positive elevations of plasma MN18. These influences did not appear to 
be associated with any specific type of β-blocker. In the same study, diuretics and ACE inhibitors 
did not appear to affect the frequency of false-positive elevation of plasma metanephrines18. Based 
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on this, the Endocrine Society advises to perform confirmatory testing after exclusion of false-
positive sources when measured with LC-ECD (2). We show that when plasma free metanephrines 
are measured with LC-MS/MS, there is no need to stop antihypertensive treatment because there is 
no effect on the plasma MN and NMN concentrations. 
The use of LC-ECD for measurement of metanephrines is associated with several, drug 
related interferences, such as acetaminophen, labetalol, sotalol and sulfasalazine19,20,25,31. With the 
introduction of the tandem mass spectrometry, the likelihood of analytical interference is strongly 
reduced23,24. It is of clinical importance to determine whether the former recommendations 
concerning drug related interferences based on LC-ECD are still valid when using LC-MS/MS. The 
lack of interference by commonly used antihypertensive drugs enhances the diagnostic accuracy of 
the LC-MS/MS assay for the determination of plasma free metanephrines and obviates the need to 
interrupt the use of these drugs prior to blood sampling.  
Our study has some limitations. Blood samples were collected with patients in seated position. 
This is in accordance with our reference values, which are also derived from a population in seated 
position. Two patients (2 out of 13; 15%) had a plasma free MN or NMN concentration more than 
10% above URL after start of the β-blocker. However, this does not necessarily indicate a causal 
relationship as these small changes might also be explained by intra-assay and biological intraday 
variations, or e.g. coffee consumption before blood sampling. 
In conclusion, treatment with β-blocking agents, diuretics or ACE inhibitors do not affect plasma 
free MN and NMN concentrations when quantified by LC-MS/MS and, therefore, withdrawal of these 
antihypertensive agents before blood sampling is not needed, when qualified by LC-MS/MS. 
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Germline mutations occur in up to 30-40% of pheochromocytoma/paraganglioma, with mutations 
in the succinate dehydrogenase (SDH) subunits B (SDHB) and D (SDHD) being the most common. 
Blood samples are favored for obtaining high quality DNA, however leukocytes can also be obtained 
by collecting saliva. The aim of this study was to determine whether SDHB and SDHD gene mutations 
in patients with (PHEO/PGL) could be determined using a salivary sample. Paired blood and salivary 
samples were collected from thirty patients: nine SDHB mutation positive, thirteen with a SDHD 
mutation, and eight without any SDHx mutations. The Oragene DISCOVER kit was used to collect and 
extract DNA from saliva. Blood DNA was extracted from EDTA blood samples. The DNA purification 
and concentration were measured by spectrophotometry. The eight exons of SDHB and the four 
exons of SDHD were amplified and sequenced by PCR-based bidirectional Sanger sequencing. Total 
DNA yields from blood DNA were similar to those obtained from saliva DNA (mean (±SD) saliva 
vs. blood DNA concentration 514.6 (±580.8) ng/µL vs. 360.9 (±262.7) ng/µL) (P=.2). The purity of 
the saliva DNA samples was lower than that of blood (mean OD260/OD280 ratio 1.78 (±0.13) vs. 1.87 
(±0.04) (P=.001), respectively), indicating more protein contamination in the saliva-extracted DNA. 
This study shows that salivary DNA collected from patients with PHEO/PGL is a good alternative for 
extraction of genomic DNA for its high DNA concentration and acceptable purity and can be used 
as an alternative to blood derived DNA in screening for SDHB and SDHD mutations. 
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INTRODUCTION
Pheochromocytoma (PHEO)s and paraganglioma (PGL)s are rare neuroendocrine tumors derived 
from sympathetic and parasympathetic paraganglia in the thorax, abdomen and head and neck 
region. In up to 40% of patients with these tumors, a germline mutation can be detected1. Mutations 
in the neurofibromatosis type 1 (NF1), Rearranged during Transfection (RET), von Hippel-Lindau (vHL), 
and succinate dehydrogenase (SDH) subunits A, B, C or D genes are the most well known causes 
of disease2-4. The number of PHEO/PGL susceptibility genes was recently increased to 215. The 
pathogenesis and progression of these tumors are very strongly influenced by genetics. In particular, 
SDHB mutations have been associated with more aggressive tumors, younger ages at presentation, 
and higher rates of metastasic disease2,6. 
Genetic testing is indicated in all patients diagnosed with a PHEO/PGL below the age of 50 years. 
Family history, clinical presentation (location, biochemical secretion pattern, and accompanying 
symptoms) and the immunohistochemical characterization of the tumors, are mainly used to 
determine which genes will be tested1,2. Based on the most recent guideline recommendations, 
genetic testing for other family members should be offered if a genetic mutation is identified in the 
proband7.  
Obtaining high quality DNA for human genetic studies is essential in the disease gene discovery 
process. Blood samples are favored for obtaining cells for high quality genetic testing. However, 
DNA can also be obtained from saliva collection, which is less expensive, noninvasive, easy to obtain 
(even at home), and can be readily sent to the hospital by regular mail. These advantages are very 
important, particularly in children, because phlebotomy is always stressful and unpleasant process 
for them. Therefore, we decided to investigate whether saliva could be used as an alternative 
method to blood for the detection of SDHB and SDHD mutations in patients with PHEOs/PGLs. 
MATERIALS AND METHODS
Study population
Saliva samples were collected from 30 consecutive patients who were seen in the Clinical Center 
of the National Institutes of Health, Bethesda, US. All patients were evaluated under the clinical 
protocol 00-CH-0093 that was approved by the Institutional Review Board of the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development. Nine patients had a known SDHB 
mutation, 13 had a known SDHD mutation, and 8 patients were of unknown SDHx mutation status.
Sequencing protocol
The Oragene DISCOVER (OGR-500) (DNA Genotek Inc. Ottawa, Canada) saliva kit was used to collect 
and extract DNA from saliva according to the manufacturer’s protocol. Briefly, patients were asked 
to fast and abstain from chewing gum and smoking at least 30 minutes before saliva collection. The 
collected saliva samples were stored at 4° degrees Celsius before DNA extraction. DNA from EDTA 
blood samples was extracted as previously described8. The DNA purification and concentration were 
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measured by spectrophotometry. The eight exons of SDHB and four exons of SDHD were amplified 
and sequenced by PCR-based bidirectional Sanger sequencing using the saliva-extracted and blood-
derived DNA. The primers used for SDHB and SDHD have been described elsewhere8. All amplified 
samples were examined by agarose gel electrophoresis to confirm successful amplification of each 
exon. Direct sequencing of the purified fragments was then done using the Genetic Sequencer 
ABI3100 Applied Biosystems (Applied Biosystems Inc, Foster City, CA, USA) apparatus. Sequences 
were analyzed using Vector NTI 10 Software (Invitrogen, Carlsbad, CA).
Statistics
Data are presented as mean ±standard deviation (SD). Differences in mean OD260/OD280 ratios 
between DNA extracted from blood or saliva were calculated with the paired T-test. A two-sided 
P<0.05 was considered statistically significant. Analysis was preformed with SPSS statistics (version 
22.0; IBM/SPSS, Armonk, New York).
RESULTS
We were able to confirm 9 out of 9 SDHB mutations and 11 out of 13 SDHD mutations in these 
patients both in saliva and blood-extracted DNA. Eight patients were screened negative for any 
SDHx mutations (Table 1). The chromatograms of sequencing analysis obtained both from the saliva 
and blood of a patient with a known SDHB mutation at exon 4 can be seen in Figure 1. In two (6.7%) 
Figure 1. Example of chromatogram of forward and reverse DNA sequence from saliva (A) and blood (B) results 
of a patient with a mutation in exon 4 of the SDHB gene. (see color image on page 185)
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patients with SDHD mutations at exon 2 (c.57delG p.Leu20CysfsX66), the salivary DNA samples were 
not successfully genotyped. Total DNA yields from saliva were similar to the ones obtained from 
blood DNA (mean (±SD) saliva vs. blood DNA concentration 514.6 (±580.8) ng/µL vs. 360.9 (±262.7) 
ng/µL) (P=.2). The purity of the saliva DNA samples was lower than blood (mean OD260/OD280 ratio 
1.78 (±0.13) vs. 1.87 (±0.04) respectively; P=.001).
DISCUSSION
This is the first study that describes the use of saliva for the screening of SDHB and SDHD mutations 
in patients with PHEOs/PGLs. We have shown that saliva can be used as an alternative method for 
the genetic testing of patients with PHEOs/PGLs and their family members and that the rate of 
mutation detection is similar to blood-extracted DNA. In contrast to blood collection, which can 
be a major obstacle for obtaining DNA, this noninvasive method can be very helpful for children, in 
particular. In addition, the sample can be collected at home and sent to the hospital by regular mail, 
which would increase the patient’s comfort and compliance significantly. This is particularly useful 
in screening large pedigrees of patients with a known mutation.
Our analysis shows that the total DNA yields are comparable between blood and saliva. However, 
the purity of saliva was lower, indicating more protein contamination in the saliva extracted DNA; to 
date more than 2000 proteins and peptides have been detected in human saliva9. 
We were not able to amplify and sequence the DNA extracted from the saliva of two patients 
with an SDHD mutation at exon 2 (c.57delG p.Leu20CysfsX66). Although we tried to optimize the 
PCR conditions, we were not able to visualize the PCR products in 1.5% agarose gel. However, 
we were able to amplify, sequence, and identify the mutation in the blood of these patients. It is 
probable that an unknown factor in the saliva of these patients impeded DNA denaturation or 
primer annealing. 
In conclusion, salivary DNA is a good alternative for extraction of genomic DNA. DNA extracted 
from saliva is of acceptable quality and quantity and therefore, can be used as an alternative to 
blood-derived DNA for the genetic screening of SDHB and SDHD mutations. Saliva collection is an 
easy-to-use, noninvasive method, in contrast to blood collection, which can be a major drawback 
for both children and adults. This method would potentially improve compliance among patients 
and, especially, related family members of patients with a known mutation during the genetic 
screening process.
Funding: This work was supported, in part, by the Intramural Research Program of the National 
Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD). 
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paragangliomas: case report and literature review
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Intestinal pseudo-obstruction is a rare and relatively unknown complication of pheochromocytoma/ 
paraganglioma (PCC/PGL). Its pathophysiology can be explained by the hypersecretion of 
catecholamines, which may reduce the peristaltic activity of the gastrointestinal tract. Clinically, this 
can result in chronic constipation, intestinal pseudo-obstruction or even intestinal perforation. 
We conducted a comprehensive literature search and retrieved 34 cases of pseudo-obstruction 
caused by either benign or malignant PCC/PGL. We also included a case from our centre that was 
not yet described earlier. We conclude that intestinal pseudo-obstruction is a rare, but potentially 
life-threatening complication of PCC/PGL. Intravenous administration of phentolamine is the most 
frequently described treatment when surgical resection of the PCC/PGL is not feasible. 
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INTRODUCTION
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare catecholamine-secreting 
neuroendocrine tumors arising from chromaffin cells of the adrenal medulla or extra-adrenal 
paraganglia, respectively. The release of catecholamines may lead to typical symptoms and signs 
such as paroxysmal headache, perspiration, pallor, palpitations and high blood pressure1. A clinical 
feature less well known is inhibition of the peristaltic activity of the gastrointestinal tract, which 
may result in chronic constipation, intestinal pseudo-obstruction or even intestinal perforation2,3. 
This complication is directly related to the hypersecretion of catecholamines, which may inhibit 
acetylcholine release from the parasympathetic nerve system and activate α1-, α2-, and β2-
adrenergic receptors of the intestinal smooth muscle cells. Recently, we encountered a patient with 
a malignant PGL who had developed an intestinal pseudo-obstruction. Clinical experience with 
the management of this rare complication is very limited, and we therefore decided to conduct 
a comprehensive review of the literature on this subject with particular emphasis on the reported 
responses to the different treatments. 
Case
A 62-year-old female patient with a malignant PGL caused by a mutation in the succinate 
dehydrogenase (SDH) subunit B, was admitted to our hospital with complaints of constipation 
and vomiting since three days. Her medical history included the surgical removal of a PGL of the 
bladder when she was 20 years of age. During this operation her left kidney was also removed 
because at that time a malignant epithelial tumor of the bladder was suspected. In 2009, she 
was admitted to the hospital because of abdominal pain and a high blood pressure of 211/145 
mmHg. Further investigations revealed a hydronephrosis due to ureteral obstruction secondary 
to a metastases of the PGL, which was treated by insertion of a double ‘J’ stent (Figure 1). Since 
Figure 1. Abdominal radiograph showing the colon diameter before the start of metyrosine. The maximal 




there were no other treatment options (peptide receptor radiation therapy with 111In-octreotide 
or 131I-metaiodobenzylguanidine (MIBG) could not be given because there was no uptake on the 
octreotide and 123I-MIBG scan) she was treated with sunitinib from April 2011 until the time of 
admission described in this case report (March 2012).
Her last bowel movements had been eight days before admission. Her blood pressure and heart 
rate were adequately controlled with doxazosin and metoprolole. On physical examination, the 
abdomen was markedly distended and hypertympanic but not tender to palpation, bowel sounds 
were absent. The plasma metanephrine and normetanephrine concentrations were 0.24 nmol/l 
(reference 0.07-0.33 nmol/l) and 149.83 nmol/l (reference 0.23-1.07 nmol/l), respectively. Figure 1 
shows a plain abdominal radiograph of the patient during her hospital stay. Neither administration 
of laxatives or prucalopride, a selective serotonine-4 (5-HT4)-receptor antagonist, resulted in any 
clinical improvement. Subsequently, endoscopic desufflation of the colon was performed because 
of an imminent risk of a blowout4. Colonoscopy did not reveal any mechanical cause for obstruction. 
Based on these findings, a diagnosis of intestinal pseudo-obstruction due to high concentrations 
of circulating catecholamines was considered. Oral treatment with phenoxybenzamine was 
started and gradually increased to a dose of 30 mg twice a day. Although this was followed by 
a return of bowel sounds and flatulence, there was no defecation. We therefore decided to 
administer metyrosine (α-methyl-L-tyrosine) in a dose of 250 mg q.i.d. Subsequently, within one 
day the intestinal pseudo-obstruction was resolved with restoration of spontaneous defecation and 
disappearance of abdominal distension. In addition, plasma normetanephrine levels were reduced 
to 65.01 nmol/l. Hereafter, the patient could soon be discharged from the hospital. Unfortunately, 
she died two months later because of progressive disease. 
Review of literature
We performed a comprehensive literature search on the clinical management of intestinal pseudo-
obstruction in patients with either benign or malignant PCC/PGL. Case reports written in English, 
and case reports written in other languages but in Latin script were retrieved from PubMed, 
Embase, Web of Knowledge and Scholar Google using the following MeSH terms or text words: 
‘intestinal pseudo-obstruction’, ‘intestinal obstruction’, ‘Ogilvie’s syndrome, ‘paraganglioma’ and 
‘pheochromocytoma’. Data on age, gender, diagnosis, symptoms and signs, treatment and outcome 
were collected.
Our search yielded 32 publications, describing 34 cases (Table 1). There was a slight preponderance 
of female subjects (59%), and age ranged from 25-70 years (mean 48.8 ± 13.1 years). Eighteen patients 
(53%) harbored a benign PCC, two patients (6%) had a benign abdominal PGL, whereas 14 patients 
(41%), including our own case, had a malignant PCC/ PGL. In nine patients (26%), a paralytic ileus was 
the initial presenting symptom at the time a diagnosis of benign PCC was made5-13. Among these 
subjects, one patient presented with a double perforation of the caecum6. Most frequently reported 
symptoms and signs were constipation (64%), abdominal pain (61%), nausea (47%), vomiting (44%), 
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and fever (18%).  On physical examination, 31 patients (91%) had abdominal distension, 17 patients 
(50%) had hypoactive or absent bowel sounds and abdominal tenderness was noted in 12 patients 
(35%). Two patients (6%) had an ischemic bowel without signs of thromboembolic occlusion of the 
mesenteric vessels and five patients (15%) developed a bowel perforation. Commonly performed 
examinations included abdominal X-ray, computer tomography (CT) scan of the abdomen and 
colonoscopy. Twenty-two patients (65%) underwent adrenalectomy, of which 17 (77%) had a 
benign PCC. In most cases (77%) adrenalectomy was conducted after pharmacological preparation 
with drugs such as phentolamine, phenoxybenzamine or neostigmine and β-receptor antagonists. 
Nine patients (26%) were treated conservatively with either α- and/or β-receptor antagonists or 
percutaneous enterogastrostomy/ enterojejunostomy or a combination of these. In one case report 
the drug treatment was not specified, and a diagnosis of pheochromocytoma-associated intestinal 
pseudo-obstruction was made post-mortem12. Intravenous administration of phentolamine was the 
most frequently applied drug treatment (7 out of 9 patients; 78%). Eventually, 18 patients (53%) fully 
recovered from the intestinal pseudo-obstruction, whereas 16 died (47%). Causes of death were 
tumor progression (n=9), treatment-related complications (n=5), intestinal pseudo-obstruction 
(n=1), or unknown (n=1).
DISCUSSION
Intestinal pseudo-obstruction is a clinical syndrome characterized by signs and symptoms suggestive 
of a mechanical intestinal obstruction in the absence of a demonstrable lesion blocking the intestinal 
lumen. In a large series of patients with acute intestinal pseudo-obstruction, the most frequently 
reported clinical features were abdominal distension (100%), abdominal pain (80%), nausea (63%) 
and vomiting (57%)14. As shown in table 2, this syndrome may arise from several etiologies and 
may present as either acute colonic pseudo-obstruction (ACPO or Ogilvie’s syndrome) or chronic 
intestinal pseudo-obstruction2,14,15. The diagnosis can only be made after exclusion of mechanical 
obstruction or a toxic megacolon2,14,15. The pathogenesis of intestinal pseudo-obstruction in PGL/
PCC is a direct consequence of the elevated levels of circulating catecholamines, which activate α1-, 
α2- and β2-receptors in the gastrointestinal tract. 
The gastrointestinal tract has its own intrinsic nervous system. This enteric nervous system is 
composed of two plexus, an outer myenteric plexus and an inner submucosal plexus. The outer 
myenteric plexus controls mainly the gastrointestinal movements, and the inner submucosal 
plexus gastrointestinal secretion and local blood flow. The intrinsic activity of the enteric nervous 
system is modulated by the activity of the parasympathetic and sympathetic nervous system. The 
parasympathetic nerve endings release acetylcholine, which stimulates the activity of the plexus 
of the entire enteric nervous system through activation of muscarinic receptors16. Activation of 
muscarinic receptors is followed by stimulation of bowel movements, gastrointestinal secretion 
and blood flow. In contrast, the sympathetic nerve endings release norepinephrine, which inhibits 
both the plexus of the enteric nervous system through activation of the α1-, α2- and β2- adrenergic 
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receptors17-19. In addition, based on in vitro electrical recordings from the outer myenteric plexus it 
has been shown that the effects of the sympathetic nervous system on the gastrointestinal tract 
are further augmented by a presynaptic norepinephrine-mediated inhibition of parasympathetic 
acetylcholine release16,20. Circulating epinephrine may also inhibit gastrointestinal peristaltic 
activity through stimulation of β2-receptors3. Moreover, catecholamine-induced stimulation of the 
α1- and α2-receptors can cause vasoconstriction, which may result in intestinal ischemia and its 
complications such as ischemic colitis, necrosis and intestinal perforation3,6,21-23. 
In general, treatment of intestinal pseudo-obstruction can initially be conservative if there is no 
abdominal pain and if the colonic distension measured on a plain abdominal radiograph is less than 
12 cm2,24. Conservative management includes fasting, nasogastric suction, intravenous replacement 
of fluids and electrolytes, and discontinuation of drugs that could adversely affect colon motility, 
such as narcotics and anticholinergic agents2,24. The risk of colonic perforation increases when the 
colon diameter exceeds 12 cm and when the distension has been present for more than 6 days25. 
Spontaneous perforation has been reported in 3-15% of patients with acute intestinal pseudo-
obstruction, which carries a high mortality rate of at least 50%24. If conservative treatment is not 
successful, endoscopic desufflation or pharmacological treatment with neostigmine, a competitive 
acetylcholinesterase inhibitor, should be considered26,27. The initial response after treatment with 
intravenous neostigmine in patients with acute intestinal pseudo-obstruction is 89%, and in 61% 
of patients this response was sustainable27,28. Immediate surgical intervention is indicated in case of 
clinical signs of ischemia or perforation14,29. 
The incidence of PCC/PGL is low and intestinal pseudo-obstruction is an uncommon complication 
in this setting, as reflected by a total number of only 34 case reports in the literature, including 
our case. Consequently, clinical experience with the management of PCC/PGL associated intestinal 
Table 2. Overview of the different etiologies of intestinal pseudo-obstruction
Acute Colonic Pseudo-Obstruction (Ogilvie’s syndrome)2,14
   Trauma (non-operative; e.g. fractures, burns)
   Infection (pneumonia and sepsis most common)
   Cardiac (myocardial infarction, heart failure)
   Obstetric or gynecological disease
   Abdominal/ Pelvic surgery
   Neurological (Parkinson’s disease, spinal cord injury, multiple sclerosis, Alzheimer’s  disease)
   Orthopedic surgery
   Miscellaneous surgical conditions (urologic surgery, thoracic surgery, neurosurgery)
Chronic Intestinal Pseudo-Obstruction15
   Degenerative neuropathies (e.g. Parkinson’s disease, amyloidosis, diabetes mellitus)
Paraneoplastic immune-mediated pseudo-obstruction (small cell lung cancer,  carcinoid and           
pheochromocytoma/paraganglioma)
   Immune-mediated pseudo-obstruction (e.g. dermatomyositis, systemic lupus  erythematosus)
   Infectious (Chagas’ disease)
   Radiotherapy/ Chemotherapy
   Genetic diseases (e.g. Hirschsprung’s  disease)
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pseudo-obstruction is very limited30. In 26% of the cases, intestinal pseudo-obstruction was the 
presenting symptom of PCC/PGL. Mortality rate is high, as from this review can be concluded that 
47% of patients are no longer alive within one year after development of the intestinal pseudo-
obstruction. If the PCC/PGL can be resected successfully, the chances of complete recovery are high 
(88%).  
Intravenous administration of phentolamine, a competitive α1- and α2-adrenergic receptor 
antagonist, was the most frequently applied pharmacological treatment (78%). Phentolamine 
inhibits α-mediated effects of catecholamines on intestinal and vascular smooth muscle cells 
and is usually administered preoperatively in PCC/PGL patients with drug-resistant hypertension 
or a hypertensive crisis31. In the majority of the reported cases, treatment with phentolamine was 
followed by clinical improvement. However, the intestinal pseudo-obstruction often recurred after 
discontinuation of this drug7,22,23,32-37. Another limitation of phentolamine is that it can only be 
administered intravenously and under close hemodynamic monitoring at the intensive care unit, 
because of the risk of severe hypotension38,39. Metyrosine could be considered as an alternative 
treatment in PCC/PGL patients with pseudo-obstruction. Metyrosine is a tyrosine analogue that 
competitively inhibits tyrosine hydroxylase. This enzyme catalyzes the conversion of tyrosine to 
dihydroxyphenylalanine (DOPA), the rate-limiting step in catecholamine biosynthesis. Metyrosine 
results in a depletion of the catecholamine stores inside the chromaffine tumor cells, which was 
also reflected by the significant decrease of plasma normetanephrine in our patient40,41. The use 
of metyrosine in patients with intestinal pseudo-obstruction might have several advantages, 
including oral administration without the need of blood pressure monitoring at the intensive care 
unit, allowing patients to use this drug at home. In clinical practice, however, the use of metyrosine 
is limited because of the high costs, limited availability and adverse effects in high doses31. Common 
side effects of metyrosine are sleepiness, depression, anxiety and galactorrhea. Occasionally 
extrapyramidal signs may arise, because of inhibition of the catecholamine biosynthesis in the 
brain. Metyrosine can cause diarrhea and crystalluria, which has been described in rats and dogs 
receiving 50 mg/kg metyrosine per day42. Although human data are scarce, patients are advised to 
drink approximately two liters per day41,42. 
In conclusion, intestinal pseudo-obstruction is a rare, potentially life-threatening complication 
in patients with PCC/PGL as a result of high circulating levels of catecholamines. While awaiting 
surgery or in case curative surgery is no longer possible, treatment with catecholamine-antagonizing 
drugs, such as phentolamine and metyrosine, or neostigmine should be considered. 
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Background: Determination of metanephrine (MN), normetanephrine (NMN) and 
3-methoxytyramine (3-MT) in saliva offers several potential diagnostic advantages in patients with 
pheochromocytoma. 
Methods: We determined metanephrine concentrations in saliva of healthy subjects and the 
relationship with simultaneously measured plasma metanephrines. We also studied the possible 
influence of pre-analytical conditions such as a collection device, awakening, posture, and eating 
on the salivary metanephrine levels. 
Results: We included 11 healthy subjects. Fasting blood and saliva samples were collected in 
seated position and after 30 minutes of horizontal rest. Plasma and salivary MN, NMN and 3-MT 
concentrations were determined using a High-Performance Liquid Chromatography tandem mass 
spectrometric technique (LC-MS/MS) with automated solid phase extraction sample preparation. 
Metanephrines were detectable in saliva from all participants both in seated and supine position. 
We found no significant correlation between the MN, NMN and 3-MT concentrations in saliva and 
plasma in seated or supine position. Furthermore, there was no difference between MN, NMN and 
3-MT samples collected with or without a collection device. 
Conclusion: Metanephrines can be detected in saliva with LC-MS/MS with sufficient sensitivity and 
precision. Our findings warrant evaluation of salivary metanephrine measurement in the work-up of 
patients suspected of having a pheochromocytoma. 
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INTRODUCTION
Sympathetic paragangliomas, either adrenal (i.e. pheochromocytoma or extra-adrenal (sympathetic 
paragangliomas)) are neuroendocrine tumors that are known for their overproduction of 
catecholamines, i.e. epinephrine, norepinephrine, and dopamine. The biochemical diagnosis of 
sympathetic paragangliomas is based on the demonstration of elevated metanephrine (MN), 
normetanephrine (NMN), or 3-methoxytyramine (3-MT) in plasma and/or urine. Measurement of 
plasma free metanephrines is currently considered to be the most accurate method for diagnosing 
these tumors1,2. However, plasma metanephrines can be affected by several pre-analytical factors 
such as position3, age4, coffee5,6, diet7 and salt intake8, certain drugs (depending on the method 
used) (e.g. mesalamine, sulfasalazine, and tricyclic antidepressants)2,9,10, previous adrenalectomy11 
and even the season of the year12. Plasma NMN and MN samples collected in seated position are 
30% and 27% higher, respectively, compared to samples drawn after 30 minutes of supine rest3. 
Therefore, the United States Endocrine Society recommends that patients rest for 20-30 minutes in 
a supine position before blood sampling2. This not only requires reference values in supine position, 
but is also more cumbersome and increases costs for venipuncture13. 
Catecholamines and metanephrines are biogenic amines that are easily transported over the 
salivary gland membrane, and should therefore be detectable in saliva. Assessment of late-night 
cortisol in saliva is now recommended as part of routine diagnostics in diagnosing Cushing’s 
syndrome mostly for logistic reasons14,15. Salivary catecholamines and metanephrines are expected 
to reflect their respective concentrations in plasma. High-Performance Liquid Chromatography 
tandem mass spectrometric technique (LC-MS/MS) with automated solid phase extraction 
sample preparation is a highly sensitive technique that enables the measurement of very low 
concentrations of catecholamines and metanephrines in saliva. Free unconjugated metanephrines 
in plasma filtrate into saliva through gap junctions between cells of secretory units16. Determination 
of metanephrines in saliva could for logistic reasons be useful in patients suspected of harboring a 
sympathetic paraganglioma. These patients could then collect saliva at home, which would improve 
patient convenience and obviates the need of extra hospital facilities and costs.  
This pilot study was initiated to determine metanephrines in saliva of healthy subjects. In 
addition, we tested the influence of several pre-analytical factors such as collection device, position, 
awakening and food consumption on the salivary concentrations of metanephrines. Also the 
relationship between salivary and plasma metanephrines concentrations was established.
PARTICIPANTS AND METHODS
Study population and design
In this single center study we examined 11 healthy nonsmoking volunteers older than 18 years. 
All healthy volunteers were seen at the Department of Endocrinology of the University Medical 




The first saliva sample was collected at home directly after awakening (between 6.00 and 7.00 
AM) in supine position (T0). Participants visited the outpatient clinic at 8.00 AM in a fasting state. 
Blood pressure was measured in seated and after 5 minutes in supine position using an automatic 
blood pressure measurement device. Blood and saliva samples were collected in seated position 
(T1). Thereafter, saliva samples were collected directly after changing into a supine position (T2). 
The second blood sample and third saliva sample were collected after 30 minutes of recumbency 
(T3). Ten minutes after blood sample collection at T3, saliva was again collected while remaining 
in supine position (T4). Thereafter, participants ate a standard breakfast, but were not allowed to 
smoke, drink caffeine containing products such as coffee or tea, or consume food products with a 
high (catechol)amine content such as walnuts, pineapple or bananas. Thirty minutes after finishing 
breakfast, participants were asked to collect saliva for the fifth time (T5). 
Salivary and plasma samples were stored on ice until transportation to the department of 
laboratory medicine. 
Approval of the study by the Medical Ethics Committee of the University Medical Center of 
Groningen in the Netherlands was requested but waved because the purpose of this study was to 
calibrate metanephrine values in saliva to the values in plasma. Therefore, according to the Dutch 
Medical Research Involving Human Subjects Act, no further Institutional Review Board approval was 
required. All participants gave oral informed consent.
Saliva collection
Saliva was collected in two ways, either by direct spitting saliva into a collection tube (without a 
collection device) or by using a polyethylene swab (salivettes®; Sarstedt, Nümbrecht, Germany), 
while participants were either in seated or supine position. Participants needed to chew or suck 
gently on the polyethylene swab for 2-3 minutes. Collected samples were immediately put on ice 
for transportation to the department of laboratory medicine and were subsequently stored at -80 
°C until further processing. 
Analytical methods
Blood samples were taken via venipuncture, with the participant either in the seated or supine 
position, using 4 ml Vacutainer Tubes (Becton Dickinson®) containing K2-EDTA as anticoagulant. 
Collected samples were immediately put on ice for transportation to the department of laboratory 
medicine. Blood samples were centrifuged for 12 minutes at 2500 g and saliva samples for 2 minutes 
at 1000 g. Samples were subsequently stored at -80 °C until processing.
Plasma free and saliva MN, NMN, and 3-MT were analyzed by High Performance LC-MS/MS 
with automated solid phase extraction sample preparation, essentially as described by de Jong 
et al.17. The only difference was that in this study a new generation and thus more sensitive mass 
spectrometer was used (Waters XEVO TQ instead of Waters Quattro Premier). Established reference 
intervals (in seated position) for plasma free metanephrines were: MN 0.07-0.33 nmol/L, NMN 0.23-
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1.07 nmol/L, 3-MT<0.17 nmol/L (17). 
The intra-assay and inter-assay analytical variation coefficients (CVs) were 2.5% -4.8% and 3.4%-
5.6% for free plasma MN, 5.1% -6.2% and 4.2%-7.1% for free plasma NMN, and 4.4% to 8.0% and 
4.5%-11.1% for free plasma 3-MT, respectively. The analytical method, which has been extensively 
validated for plasma free metanephrines, was validated for saliva, using a limited validation protocol 
in which relevant parameters were tested. We used three different saliva pools with low, medium 
and high concentrations of MN, NMN and 3-MT.The low saliva pool was unspiked saliva (MN 0.070 
nmol/L, NMN 0.40 nmol/L, 3-MT 0.020 nmol/L), medium (MN 0.93 nmol/L, NMN 2.6 nmol/L, 3-MT 
0.57 nmol/L) and high (MN 10 nmol/L, NMN 27 nmol/L, 3-MT 6.8 nmol/L) saliva pools were spiked 
with increasing concentrations of MN, NMN and 3-MT. The following parameters were tested: intra-
assay (n=10), inter-assay (n=6 different days), lower limit of quantification (LLOQ) by serially dilution 
of the low saliva sample and analyzing the dilutions on four different days. LLOQ was set at where 
CV≥20%. Recovery was determined by spiking three different levels of MN, NMN and 3-MT on the 
low and medium saliva pools on four different days. 
Intra- and interassay CVs were 1.4%-7.0% and 3.2%-8.3% for free salivary MN, 1.7%-1.8% and 
1.7%-3.2% for free salivary NMN, and 1.4% to 6.1% and 1.4%-7.0% for free salivary 3-MT, respectively. 
Lower limit of quantifications in saliva were 0.03 nmol/L, 0.035 nmol/L, and 0.010 nmol/L for MN, 
NMN and 3-MT, respectively. Recovery for MN was 106±10%, for NMN 101±5% and 3-MT 102±6%.
Statistical Analysis
Data are presented as mean ±standard deviation (SD) or as median with inter quartile range [IQR] 
where appropriate. Differences between salivary metanephrine samples collected with and without 
a collection device, in seated and supine position, before and after breakfast and after awakening 
were calculated with the Friedman’s two way ANOVA analysis. 
Non-parametric correlation analysis (Spearman’s ρ) was used to examine the relationship 
between blood and saliva samples. NMN/MN and 3-MT/NMN ratios in plasma and saliva were 
calculated. A two-sided P<.05 was considered statistically significant. Analyses were performed with 






Four men and 7 women with a mean age (±SD) of 39±16 years participated. Mean blood pressure 
and pulse in seated and supine position were 126±17/80±8 mmHg, 70±9/min and 123±19/71±9 
mmHg, 62±10/min, respectively.
Metanephrine concentrations simultaneously measured in saliva and plasma samples
Median concentrations of metanephrines in saliva and plasma at the different time points are shown 
in Table 1. Seated NMN/MN and 3-MT/NMN ratios in plasma and saliva were, 1.94 [1.27-2.46] vs. 7.21 
[5.33-8.16] (P=.08) and 0.05 [0.04-0.06] vs. 0.12 [0.08-0.14] (P=.08). Supine NMN/MN and 3-MT/NMN 
ratios in plasma and saliva were, 1.49 [1.15-2.08] vs. 4.92 [3.62-5.25] (P=.08) and 0.05 [0.04-0.10] vs. 
0.11 [0.08-0.16] (P=.17).
Influence of collection device on the concentration of metanephrines 
There were no differences in concentrations of metanephrines between samples collected with 
or without a saliva collection device in either seated position or recumbent position (data not 
shown). Therefore, all samples described in this study are calculated based on samples taken with a 
polyethylene swab as device (salivettes®).
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Data in median [interquartile ranges]. Concentrations of plasma and salivary metanephrine, normetanephrine 
and 3-methoxytyramine in nmol/L. *P<.05 seated vs. supine position; †P<.05 before vs. after breakfast; ¶P<.05 
on awakening vs. after 30 minutes of supine rest in the hospital. MN, metanephrines; NMN, normetanephrines; 
3-MT, 3-methoxytyramine. NA, not available. 
Table 1. Median plasma and salivary concentrations of metanephrines in 11 healthy volunteers
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Correlations between salivary and plasma metanephrines
There was no significant correlation between the MN, NMN, and 3-MT concentrations in saliva and 
plasma in the seated position (T1), ρs= .08 (P=.81), ρs=0.33 (P= .32) and ρs=-0.32 (P=.37) respectively 
(Figure 1). 
There was also no significant relationship between MN, NMN, and 3-MT concentration in saliva 
and plasma in supine position (T3), ρs=0.31 (P=.36), ρs=0.57 (P=.07) and ρs=-0.33 (P=.36) (Figure 1). 
Figure 1. Individual relationship between salivary and plasma metanephrines in seated and supine position
MN, metanephrine; NMN, normetanephrine; 3-MT, 3-methoxytyramine
Influence of posture during sampling on salivary and plasma metanephrines
Plasma MN, NMN, and 3-MT concentrations collected in supine position were significantly 
lower compared to samples collected in seated position (MN -16.4%, NMN -27.5% and 3-MT 
-8.3% respectively, P<.05; Table 1, Figure 2). Salivary NMN collected in supine position was also 
significantly lower compared to samples collected in seated position (NMN 38.4%, P<.05). There 
78
Chapter 6
were no significant effects of posture during sampling on the salivary MN and 3-MT concentrations 
(P=.53 and P=.10; Table 1, Figure 2). 
Influence of eating on salivary metanephrines
Salivary MN and NMN concentrations were significantly lower after breakfast (T5) compared 
to samples collected fasting in seated position (T1) (both P<.05) (Table 1). Only salivary MN was 
significantly lower after breakfast (T5) compared to samples collected fasting after 30 minutes of 
supine rest (T3) (P<.05). 
Figure 2. Comparison between salivary and plasma metanephrines in seated and supine position
MN, metanephrine; NMN, normetanephrine; 3-MT, 3-methoxytyramine
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Awakening response 
Salivary MN, NMN and 3-MT concentrations on awakening (T0) (around 6:00- 7:00 AM) were 
significantly higher than after 30 minutes of recumbency in the hospital (around 9:00 AM) (T3) (all 
P<.05) (Table 1). 
DISCUSSION
In the present study, we show that metanephrines can readily be measured in saliva of healthy 
volunteers using mass spectrometry based techniques. Salivary metanephrines were influenced by 
pre-analytical conditions such as position during sample collection and eating. 
Whole saliva is a clear, slightly acidic (pH 6.0-7.0 or 5.5-6.0 when not stimulated) and complex 
biological fluid composed of secretions from salivary glands and a variety of enzymes, hormones, 
antibodies, antimicrobial constituents, and growth factors entering the saliva from the blood by 
either passive or active intracellular diffusion or extracellular ultrafiltration18,19. Catecholamines and 
unconjugated metanephrines in plasma filtrate into saliva through gap junctions between cells of 
secretory units16,20. The hormone concentration in the saliva is 300-3000 times lower than in the 
plasma16. We found average concentrations of free metanephrines in saliva to be comparable to 
concentrations measured in blood.
Stefanescu et al. measured salivary free MN and NMN levels in 30 patients with a 
pheochromocytoma and compared these to 70 normotensive healthy controls using an enzyme-
linked immune sorbent assay (ELISA)21. The reported concentrations in healthy controls were 
similar to ours. Both salivary and plasma MN and NMN levels were increased in patients with 
pheochromocytoma when compared to healthy controls. In the present study, we used LC-MS/MS 
with automated solid phase extraction sample preparation to analyze both salivary and plasma 
samples. We could not reproduce a linear relationship between salivary and plasma MN and NMN 
levels21. In the present study, there was a only found a tendency towards a statistical significant 
correlation between plasma and saliva NMN in supine position, but no statistical significant 
correlation between MN, NMN in seated position, and 3-MT concentrations in saliva and plasma. 
This could be explained by differences in group size or more importantly differences in analytical 
techniques applied for quantification of metanephrines22. In addition, variations in sample clean up 
might result in different recoveries from saliva, since it has been shown that binding proteins such 
as albumin and proline rich proteins are present in saliva as well23. 
The tendency towards difference in NMN/MN ratio between plasma and saliva might imply 
that there is a decreased filtration of the free MN fraction from plasma into saliva, or secretion of 
catecholamines by the salivary glands and subsequent metabolization of these catecholamines by 
COMT in saliva (24, http://www.proteinatlas.org/ENSG00000093010-COMT/tissue, date: 05/26/2015). 
As we did not observe difference between passive drooling and saliva collected with a device, it is 
unlikely that the use of a device (polyethylene salivettes®) influenced the recovery of metanephrines. 
The practical advantage of using a collection device like polyethylene salivettes® is that they increase 
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patient comfort and that they have been found suitable for determining several (polar) hormones 
and therapeutic drugs in saliva25.
We found a decrease of salivary metanephrines 30 minutes after eating breakfast compared to 
the values during fasting, which was probably explained by the stimulation of saliva production by 
chewing. Higashi et al. found a lower concentration of catecholamine end products (homovanillic 
acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHGP)) after use of chewing gum26. Therefore, 
we suggest that salivary samples should preferably be obtained while fasting or at least 30 minutes 
after eating.
Salivary concentrations of metanephrines immediately after awaking were elevated, i.e. 
comparable to the well documented rise of salivary cortisol. The cortisol awakening response 
was found to be decreased in patients with chronic pain or psychiatric conditions (posttraumatic 
stress disorders, chronic fatigue syndrome or sleep disorder), while healthy subjects can exhibit 
elevated cortisol response under certain stress conditions27,28. Similar to cortisol, an increase of 
plasma catecholamine levels directly after awakening has previously been described29. In addition, 
it has been suggested that catecholamine secretion demonstrates diurnal variation30. Salivary 
concentrations of metanephrines immediately after awakening were found to be higher than those 
in supine position collected between 8.00 and 9.00 am. This suggests that salivary metanephrines 
could be an easy to collect biomarker for studying diurnal variations of catecholamine levels or the 
relationship between catecholamine secretion and stress-related disorders. 
Measurement of metanephrines in saliva instead of plasma could offer several advantages 
for clinical practice. It is noninvasive and free of venipuncture related side effects such as pain or 
hematoma formation and it offers the possibility to determine simultaneously other hormones such 
as cortisol. In addition, it can readily be repeated at various intervals and samples can be collected 
at home, which is likely to be more cost-effective compared to an in-hospital venipuncture13. Thus, 
measurement of salivary metanephrines would be particularly suitable for children as well as for 
periodic screening in patients with a hereditary pheochromocytoma/paraganglioma. Although 
we did not find a difference between samples with or without a collection device, we would still 
recommend the use of such a device as it is a more convenient method for the patient and it 
provides the possibility to measure other hormones in saliva as well25. 
Assessment of salivary metanephrines might become a novel and clinically useful biochemical 
tool for the diagnosis of pheochromocytoma. Obviously, this requires determination of salivary 
metanephrines in a sufficient number of healthy controls and patients with a pheochromocytoma 
in order to establish reference ranges for these metabolites.
In conclusion, LC-MS/MS enables to detect salivary MN, NMN and 3-MT. The potential diagnostic 
value of this test for the diagnosis of sympathetic paraganglioma needs to be explored in further 
studies, taking into account the above described pre-analytical conditions. 
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Dopamine acts both as a neurotransmitter and as a hormone, exerting its function via dopamine 
receptors that are present in a broad variety of organs and cell systems. Circulating dopamine is 
primarily stored in and transported by blood platelets. Recently, the important contribution of 
dopamine in the regulation of angiogenesis has been recognized. In vitro and in vivo studies have 
shown that dopamine inhibits tumor growth through activation of the dopamine receptor type 
2, thereby inhibiting the proangiogenic effects of vascular endothelial growth factor and hypoxia 
inducible factors. In pheochromocytoma (PCC) and paraganglioma (PGL), however production 
of dopamine has been shown to be an independent determinant of malignancy. ‘In this review, 
we discuss the role of dopamine in the angiogenesis pathway and the seemingly contradicting 
relationship between pheochromocytoma-paraganglioma dopamine production and tumor 
behavior.’
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INTRODUCTION 
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors derived 
from chromaffin cells of adrenal medulla and paraganglia, respectively1. PCC/PGL can be 
diagnosed by the demonstration of increased catecholamines, preferentially by measurement of 
their free or unconjugated O-methylated metabolites, i.e. metanephrine, normetanephrine, and 
3-methoxytyramine (3-MT) in plasma or urine. Until recently, the biochemical diagnosis of PCC/
PGL was mainly based on demonstrating overproduction of norepinephrine or epinephrine or 
their respective metabolites, with no special interest in dopamine. In 1956, it was already shown 
that increased synthesis of dopamine was associated with malignant behavior of PCC/PGL2. The 
relevance of these early observations was only recently substantiated by the finding of a strong 
correlation between increased tumor dopamine production and germline mutations of the 
succinate dehydrogenase (SDH) subunit B (SDHB) gene in malignant PGLs3-5. In 1957, Arvid Carlsson 
demonstrated that dopamine is a neurotransmitter in the brain, and not merely a precursor for 
norepinephrine as had been assumed earlier6. Subsequently, it became evident that dopamine has 
widespread effects in the human body (Table 1). Interestingly, recent studies showed major effects 
of dopamine on inhibiting angiogenesis and (tumor)neovascularization7-14. These insights shed 
new light on dopamine metabolism in relation to tumor angiogenesis and potentially constitute 
important new targets for treatment15-17. Paradoxically, increased dopamine concentrations are 
associated with more malignant tumor behavior in PCC/PGL3-5,18. In this review, we discuss the roles 
of dopamine with special focus on its relations with vascular endothelial growth factor (VEGF) and 
hypoxia inducible factor (HIF) related angiogenesis pathways. 
PHYSIOLOGY OF DOPAMINE 
Physiological functions of dopamine
Dopamine synthesis and/or storage takes place in a variety of organs (Table 1). In the brain, 
dopamine is involved in several processes such as cognition, motion control, emotion, pain 
perception, sexual behavior, food intake and rewarding processes19-21. Dopamine does not cross 
the blood-brain barrier, keeping dopaminergic signaling in the brain functionally separated from 
peripheral dopamine actions22. Peripheral dopamine-secreting tissues can be categorized into two 
groups according to the pathway of dopamine biosynthesis. The first group includes tissues like the 
adrenal medulla and peripheral sympathetic nerves that are able to take up tyrosine. The second 
group consists of cell systems that actively take up of L-3,4-dihydroxyphenylalanine (L-DOPA) which 
is then decarboxylated to dopamine inside the cell (Figure 1)20,23,24. Cells that take up L-DOPA were 
previously designated amine precursor uptake and decarboxylation (APUD) cells23.
By binding to the different dopamine receptors that are present in a variety of organs, dopamine 
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The primary precursor for the catecholamine biosynthesis is tyrosine, which is either absorbed in 
the gastrointestinal tract from protein-rich foods or formed after hydroxylation of the essential 
amino acid, phenylalanine25,26. The conversion of phenylalanine to tyrosine occurs in the brain, liver, 
adrenal medulla, and peripheral sympathetic nerves26. In the cytosol of catecholaminergic neurons 
and the adrenal medulla, tyrosine is converted to L-DOPA by the enzyme tyrosine hydroxylase (TH, 
EC 1.14.16.2) (Figure 1). The hydroxylation of tyrosine by TH is the rate-limiting step in the dopamine 
biosynthesis27,28. Conversion of L-DOPA to dopamine is catalyzed by the enzyme aromatic L-amino 
acid decarboxylase (AADC, EC 4.1.1.28). Depending on the presence and activity of dopamine 
β-hydroxylase (DBH, EC 1.14.17.1) and phenylethanolamine-N-methyltransferase (PNMT, EC 
2.1.1.28), dopamine can be further converted to norepinephrine and epinephrine, respectively27. 
The total amount of dopamine that is converted into norepinephrine is tissue-specific and varies 
Figure 1. Biosynthesis and metabolism of dopamine. (see color image on page 186)
Dopamine is deaminated by monoamine oxidase (MAO) to dihydrophenylacetaldehyde (DOPAL). DOPAL 
is metabolized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (AD), and to 
3,4-dihydroxyphenylglycol (DOPET) by aldehyde reductase (AR). DOPET is metabolized by catechol-O-methyl 
transferase (COMT) to 4-hydroxy-3-methoxyphenylethanol (MOPET). DOPAC and MOPET are metabolized to 
homovanillic acid (HVA), the end product of dopamine metabolism.
Abbreviations: PAH, phenylalanine hydroxylase; TYR, tyrosinase; TH, tyrosine hydroxylase; L-DOPA, L-3,4-
dihydroxyphenylalanine; AADC, aromatic L-amino acid decarboxylase; DBH, dopamine β-hydroxylase; PNMT, 
phenylethanolamine-N-methyltransferase; SULT1A3, sulfotransferase type 1A3; ARS, arylsulfatases; MAO, 
monoamine oxidase; COMT, catechol-O-methyl transferase; DOPAL, dihydrophenylacetaldehyde; 3-MT, 
3-methoxytyramine; AR, aldehyde reductase; AD, aldehyde dehydrogenase; DOPET, 3,4-dihydroxyphenylglycol; 
DOPAC, 3,4-dihydroxyphenylacetic acid; MOPET, 4-hydroxy-3-methoxyphenylethanol; ADH, alcohol 
dehydrogenase; HVA, homovanillic acid; BH4, tetrahydrobiopterin.  (see color page 186)
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between 50% and 90%29. For example, in the heart and the sympathetic nerves, about 90% of the 
dopamine located in storage vesicles is converted into norepinephrine29,30. In contrast, in the human 
omentum less than 50% of the dopamine is metabolized to norepinephrine29,31. Cofactors in the 
dopamine synthesis pathway are molecular oxygen (O2), reduced iron (Fe
2+), tetrahydrobiopterin 
(BH4), and pyridoxal-5-phosphate (vitamin B6), as depicted in Figure 132. 
Apart from this classic biosynthetic pathway, there are two alternative pathways for dopamine 
synthesis which have been demonstrated by a series of in vivo experiments in animals. One is 
a cytochrome P450-mediated pathway that has been demonstrated in rats. In this pathway, 
decarboxylation precedes hydroxylation, thus tyrosine is decarboxylated to tyramine by AADC 
which is then hydroxylated to dopamine by cytochrome P450 2D6 (CYP2D6) in the liver (Figure 
1)33,34. Another dopamine biosynthetic pathway involves tyrosinase (TYR, EC 1.14.18.1), a key 
enzyme in melanin biosynthesis, which also converts tyrosine to L-DOPA (Figure 1)35. In TH-knockout 
mice, TYR contributes to catecholamine biosynthesis in the brain and peripheral cells of the heart 
that normally synthesize catecholamines via TH36. In addition, albino mice lacking both TYR and TH 
still appear to have some source of catecholamine secretion36. It is not clear whether this residual 
dopamine is produced via the CYP2D6 pathway or by another unknown route. These pathways have 
not yet been investigated in humans but could be of interest e.g. for patients with TH deficiency, a 
rare disorder resulting in cerebral catecholamine deficiency37.
Cellular dopamine transport
Dopamine storage and release
After its synthesis or reuptake, dopamine is transported from the cytosol into storage vesicles 
by vesicular monoamine transporters (VMAT1 and VMAT2), as depicted in figure 2. VMAT1 is 
preferentially expressed in neuroendocrine cells, including chromaffin and enterochromaffin cells, 
whereas VMAT2 is also found in cells of the central and peripheral nervous system38. The driving 
force for vesicular monoamine transport is provided by an ATP-dependent vesicular membrane 
proton pump that maintains an H+ electrochemical gradient between cytoplasm and granule 
matrix. For dopamine to be transported into the vesicle by VMAT, an H+-electron is exchanged39-41. 
Exercise may cause disruption of this gradient by hypoxia or ischemia, resulting in a rapid release 
of catecholamines from storage vesicles into the cytoplasm39,42. In patients with a PCC, plasma 
concentrations of epinephrine, norepinephrine, and dopamine are increased after an exercise test 
and associated with reduced pH levels43. Additionally, post-exercise levels of epinephrine and the 
epinephrine/dopamine ratio are elevated in patients with a PCC compared to healthy controls42. 
In addition, it has been demonstrated that an increased production of lactate is accompanied by a 
higher release of norepinephrine in the brain, and it has been suggested that his might contribute 
to the positive effects of exercise on well-being44. Recently, an alternative pathway for brain 
norepinephrine release was described that involves lactate produced by astrocytes44. It is not yet 




Acting both as a neurotransmitter and a hormone, dopamine has autocrine/paracrine functions as 
well as endocrine/exocrine functions. Cellular uptake of dopamine is facilitated by the dopamine 
transporter (DAT) and is coupled to the NA+/K+ ATPase dependent Na+ transport across the cell 
membrane (Figure 2)45. DAT function requires the sequential binding and cotransport of two Na+ 
ions and one Cl- ion46. DAT can act as an outward-facing transporter orientated either towards the 
synaptic cleft or circulation thereby facilitating diffusion into the cell, or act as an inward-facing 
transporter, thus facilitating dopamine diffusion out of the cell47. The primary function of DAT as 
outward-facing transporter is to remove dopamine from the synaptic cleft or circulation, thereby 
terminating the actions of dopamine and recycling dopamine for reuse. Subsequently, dopamine 
enters storage vesicles through VMAT to remain available for exocytosis. 
The number of outward-facing DAT is regulated by the amount of dopamine in the synaptic 
cleft or circulation. In case of acutely elevated dopamine concentrations, DAT is recruited to the cell 
membrane47. Continuous presence of dopamine desensitizes DAT activity by decreasing the number 
of DAT on the cell membrane. DAT activity is terminated through a process involving invagination of 
the transporter into membrane pits, which are subsequently internalized into endosomal vesicles47. 
Figure 2 Uptake and storage of dopamine from the extracellular milieu into the vesicle of neuronal and non-
neuronal cells 
The dopamine transporter (DAT) transports dopamine (DA) into the neuronal or non-neuronal cell. In the 
cytoplasm, dopamine is taken up into storage vesicles via the vesicular monoamine transporter (VMAT). 
It is presumed that, when dopamine binds to DAT, together with Na+ and Cl-, they promote a change in the 
conformation of DAT from a primarily outward-facing to a predominantly inward-facing transporter. In 
sympathetic nerves, dopamine can also be released by exocytosis47.  (see color image on page 187)
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Dopamine receptors 
Cytoplasmatic vesicles store dopamine until an action potential triggers its release through 
exocytosis. Tissue specific response is mediated through specific dopamine receptors which are 
expressed in various tissues and cells, as described in Table 1. Five subtypes of dopamine receptors 
have been identified (D1 - D5). These subtypes can be divided in two families, the D1-like family (D1 
and D5) and the D2-like family (D2, D3 and D4 ). The D1-like family increases intracellular cAMP on 
activation through G protein coupled activation of adenyl cyclase, whereas the D2-like receptors 
inhibit intracellular adenylyl cyclase and activate the Na+/H+ exchanger and potassium channels on 
stimulation48. 
After exocytosis, dopamine is either retrieved through reuptake into the secreting cell by the 
dopamine transporter (DAT) (Figure 2) as discussed above, or is inactivated by one of the enzymes 
described in the next section. 
Dopamine metabolism
There are three enzymes involved in the metabolism of dopamine: the first is monoamine oxidase 
(MAO-A or MAO-B, EC 1.4.3.4), the second catechol-O-methyltransferase (soluble or membrane 
bound COMT, EC 2.1.1.6) and the third sulfotransferase type 1A3 (SULT type 1A3, EC 2.8.2.1). 
MAO is amongst others located in sympathetic nerves and in the adrenal gland, COMT is mainly 
present in the brain and adrenal gland whereas SULT type 1A3 is predominantly expressed in non-
neuronal cells. MAO catalyzes the first step of a two-step reaction (Figure 1)49. MAO-A preferentially 
oxidizes biogenic amines such as serotonin, norepinephrine and epinephrine. Dopamine is 
metabolized equally by MAO-A and MAO-B50, which convert dopamine to the acidic metabolites 
3,4-dihydroxyphenylacetic acid (DOPAC) or 3,4-dihydroxyphenylethanol (DOPET) via the unstable 
aldehyde intermediate metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL)27,28,51. Dopamine 
and DOPET lack a β-hydroxyl group in contrast to norepinephrine and epinephrine. The absence 
of the β-hydroxyl group favors oxidation by aldehyde dehydrogenase. Therefore, dopamine is 
preferentially metabolized to DOPAC27. The second step of the inactivation is the O-methylation of 
DOPAC to homovanillic acid (HVA) (Figure 1). A substantial portion of HVA (35-50%) is excreted in 
urine. The remaining part is eliminated from the circulation by the liver31,52.
In contrast to sympathetic nerves, which only contain MAO, adrenal chromaffin cells contain 
both MAO and COMT27. COMT in chromaffin cells is mainly present as the membrane-bound form, 
with a much higher affinity for catecholamines than the soluble form found in most other organs, 
such as the liver and kidneys. As a result, dopamine in the adrenal gland is first O-methylated by 
COMT to 3-methoxytyramine (3-MT)27,51. Subsequently, 3-MT is further metabolized by MAO to HVA 
(Figure 1). 
In addition, dopamine may also be metabolized by what has been called a “third catecholamine 
system”53. In this proposed system, dopamine, synthesized from decarboxylation of L-DOPA in non-
neuronal cells such as gastrointestinal cells, could act locally as an autocrine/paracrine effector and 
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could undergo inactivation by sulfoconjugation before entry into the bloodstream53. Dopamine 
and its metabolites are metabolized to sulfate conjugates by SULT1A3. The enzyme SULT1A3 has a 
particular high affinity for dopamine and 3-MT, and is found in high concentrations in the cytosol 
of gastrointestinal cells, which therefore represent a major source of sulfate conjugates39. SULT1A3 
can also be found in blood platelets, lungs, kidneys, and in the brain53. Arylsulfatases (ARS) located 
in the lysosome and in the endoplasmatic reticulum can reverse the sulfation through hydrolysis 
of sulfate esters (Figure 3)54. In general, sulfation is an inactivating mechanism and a means of 
detoxification of certain substances54. Thus, sulfation of dopamine may be thought of as part of 
a gut-blood barrier by detoxifying catecholamines that enter the gastrointestinal lumen after 
ingestion of catecholamine rich food products (e.g., fruits, tomatoes, nuts, potatoes, beans) as well 
as endogenously produced dopamine55. Theoretically, this system may also function as a buffering 
system, reversibly deactivating dopamine to dopamine-3-O-sulfate if dopamine concentrations are 
too high, and converting dopamine-3-O-sulfate back to dopamine if needed.
INTERACTION BETWEEN DOPAMINE AND ANGIOGENESIS 
Normal angiogenesis 
Angiogenesis is an important adaptive process to guarantee a continuous supply of nutrients and 
disposal of waste products, such as during embryogenesis or during repair of damaged blood 
vessels. In addition, angiogenesis is a vital process to prevent hypoxic situations, caused by e.g. 
exercise or impaired blood supply. Angiogenesis is mediated by circulating HIFs, e.g. HIF-α and 
HIF-β. There are three different HIF-α isoforms: HIF-1α, HIF-2α, and HIF-3α, with HIF-1α and HIF-2α 
being most sensitive to oxygen tension, and three HIF-β isoforms: HIF-1β, HIF-2β and HIF-3β56-58. 
Under normoxic conditions, HIF-α is rapidly degraded by the prolyl hydroxylase (PHD) proteins 
which promote the interaction with the von Hippel Lindau tumor suppressor protein (pVHL) with 
the E3 ligase complex (Figure 4). This leads to ubiquitination of HIF-α58,59. A second pathway of HIF-α 
inactivation is hydroxylation of an asparagine residue (Asn 803) in the C-terminal transactivation 
domain of HIF-α by factor inhibiting HIF-1 (FIH-1) (Figure 4)58-60. 
In hypoxic conditions, HIF-α is stabilized and forms an active transcription factor complex with 
HIF-β in the nucleus of the cell (Figure 4). This HIF complex (HIF-α/HIF-β heterodimer) binds in the 
nuclei of surrounding cells in a paracrine/autocrine manner to the promoter region of target genes, 
such as those encoding VEGF and vascular permeability factor (VPF). VEGFA and VPF stimulate 
Figure 3 Chemical equation of dopamine sulfation
Dopamine (DA) and its metabolites are metabolized to sulfate conjugates by sulfotransferase type 1A3 (SULT1A3). 
Sulfation is a reversible process, as arylsulfatases (ARS) located in the lysosome and in the endoplasmatic 
reticulum are able to catalyze the hydrolysis of sulfate esters formed by SULT1A3. 
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angiogenesis by binding to the VEGF-2 receptor on vascular endothelial tissue, which enhances 
microvascular permeability and endothelial proliferation and induces the proliferation and 
migration of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) from the bone 
marrow to the site of action7,61-63. These series of events contribute to the development of new blood 
vessels in response to hypoxia. In this process, dopamine acts as an important regulator by exerting 
negative feedback control through direct inhibition of VEGF.  
Figure 4 Schematic representation of hypoxia inducible factor (HIF)-α under normoxic and hypoxic conditions
When tissue oxygen concentration is normal, HIF-α is hydroxylated by the oxygen sensitive prolyl hydroxylase 
domain proteins (PHD) or factor inhibiting HIF-1 (FIH-1), promoting the interaction with von Hippel Lindau 
protein (pVHL). This targets HIF-α for ubiquitin-mediated proteolysis, resulting in proteolytic degredation. 
When tissue oxygen concentration is low, the activity of PHD and FIH is reduced and degradation of HIF-α is 
impaired. The ensuing elevation of HIF-α levels allow the formation of an active transcription complex with 
HIF-β. This HIF-α/β complex binds to the hypoxia responsive element (HRE) on the promoter region of certain 
genes of target cells, e.g. those encoding vascular endothelial growth factor (VEGF), vascular permeability factor 
(VPF) and tyrosine hydroxylase (TH). In patients with a VHL gene mutation, the interaction between pVHL and 
hydroxylated HIF-α is disrupted, which reduces the ubiquitin-mediated proteolysis of HIF-α. This causes HIF-α 
accumulation,  which mimics a hypoxic state57-59. (see color image on page 188)
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Dopamine and tumor angiogenesis 
Activation of the dopamine D2-receptor inhibits the pro-angiogenic effects of VEGF and VPF by 
preventing phosphorylation of the VEGF-2 receptor (Figure 5)7,8. In 1978, it was already shown that 
administration of dopamine improved survival of B-16 melanoma mice compared to non-treated 
controls9. In addition, tumor endothelial cells collected from B-16 melanoma tumor-bearing mice 
with ablated peripheral dopaminergic nerves had strikingly more VEGF-2 receptor phosphorylation 
compared to B-16 tumor bearing mice with intact peripheral dopaminergic nerves10. Moreover, 
VEGF-2 receptor phosphorylation was found to be markedly upregulated in B-16 tumor endothelial 
cells collected from dopamine D2-receptor knockout mice7,9. 
An anti-angiogenic effect of dopamine has also been suggested in preclinical models with 
human cancers. In vivo results with mice bearing ovarian cancer suggested that dopamine reduces 
chronic stress-mediated cancer growth in ovarian carcinoma64. Dopamine and TH were absent in 
Figure 5 Schematic representation of dopamine (DA) release and proposed actions of DA and vascular 
endothelial growth factor (VEGF) in various tissues
DA and VEGF are released from activated platelets and neuroendocrine cells (NECs)/ hypoxic endothelial 
cells (ECs). Dopamine can  also be released by sympathetic nerves after excitation. Dopamine inhibits the 
phosphorylation (i.e. activation) of the VEGF-2 receptor through activation of the D2- receptor. As a result, 
proliferation and migration of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) from the 
bone marrow is inhibited (60-63).
Abbreviations: VMAT, vesicular monoamine transporter; DAT, dopamine transporter; L-DOPA, L-3,4-
dihydroxyphenylalanine; AADC, aromatic L-amino acid decarboxylase; TH,  tyrosine hydroxylase.
(see color image on page 189)
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both human and rat gastric cancer tissue, in contrast to normal stomach tissues of humans and rat17. 
In addition, a low dose of dopamine significantly reduced tumor angiogenesis in human tumor 
endothelial cells expressing dopamine D2-receptors by inhibiting VEGF-2 receptor phosphorylation. 
In line, dopamine treatment of mice after xenotransplantation of human gastric cancer resulted 
in a 3-fold decrease of tumor diameter compared to non-treated mice17. Finally, in vivo and in vitro 
experiments have shown that the dopamine D2-receptor agonist bromocriptine partially inhibited 
growth of human small cell lung cancer11,12. 
In addition to the inhibitory effects of dopamine on tumor growth, dopamine could also increase 
the efficacy of anticancer drugs. Conceivably, the mechanism underlying this beneficial effect of 
dopamine may involve improvement of vessel morphology and function by acting on pericytes 
and endothelial cells. Impaired blood flow in the tumor vascular bed caused by structurally and 
functionally abnormal blood vessels hinders the delivery of chemotherapeutic agents and also 
aggravates tumor hypoxia. Dopamine acts through the D2-receptor present in these cells to up-
regulate directly the expression of angiopoietin 1 in pericytes and the expression of the zinc finger 
transcriptional factor, Krüppel-like factor-2 (KLF2) in tumor endothelial cells, resulting in significantly 
enhanced drug delivery of anticancer drugs to the vascular bed of the tumor13. In addition, 
dopamine treatment significantly decreased vascular permeability and microvessel density in 
tumor tissue in preclinical models14. These results were confirmed by in vivo studies showing that 
dopamine treatment increased vessel stabilization through activation of the D2-receptor in prostate 
and colon cancer bearing mice13. In vitro results demonstrated that binding of dopamine to the 
D1- receptor enhanced vessel stabilization by increasing pericyte migration to tumor endothelial 
cells. Both dopamine and a dopamine D1-agonist increased platinum concentration in tumor 
xenografts following cisplatin administration65. Furthermore, dopamine treatment has been shown 
to significantly improve the efficacy of commonly used anticancer drugs such as doxorubicin and 
5-fluorouracil in mice with human tumor bearing colon cancer or breast cancer14. In addition, 
expression of dopamine D1-receptors was found in 30% of patients with primary breast carcinomas, 
and was associated with larger tumors, higher tumor grades, node metastasis and shorter patient 
survival. Furthermore, in vitro activation of the D1-receptor/cGMP/protein kinase G pathway 
suppressed cell viability, inhibited invasion and induced apoptosis66. The authors suggest that 
fenoldopam could be a novel therapeutic agent for patients with D1-receptor expression tumors.
Thus, administration of dopamine and dopaminergic drugs might decrease tumor growth by 
inhibiting angiogenesis through inhibition of VEGF-2 receptor phosphorylation and by improving 
the delivery of anticancer drugs at the site of the tumor.
Dopamine and coagulation
In addition to the inhibiting actions of dopamine on hypoxia driven angiogenesis, dopamine also 
exerts a certain degree of inhibition when angiogenesis is activated by the coagulation system. 
Dopamine and VEGF are stored in dense granules and α-granules of circulating platelets (Figure 
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5)67,68. After injury of a blood vessel, von Willebrand Factor (vWF) promotes platelet aggregation 
and platelet adhesion to the subendothelial tissue, resulting in the release of dopamine and VEGF. 
Dopamine inhibits the histamine-induced vWF secretion by endothelial cells, thereby inhibiting 
primary homeostasis69. In concordance, treatment with dopamine D2-, D3-, and D4- receptor agonists 
inhibited histamine-induced vWF secretion69. Furthermore, dopamine receptor antagonists are 
associated with an increased risk of tromboembolic events70. 
Several studies have shown enhanced platelet activation in patients with cancer71,72. Tumor 
cells induce platelet activation and aggregation by direct cell-cell contact or by releasing platelet 
stimulating factors such as ADP, thrombin, and vWF. These factors form a bridge between tumor cells 
and platelets, upon which platelets become activated with release of several substances including 
dopamine and VEGFA71,72. 
DOPAMINE SYNTHESIS AND HYPOXIA ARE LINKED IN PCC/PGL
Paraganglia and adrenal medulla are dopaminergic, oxygen sensitive organs 
Sympathetic and parasympathetic paraganglia share the same embryological origin. Both derive 
from the neuronal plate, which later develops into the neural crest73. Sympathetic paraganglia 
contain chromaffin cells whereas parasympathetic paraganglia consist of glomus cells. The 
sympathetic and parasympathetic paraganglia as well as the adrenal medulla contain chief or type 
1 cells and sustentacular cells, also called type 2 cells. Type 1 cells have neurosecretory granules 
with catecholamines that can be released upon stimulation74. Type 1 cells are sensitive to the 
partial pressure of oxygen and release catecholamines in response to hypoxia. The stimulation 
of catecholamines by type 1 cells in response to hypoxia has been extensively studied in the 
carotid body. Hypoxia reduces conductance of the oxygen sensitive potassium channels in the 
cell membrane of type 1 cells75. As a result, depolarization occurs which is followed by opening of 
voltage-gated calcium channels and enhanced calcium influx into the cell and neurotransmitter 
secretion by type 1 cells. The release of dopamine stimulates the respiratory center causing 
hyperventilation. Research in rabbit carotid bodies has shown that dopamine blocks the activity of 
calcium channels, thereby inhibiting further neurotransmitter release, making it part of an autocrine 
negative feedback loop76. This mechanism of oxygen sensing based on the inhibition of membrane 
potassium channel activity has also been demonstrated in the adrenal medulla and PC12 cells (a cell 
line derived from PCC of rat adrenal medulla)77,78. 
Hypoxia enhances the transcription of TH as well as the stability of TH mRNA, the key enzyme 
in catecholamine biosynthesis77,78. This effect of hypoxia is mediated by the HIF complex, which 
binds to the hypoxia-responsive element (HRE) in the proximal region of the TH promoter of 
PC12 cells79,80. Moreover, hypoxia was shown to induce HIF-mediated TH mRNA expression in 
rat mesencephalic cultures81. Injection of desferrioxamine, an iron chelator that also induces the 
accumulation of HIF-1α, caused TH gene expression in rats82. In addition, it has been found that 
neuronal precursor cells of HIF-1α knockout mice showed less dopaminergic differentiation and a 
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decrease in expression of dopaminergic marker molecules such as TH and aldehyde dehydrogenase 
of 41% and 61%, respectively83. Furthermore, in vivo results in chicken embryos showed that TH is 
also regulated by HIF-2α84.These observations indicate that both HIF-1α and HIF-2α could promote 
TH gene transcription and dopamine biosynthesis77,85. Transcription of the TH gene is indirectly also 
regulated by pVHL through its effects on the concentration of HIFs79. 
In addition to these in vitro and in vivo results, hypoxia mediated catecholamine release has also 
been described in the human fetus86,87. Notably, innervation of the adrenal medulla is immature 
or absent at birth87. The hypoxia mediated catecholamine release by adrenomedullary type 1 cells 
in the neonate plays a critical role in the ability to survive stressors occurring around delivery and 
the transition to extrauterine life87. This mechanism is lost postnatally, simultaneously with the 
maturation of the sympathetic nerves innervating the adrenal medulla87.
The carotid bodies of rats living at high altitude were shown to contain TH and dopamine levels 
which were 6 and 43 times higher, respectively, than those in age-matched rats at sea level88. In 
addition, the carotid bodies of these rats contained more chemosensitive cells, fibroblasts, and more 
blood vessels88. In humans, carotid body tumors were estimated to be about 10 times more frequent 
in a population living at high altitudes than in a population at sea level due prolonged and severe 
hypoxia which caused hyperplasia of the chemoreceptor tissue89. In conclusion, parasympathetic 
and sympathetic paraganglia are oxygen sensitive organs, responding to hypoxia with the release 
of dopamine, which in turn stimulates the respiratory center. 
PCC/PGL are highly associated with hypoxia
Currently, about 35% of PCC/PGLs are considered to be hereditary90. PCC can be part of other 
hereditary tumor syndromes, including multiple endocrine neoplasia type 2 (MEN type 2), von 
Hippel-Lindau (VHL) syndrome, and von Recklinghausen’s disease, with mutations in RET, VHL 
and neurofibromatosis (NF) type 1 genes, respectively91. More recently, mutations of the genes for 
SDH subunit A, B, C or D (SDHA, SDHB, SDHC or SDHD), SDH complex assembly factor 2 (SDHAF2)92, 
transmembrane protein 127 (TMEM127)93, Myc-associated factor X (MAX)94, Harvey rat sarcoma viral 
oncogene (H-RAS)95, Kirsten rat sarcoma viral oncogene (K-RAS)96, fumarate hydratase (FH)97, kinesin 
family member 1B transcript variant β (KIF1Bβ)98, isocitrate dehydrogenase 1 (IDH1)99, PHD1100, 
PHD2101,102, and HIF-2α103-105 have been identified as a possible cause of PCC/PGL. In recent years, 
detailed information has been gained on the pathophysiology of these mutations106. Transcriptomic 
studies have identified two main molecular pathways that underlie development of these tumors, 
one in which the hypoxic pathway is activated (cluster 1; SDHx and SDHAF2 genes (cluster 1A) and 
VHL (cluster 1B)) and another in which the mitogen-activated protein kinase (MAPK) and mTOR 




Cluster 1 mutations in PCC/PGL are associated with HIF-α stabilization and dopamine 
synthesis
Recently, a biochemical link between SDHx-related mutations and VHL has been found. In patients 
with a VHL gene mutation, the interaction between pVHL and hydroxylated HIF-α is disrupted, 
which reduces the ubiquitin-mediated proteolysis of HIF-α (Figure 4). This results in an accumulation 
of HIF-α, mimicking a hypoxic state as shown in figure 6110,111. The SDHA, SDHB, SDHC and SDHD 
genes encode for the four SDH subunits which together form the mitochondrial complex II, which is 
bound to the inner mitochondrial membrane. SDHA and SDHB are the catalytic subunits and SDHC 
and SDHD are the anchor subunits. Complex II creates the link between the tricarboxylic acid cycle 
(Krebs cycle) and the mitochondrial electron transport chain. It catalyzes the conversion of succinate 
into fumarate and transfers the generated electrons to ubiquinone. A pathogenic SDHx mutation 
causes an enzyme deficiency, which results in an elevated intracellular concentration of succinate 
(Figure 6). Succinate directly inhibits the activity of 2-oxyglutarate-dependent dioxygenases such as 
PHD. As a result, a pseudo-hypoxic state is created due to a decreased degradation of HIF-α. 
FH is a mitochondrial enzyme and catalyzes the conversion of fumarate to malate as part of 
the tricarboxylic acid cycle. Germline mutations in FH predispose to hereditary leiomyomatosis 
and renal cell cancer, but have recently also been linked to PCC112. A decrease in FH activity results 
in the accumulation of fumarate. Like succinate, fumarate is also a competitive inhibitor of the 
2-oxyglutarate-dependent dioxygenases, and may thus lead to stabilization of HIF-α (Figure 6)113.
PCC/PGL and dopamine production
We recently documented the presence of catecholamine synthesizing enzymes in parasympathetic 
head and neck PGL tissues114. Elevated levels of 3-MT in plasma or urine have been found in 19-28% 
of patients with a head and neck PGLs115-117. In addition, we have recently demonstrated a higher 
concentration of dopamine in platelets from patients with head and neck PGLs as compared with 
healthy controls118. 
An increased plasma free 3-MT was demonstrated in 72% percent of patients with a SDHB 
mutation and 67% of patients with a SDHD mutation119. This increase of dopamine production 
might be explained by an enhanced TH gene transcription due to an increased HIF-α activity. In 
the same study, only 17% of patients with VHL disease were found to have an elevated plasma free 
3-MT concentration, despite the fact that degradation of HIF-α is also decreased in these patients. 
It is unclear how the difference in plasma 3-MT concentration between SDHx and VHL-related PGL 
tumors can be explained.
Dopamine production predictor for malignancy in PCC/PGL
PCC/PGLs are predominantly benign tumors, but malignancy may occur in up to 10% of all PCC/
PGL120. Malignancy is defined as local invasion or the presence of metastases of chromaffin tissue 
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Figure 6 Proposed mechanism of the interplay between the mitochondrial complex II and fumarate hydratase 
in the stabilization of the hypoxia-inducible factor (HIF)-α signalling pathway.
The mitochondrial complex II, located on the inner mitochondrial membrane, consists of succinate 
dehydrogenase (SDH)-proteins and catalyzes the conversion of succinate to fumarate. Fumarate hydratase (FH), 
another mitochondrial enzyme, converts succinate to malate. In case of a mutation in one of the SDH subunits 
(SDHA, SDHB, SDHC or SDHD gene mutations) or FH genes, the intracellular concentration of succinate and 
fumarate rise, resulting in inhibition of 2-oxyglutarate-dependent dioxygenases, including prolyl hydroxylase 
domain proteins (PHD), histone lysine demethylases (KDMs) and the ten-eleven translocation (TET) enzymes. 
This leads to  HIF stimulated increase of transcription of the gene encoding tyrosine hydroxylase (TH), and to 
hypermethylation of the dopamine D2-receptor gene
77,79,85,107,111,154.  (see color image on page 190)
at sites where no chromaffin tissue should be expected1. In general, the risk of malignancy is 
higher in extra-adrenal tumors larger than 5 cm than in smaller intra-adrenal tumors121,122. Recent 
investigations show that the risk of malignant disease is particularly increased in tumors caused by a 
SDHB mutation3,122-124. Currently, there are no sufficiently reliable diagnostic markers for malignancy, 
but large tumor size, extra-adrenal tumor location, elevated plasma 3-MT concentration and the 
100
Chapter 7
presence of a SDHB mutation have been identified as independent risk factors3-5. Thus, despite the 
suggestion of an increase in dopamine biosynthesis, patients with SDHB gene mutations are at risk 
for developing multiple and more malignant PGLs in the head and neck, thorax, and abdominal 
region3,122. 
 
Dopamine in malignant PCC/PGL
As described in the previous sections, dopamine inhibits angiogenesis in preclinical models. It was 
shown that dopamine inhibits phosphorylation of the VEGF-receptor type and exerts several other 
antiproliferative effects. It was shown that malignant PCC/PGL give rise to increased plasma 3-MT 
concentrations. In the next section we discuss several mechanisms by which tumors adapt to the 
presence of dopamine. 
Adaptation to high dopamine levels in carcinomas tissue
Malignant tumors may still grow despite the local production of dopamine with its antitumoral 
effects. It seems that tumors adapt to the effects of dopamine by reducing the dopamine 
concentration in tumors by limiting the perivascular innervations and by decreasing the number 
of dopamine receptor binding sites15,16. In malignant human stomach tissue, the presence of 
the dopamine D2-receptor was confirmed but the concentration of dopamine binding sites was 
decreased compared to normal and benign tumor tissue15. These results were confirmed in malignant 
human colon tissue16. There is also evidence that tissues immediately adjacent to growing tumors 
lack perivascular innervations. In particular, nerves showing positive immunostaining for TH are 
absent125. Normally, perivascular nerve fibers surrounding the interlobular blood vessels in human 
liver contain TH. In colorectal liver metastases, however, perivascular nerves were absent125,126. A 
similar loss of perivascular nerves was observed in colorectal cancer127. These observations suggest 
that the tumor itself may influence neural integrity in perivascular plexuses, perhaps by secretion of 
an inhibitory factor127. 
Adaptation to high dopamine in malignant PCC/PGL
A relationship between low dopamine content, dopamine receptor density, and malignancy has 
been established in human stomach and colon tissue, but little is known about the pathophysiologic 
role of dopamine in the tumor behavior of PCC/PGL15,16,128. PCC/PGL give rise to increased production 
of dopamine and these tumors express dopamine D2-receptors as D2-receptor mRNA has been 
found in these tumors129,130. The mean levels of D2-receptor mRNA were significantly higher in PCC 
than in PGL. Interestingly, D2-receptor mRNA levels seem to vary across the different hereditary 
tumor syndromes. D2- receptor mRNA levels were lowest in tumors from patients with a VHL 
mutation, intermediate in tumors from patients with a SDHx mutation and highest in tumors from 
patients with MEN type 2 syndrome or those without a germline mutation. However, statistical 
significance could not be reached due to the low number of cases130. Interestingly, the increased 
101
Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma
7
succinate concentrations in SDHx-related PCC/PGL may cause DNA hypermethylation of the gene 
encoding the dopamine D2-receptor through inhibition of the histone lysine demethylases (KDMs) 
and the ten-eleven translocation (TET) enzymes, as has been shown in SDH-knockout mice131,132. 
It is currently unknown whether there is a decrease in dopamine receptor density or perivascular 
dopaminergic innervations in human PCC/PGLs. Conceivably, other mechanisms might be involved 
whereby malignant PCC/PGL escape from the antiproliferative effects of dopamine. 
It has been suggested that succinate might act as a competitive inhibitor of histone and 
DNA methylases and could thereby enhance the hypermethylation of the PNMT gene108,131. A 
reduced expression of PNMT could lead to a dedifferentiated catecholamine secretory profile 
with predominant secretion of norepinehrine and dopamine. Together with the aforementioned 
upregulated of TH transcription, this could be an additional explanation for the predominantly 
dopaminergic secretion that is frequently seen in these tumors. Future research is needed to further 
elucidate the possible pathophysiological role of dopamine in the development of PCC/PGL and 
to determine whether it is a determinant of malignant behavior in these neuroendocrine tumors. 
CONCLUSION
Dopamine has widespread effects throughout the human body. It is stored and secreted from many 
different organs and is part of a negative feedback loop for angiogenesis. Dopamine counteracts 
the actions of HIF-α and VEGF by blocking the phosphorylation of the VEGF-2 receptor. Dopamine 
mediated activation of the D2-receptor inhibits endothelial cell proliferation, vascularization and 
tumor growth. Neoplasms may circumvent the actions of dopamine by reducing sympathetic 
nervous activity or by lowering the concentration of dopamine D2-receptor binding sites. Until now, 
little is known about the role of dopamine in the development and progression of catecholamine 
secreting PCC/PGL. Although there is an increased dopamine synthesis and secretion in patients 
with SDHB- and SDHD-related PCC/PGL, these tumors are more often multifocal and behave more 
aggressively. SDHx-related gene mutations in PCC/PGL might be associated with a decreased 
concentration of D2-receptors, but further research is needed to further clarify the relationship 
between dopamine and tumorigenesis of PCC/PGL. 
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Background/ Aim: Increased dopamine production may be a feature of head and neck paraganglioma 
(HNPGL). 18F-fluorodihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) 
scintigraphy has a high sensitivity for detecting HNPGLs. These observations strongly suggest 
that HNPGLs have the capacity for L-3,4-dihydroxyphenylalanine uptake and conversion towards 
dopamine. Therefore, our aim was to demonstrate the presence of catecholamine-synthesizing 
enzymes, i.e. tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC) and dopamine 
β-hydroxylase (DBH) in HNPGL tissue. 
Methods: A single-center study was performed among patients who underwent surgery 
for HNPGL at a single university referral center between 1994 and 2012. HNPGL tissue was 
immunohistochemically stained for TH, AADC and DBH. Data on paraganglioma-associated 
germline mutations, preoperative biochemical phenotype, and imaging studies were retrieved. 
Catecholamine excess was defined as preoperative plasma and/or urinary levels of metanephrine, 
normetanephrine or 3-methoxytyramine above the upper reference limit.
Results: Nineteen HNPGLs from 18 patients were evaluated. All tumor tissues (100%) stained 
positive for AADC, 6 (32%) for TH, and 2 (11%) for DBH. Of 3 HNPGLs staining positive for DBH, 2 
were also positive for AADC and TH. Catecholamine excess was only present in 1 patient (5%). The 
HNPGLs of this single patient only showed positive staining for AADC.  
Conclusions: Catecholamine-synthesizing enzymes, in particular AADC, are expressed in the 
majority of HNPGL tissues. 
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INTRODUCTION
Paragangliomas (PGLs) of the head and neck (HNPGLs) are rare neuroendocrine tumors that arise 
from parasympathetic paraganglia in the head, neck and mediastinal region1. These tumors are 
designated according to their anatomical location as carotid body PGLs, jugulotympanic PGLs or 
vagal PGLs1. HNPGLs are often associated with germline mutations in the von Hippel-Lindau (vHL), 
succinate dehydrogenase (SDH), subunit A (SDHA), subunit B (SDHB), subunit C (SDHC), subunit D 
(SDHD), assembly factor 2 (SDHAF2) or transmembrane protein (TMEM) 127 genes2-5. 
HNPGLs lack the characteristic norepinephrine and epinephrine production of 
pheochromocytomas, but excess dopamine secretion, as reflected by elevated dopamine and/
or 3-methoxytyramine (3-MT) in urine or plasma has been demonstrated in 19-28% of patients 
with a HNPGL6-9. The first step of catecholamine biosynthesis is the conversion of tyrosine to 
L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH; EC 1.14.16.2) which is the 
rate-limiting step in catecholamine synthesis. This is followed by the conversion of L-DOPA to 
dopamine by aromatic L-amino acid decarboxylase (AADC; EC 4.1.1.28), as illustrated in figure 1. 
In addition, AADC converts 5-hydoxytryptophan (5-HTP) to 5-hydroxytryptamine (5-HT, serotonin). 
Conversion of dopamine into norepinephrine and epinephrine is catalyzed by the activity of 
dopamine-β-hydroxylase (DBH; EC 1.14.17.1) and phenylethanolamine-N-methyltransferase 
(PNMT; EC 2.1.1.28), respectively10,11. Of interest, recent studies have suggested that 6-[18F]-
fluoro-L-3,4-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) has a high 
sensitivity for the detection of HNPGLs12. Uptake of this tracer by the large amino acid transporter 
2 into the neuroendocrine cells is followed by decarboxylation by AADC to18F-fluorodopamine, 
Figure 1. Metabolic pathways in catecholamine and serotonin synthesis. AADC converts both L-DOPA to 




















which is subsequently stored in intracellular vesicles by the vesicular monoamine transporter12-18. 
Thus far, little is known about the presence of AADC in HNPGL tissue. In one report AADC was 
immunohistochemically demonstrated in 3 carotid body PGLs19.  
The aim of the present study was to examine whether the catecholamine-synthesizing enzymes 
TH, AADC and DBH are expressed in HNPGL tissue. Based on the biochemical secretion profile, one 
would expect expression of TH and AADC, but not of DBH. Demonstration of AADC would support 
the contention that these tumors are capable of synthesizing dopamine.
MATERIALS AND METHODS
Study population
Paraffin-embedded tumor samples were obtained from HNPGL patients who had undergone 
surgery for biopsy or tumor resection at the University Medical Center Groningen between 1994 
and 2012. The preoperative diagnosis of a HNPGL was based on clinical symptoms, the original 
report of anatomical imaging studies (i.e. computed tomography or magnetic resonance imaging) 
or nuclear imaging studies (i.e. 111In-octreotide, 123I-metaiodobenzylguanide (MIBG) or 18F-DOPA-
PET). Preoperative data on catecholamine excess were obtained from medical charts. The tissue 
samples used in this study were obtained from archival material. Therefore, no further Institutional 
Review Board approval was required, according to the Dutch Medical Research Involving Human 
Subjects Act. Informed consent for the tissue staining of catecholamine synthesizing enzymes was 
obtained from all patients who were still alive.
Laboratory analysis
Isotope dilution mass spectrometry-based measurements were used for urinary and/or plasma 
metanephrine, normetanephrine and 3-MT levels. Urinary deconjugated metanephrines 
concentrations were determined by isotope diluting gas chromatography mass spectrometry, as 
described by Kema et al.20. Urinary deconjugated metanephrine concentrations were normalized 
to the urinary excretion of creatinine, measured using a picric acid-based method before 2005, or 
measured using an enzymatic method after 2005 (Roche Diagnostics, Almere, The Netherlands), and 
expressed in units of micromoles per mol creatinine. Reference intervals for urinary metanephrines 
were as follows: metanephrine 33-99 μmol/mol creatinine, normetanephrine 64-260 μmol/mol 
creatinine and 3-MT 45-197 μmol/mol creatinine, as reported previously by Willemsen et al.21. 
The plasma free metanephrine assay was performed with a High-Performance Liquid 
Chromatography tandem mass spectrometric technique (HPLC-MS/MS) with automatic solid-phase 
extraction sample preparation, as described by de Jong et al.22. Established reference intervals for 
plasma free metanephrines were as follows: metanephrine 0.07-0.33 nmol/L, normetanephrine 
0.23-1.07 nmol/L and 3-MT<0.17 nmol/L22. Measurement of plasma and urinary metanephrine 
concentrations was performed without prior dietary restrictions.
Excess catecholamine secretion was defined as preoperative plasma and/or urinary 
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metanephrine, normetanephrine or 3-MT exceeding the upper reference limit.
Immunohistochemistry
Immunohistochemistry was performed using the EnvisionTM Detection Systems Peroxidase/DAB, 
Rabbit/Mouse kit (No. K4065; Dako, Glostrup, Denmark), as previously described23. In brief, paraffin-
embedded sections, mounted on 3 aminopropyltriethoxysilane, were deparaffinized according to 
standard procedures, which was followed by a 20-minute microwave pretreatment in Tris-EDTA 
buffer (pH9.0). Then, the slides were incubated overnight at 4° C with anti-TH polyclonal antibodies 
(raised in rabbits with use of rat TH; Chemicon International; 1/1000 dilution), anti-AADC polyclonal 
antibodies (raised in rabbits; Chemicon/Millipore AB136; 1/100 dilution) and anti-DBH polyclonal 
antibodies (AB63939; ABCAM; 1/100 dilution). As controls we used healthy human adrenal medulla 
for each of the respective staining procedures for TH, AADC and DBH. Negative controls were 
performed by omission of the primary antibody.
Assessment of immunohistochemistry
The immunohistochemical sections were evaluated by one expert pathologist (R.R.d.K.). In addition 
to determining the site of intracellular staining within the tumor, the proportion of immunoreactive 
cells was categorized into 4 groups: 1-25, 26-50, 51-75 or 76-100% positive cells. The intensity of 
staining was classified using a 3-level scale, ranging from negative to weakly positive or strongly 
positive. The assessments were made without knowledge of the catecholamine secretory profile. 
For all samples, the diagnosis (HNPGL) was evident from the available tissue specimens. 
Statistical analysis
Data are presented as mean ± standard deviation or as median with interquartile ranges where 




In 18 patients, a total of 19 HNPGLs were resected. Information about the location of tumors, 
catecholamine secretion and results of nuclear imaging studies are provided in table 1. HNPGLs were 
classified as sporadic in case of a negative family history and the absence of a germline mutation in 
one of the susceptibility genes. All patients with a sporadic mutation were negative for SDHB and 
SDHD germline mutations. In addition, a proportion of patients with a sporadic HNPGL were also 
found to be negative for a germline mutation in one of the following susceptibility genes: SDHC 
(patient No. 1, 5-7, 13-15, 17, 18), SDHA (No. 5-7, 14, 15, 18), SDHAF2 (No. 1, 5-7, 14, 15, 18),  TMEM127 
(No. 7, 14, 18), MAX (No. 7, 14, 18), vHL (No. 7, 14, 18) and RET (No. 7, 14, 18).
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Table 1. Characteristics of the 18 patients
Sex, male/female 5/ 13
Age at first operation, years 55±15
Tumor location
   Vagal PGL 3
   Jugulotympanic PGL 13
   Carotid body PGL 3
Germline mutations
   SDHB (del exon 3/ c.292T>C) 5 (4/ 1)
   SDHD (c.292T>C) 1
   Sporadic 12
Nuclear imaging (positive/negative)
   123I-MIBG 4/ 9
   111In-Octreotide 12/ 1
   18F-DOPA-PET 5/ 1
Preoperative biochemistry 
   Urinary MN, μmol/mol creatinine 47 [35-69]
   Urinary NMN, μmol/mol creatinine 126 [89-172]
   Urinary 3-MT, μmol/mol creatinine 86 [59-107]
   Plasma MN, nmol/L 0.2 [0.14-0.28]
   Plasma NMN, nmol/L 0.73 [0.59-0.88]
   Plasma 3-MT, nmol/L 0.06 [0.06-0.07]
Values are expressed as number, mean ±SD or median [interquartile range]. MN, Metanephrine; NMN, 
Normetanephrine.
Immunohistochemistry
Results for the immunohistochemical staining of TH, AADC and DBH are listed in table 2. All tumor 
tissues (100%) were positive for the AADC enzyme (13 strongly positive and 6 weakly positive), six 
(32%) stained positive for the TH enzyme (all strongly positive), and two (11%) for the DBH enzyme 
(all strongly positive). Representative examples of immunohistochemical staining for these three 
catecholamine-synthesizing enzymes are shown in figure 2. The percentage of tissue staining per 
enzyme category is illustrated in figure 3. One of the 2 tissues staining positive for DBH were also 
positive for TH and AADC. All 6 HNPGLs that stained positive for TH, stained also positive for AADC 
(100%). In contrast, there were 13 HNPGLs staining positive for AADC (65%) which were negative 
for TH.  
There was one patient in whom two HNPGLs (No. 4 and 18) had been surgically removed (one 
jugulotympanic and one vagal PGL) and there was 1 patient in whom a biopsy was performed 
before surgical excision of the tumor (No. 7). The biopsy tissue (not included in table 2) stained 
strongly positive for TH and AADC in 76-100% of cells and strongly positive for DBH in 1-25% of cells. 
In this patient, there was a discrepancy in DBH staining between the biopsy and tumor. 
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Immunohistochemistry in relation to biochemistry and imaging
Results of preoperative metanephrines measurement were available in 17 of the 18 patients (table 
2). In all patients with a positive 18F-DOPA-PET scan (n=5) the tumor tissue stained positive for the 
AADC enzyme. There was one patient (No. 10) with a negative 18F-DOPA-PET scan in whom the 
tumor tissue stained positive for AADC. This patient had a small tumor with an average diameter of 
0.5 cm, which was below the detection limit of the PET camera at the time of evaluation. 
There was one patient (No. 7) with an elevated urinary metanephrine excretion. The tumor tissue 
of this patient stained positive for TH and AADC, but was negative for DBH. Of notice,  preoperative 
imaging studies with 123I-MIBG and 111In-octreotide did not demonstrate any lesion outside the head 
and neck region. 
Figure 2. Immunohistochemical staining for catecholamine-synthesizing enzymes in HNPGL of case 1 (see table 
2). HE staining (A). Positive TH staining, 1-25% positive cells (B). Positive AADC staining, 26-50% positive cells (C). 
Positive DBH staining, 25-50% positive cells (D). (see color image on page 191)
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DISCUSSION
In the present study, we show for the first time in a relatively large cohort the presence of 
catecholamine-synthesizing enzymes in HNPGL. AADC, TH and DBH were immunohistochemically 
detectable in 100, 32 and 11%, respectively, of the HNPGLs studied. 
Immunoreactivity for catecholamine-synthesizing enzymes in HNPGLs has previously been 
studied in only four small case series19,24-26. The study by Lloyd et al.24 included 5 HNPGL tissues 
and showed immunoreactivity for TH and focal staining of DBH in two carotid body PGLs, whereas 
immunoreactivity for TH and DBH was negative in three jugular PGLs. Takahashi et al.25 found TH 
immunoreactivity in two carotid body PGLs and one jugular PGL from three different patients. In 
that study, no other catecholamine-synthesizing enzymes were examined. In another case series, 
positive staining for TH in HNPGL tissue was demonstrated in five out of eight patients26. Finally, in 
a small series of 3 patients with carotid body PGLs, one stained positive for TH, whereas all 3 were 
positive for AADC and DBH19. 
In pheochromocytomas, known for their catecholamine secretion, the presence of catecholamine-
synthesizing enzymes has been demonstrated in large series by both immunohistochemical enzyme 
staining as well as by measurement of enzyme-specific mRNA expression. Kimura et al.19 showed 
positive immunohistochemical staining of all these three catecholamine-synthesizing enzymes in 
50 pheochromocytoma tissue samples, whereas Meijer et al.19,27 described positive TH staining in 
all 20 (100%) and DBH in 15 out of 20 (75%) pheochromocytoma tissues samples. AADC staining, 
however was not performed in that study.  
We did not analyze catecholamine or metanephrine content in the tumor tissue. Previously, a 
positive correlation has been demonstrated between epinephrine and norepinephrine contents 
in pheochromocytoma tissue and metanephrine and normetanephrine levels in plasma or urine28. 
However, data on catecholamine content in HNPGLs are very limited. There are only a few cases 
reporting the presence of norepinephrine with or without epinephrine in HNPGL tissue29.
The immunohistochemical staining pattern of AADC, DBH and TH in HNPGL is compatible with 
the biochemical catecholamine secretion profile generally found in these tumors, i.e. predominantly 
hypersecretion of dopamine, whereas hypersecretion of norepinephrine only occurs in rare 
instances6-8. In our study, the immunohistochemical staining did not correlate with the biochemical 
staining profile, as none of our patients had an elevated plasma 3-MT. This is at variance with a 
previous report by van Duinen et al.8, who found an elevated plasma 3-MT in 28% of patients 
with HNPGL. Notably, the plasma metanephrines in that study were determined in our laboratory 
using exactly the same assay. This variation in plasma 3-MT concentrations might be explained 
by differences between the populations studied. The study by van Duinen et al.8 included mainly 
SDHD mutation carriers (n=86; 69%) whereas most patients in our study had sporadic tumors (n=12; 
67%). Dopamine production has been shown to be particular prevalent among SDHD mutation 
carriers30. This might result from an indirect stimulatory effect of SDHx mutations on the TH enzyme 
activity. The SDHA, -B, -C and -D genes encode the four subunits of SDH which together form the 
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mitochondrial complex II. A mutation in one of these subunits has an inhibitory effect on prolyl 
hydroxylase domain proteins and diminishes the degradation of hypoxia-inducible factor α . This 
might have an effect on the dopamine secretion31,32.
The normal plasma 3-MT concentrations in combination with the positive AADC staining 
of HNPGL tissue in all our patients suggests  that the locally produced dopamine is not released 
into the circulation but is mainly effective in an autocrine and/or paracrine fashion. Alternatively, 
it could be related to lack of sufficient sensitivity of the biochemical methods used to measure 
dopamine production. Free circulating dopamine is rapidly incorporated by circulating platelets 
and metabolized by circulating COMT. Therefore, the biochemical diagnosis of HNPGL might be 
improved through development of a highly sensitive dopamine or plasma 3-MT assay. 
Another discrepancy was found in one patient (No. 7) with an elevated urinary metanephrine 
excretion, despite negative immunohistochemical staining for DBH of the HNPGL tissue. Scintigraphy 
with 123I-MIBG and 111In-Octreotide in this patient did not demonstrate a PGL/pheochromocytoma 
location outside the head and neck region, but results of these imaging modalities might have been 
false-negative. In contrast, the absence of catecholamine secretion despite the presence of DBH 
staining in 15% of cases could be caused by al low catalytic activity of DBH. We can only speculate 
about the factor(s) that contributed to this discrepancy, but a lack of vitamin C, the co-factor for 
DBH, could be one possible explanation. 
The presence of AADC in HNPGL cells is in agreement with the notion that these cells are part 
of the amine precursor uptake and decarboxylation (APUD) concept as postulated in the late 
1960s by Pearse33. Three cases were reported of a carcinoid APUDoma arising within a carotid body 
paraganglioma or jugulotympanic PGL34-36. APUDomas decarboxylate biogenic amines, which 
could imply that HNPGLs have the ability for uptake and decarboxylation of L-DOPA or 5-HTP 
and to store the resultant dopamine or serotonin into intracellular vesicles (Figure 1). Serotonin 
production, measured as its metabolite 5-hydroxyindolacetic acid, has not been shown in patients 
with HNPGLs37. However, platelet serotonin level is a more sensitive method to detect the serotonin 
secretion38. This has not been studied yet in these patients. In addition, the presence of AADC in 
HNPGL is in agreement with the high sensitivity of 18F-DOPA-PET in patients with HNPGL12,13,15,16. 
Intracytosolic conversion of 18F-DOPA into 18F-dopamine by AADC enhances the efficacy of 18F-DOPA 
as a tracer39. 
Our study has several limitations. The immunohistochemistry results might have been affected 
by sampling error, as illustrated by the different staining patterns in biopsy material compared with 
the primary tumor that was observed in one HNPGL patient (No. 7). Alternatively, this might reflect 
the presence of heterogeneous cell populations in a single patient with HNPGL. We were not able 
to examine the relationship between specific germline mutations and tissue staining pattern for 
catecholamine-synthesizing enzymes, due to the few patients with a hereditary HNPGL in our series.
In conclusion, catecholamine-synthesizing enzymes, especially AADC, are present in HNPGLs. 
As AADC catalyzes the conversion of L-DOPA to dopamine, our findings raise the possibility that 
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the development of a more sensitive assay for the detection of dopamine overproduction might 
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Aim: This study aimed to determine the prevalence of excess dopamine in relation to clinical 
symptoms and nuclear imaging in head and neck paraganglioma (PGL) patients.
Patients and Methods: Thirty-six consecutive patients with head and neck PGLs, evaluated between 
1993 and 2009, were included. Clinical symptoms, dopamine excess (urinary 3-methoxytyramine 
(3-MT) or dopamine and/or plasma dopamine or 3-MT) and (nor)epinephrine excess (urinary (nor)
metanephrine) as well as 111In-octreotide and 123I-metaiodobenzylguanide (MIBG) scintigraphy were 
documented. 
Results: Dopamine excess was found in seven patients (19.4 %), but was unrelated to clinical signs 
and symptoms. Excretion of other catecholamines was unremarkable, except in one patient with 
adrenal pheochromocytoma.  123I-MIBG uptake (present in 36.1 % of patients) was associated with 
dopamine excess (P=.03).
Conclusion: Dopamine excess is present in a considerable percentage of patients with head and 
neck PGL, and its measurement could be useful in follow-up. Measurement of other catecholamines 
is required to rule out co-existent pheochromocytoma.
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INTRODUCTION
Head and neck paragangliomas (PGL) are neuroendocrine tumors which originate from the 
paraganglia of the autonomic nervous system1. Head and neck PGLs represent 0.6 % of all tumors in 
the head and neck region2, and these PGLs are classified according to their site of development as 
carotid body PGLs, arising at the bifurcation of the carotid arteries, vagal PGLs, arising at the vagal 
nerve, tympanic PGLs arising at the tympanic plexus, jugular PGLs arising at the wall of the jugular 
bulb and PGLs of the temporal bone associated with the facial nerve (temporal PGLs). Measurement 
of epinephrine and norepinephrine metabolites in urine and plasma remains the cornerstone of 
the biochemical evaluation of intra-adrenal PGL (pheochromocytomas) and functional PGL3,4. In 
contrast to pheochromocytomas, catecholamine excess is considered to be infrequent in head 
and neck PGL5. In a recent National Institutes of Health series predominant dopamine secretion 
was found in only nine of 120 PGLs and pheochromocytoma patients with catecholamine excess6. 
Dopamine excess is not routinely measured in patients with head and neck PGLs and has been 
only documented in a limited numbers of patient series7-11. Dopamine excess in patients with 
pheochromocytomas and PGLs has been linked to atypical symptoms like nausea and weight 
loss6,11-13. Moreover, catecholamine excess can lead to hemodynamic instability, particularly during 
diagnostic and surgical interventions of these tumors14.
The present prospective cohort study was initiated to document the prevalence of catecholamine 
excess, with an emphasis on elevated dopamine secretion in relation to clinical signs and 
symptoms, in consecutive patients with head and neck PGLs. Since PGLs are considered to express 
cell membrane-bound norepinephrine transporters15, this study also assessed the association of 
elevated dopamine secretion with nuclear imaging. 
PATIENTS AND METHODS
Patients
Consecutive patients, who were referred to the outpatient clinic of the department of endocrinology 
of the University Medical Center of Groningen between January 1993 and January 2009 and who 
were found to have a head and neck PGL were included in the present cohort. The diagnosis of head 
and neck PGL was based on clinical symptoms, morphological imaging (Computed Tomography 
(CT) or Magnetic Resonance Imaging (MRI)), and nuclear imaging, including 111In-octreotide and 
123I-MIBG scintigraphy16. In 6 patients (18F)-dihydroxyphenylalanine (18F-DOPA) positron emission 
tomography (PET) was also performed. Since cytological or histological verification of PGL is not 
feasible or justifiable in many patients, clinical presentation combined with morphological and 
nuclear imaging was used to establish the diagnosis. To this end, all individual cases were discussed 
in a multidisciplinary team. Head and neck PGLs were categorized as carotid body PGLs, jugular 
PGLs, vagal PGLs, tympanic PGLs and temporal PGLs. Data on clinical symptoms of patients were 
obtained from the medical charts. Complaints, possibly related to tumor localization, catecholamine 
excess (with the emphasis on dopamine), nausea, weight loss, blood pressure and the use of 
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antihypertensive drugs were also documented. Blood pressure was measured after ten minutes of 
supine rest using a sphygmomanometer. Hypertension was defined as a blood pressure above 140 
mmHg systolic and/or 90 mmHg diastolic, and/or the use of antihypertensive medication.
Laboratory analysis
Twenty-four hour urine collections were obtained for measurement of total fractionated 
metanephrines (normetanephrines: upper reference limit 260 µmol/mol of creatinine; 
metanephrine: upper reference limit 99 µmol/mol of creatinine) and 3 methoxytyramine (3-MT): 
upper reference limit 197 µmol/mol of creatinine) and dopamine (upper reference limit 300 µmol/
mol of creatinine)17,18. These reference ranges were documented as the mean ±2 SD in a healthy 
population that consisted of 30 men en 30 women in which 24 hour urine collections were obtained 
while the patients consumed their habitual diet17. All urine measurements were expressed per mol 
of creatinine, in order to correct for sampling errors17. In addition to urine collection, blood samples 
were obtained from an indwelling intravenous catheter with the patient being in the supine 
position for at least ten minutes. Plasma was analyzed for dopamine (upper reference limit 0.05 
nmol/L)18. Dopamine excess was defined as plasma dopamine, plasma 3-MT, urinary dopamine, or 
urinary 3-MT above the upper reference limit. 
Imaging
CT and MRI were carried out at the Department of Radiology as described16. 111In-octreotide and 
123I-MIBG scintigraphy were performed 24 hours after administration of 200 MBq of the respective 
isotope16. 18F-DOPA-PET images were obtained 60 minutes after intravenous use of the tracer 
(180±50 MBq) as described in detail elsewhere19.
Statistical analyses 
Statistical analyses were performed using SPSS version 16.0. Data are given in median (range), 
mean ± standard deviation and percentages. Inter-group differences in continuous variables were 
determined with Mann-Whitney U-tests or Student’s t-tests where appropriate. Differences in 
proportions of categorical variables were determined by Chi-square analysis. A two-sided P-value 
<.05 was considered statistically significant. 
RESULTS
Patient characteristics, clinical symptoms and nuclear imaging
A total of 21 women and 14 men were included in the study. Their clinical characteristics, tumor 
localization and signs and symptoms are presented in table 1. Six patients (16.7%) presented with 
two or more head and neck PGLs. A unilateral pheochromocytoma was present in one patient, who 
was found to have a succinate dehydrogenase type D (SDHD) mutation. Genetic test results were 
available for eight additional patients. Two of these patients also had a SDHD mutation and one 
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patient was found to have a SDHB mutation. 
Hypertension was present in 26 patients (72.2%). Sixteen of them (44.4%) were using 
antihypertensive medication. Six patients were using a β-blocker, eight were using an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin (AT) receptor blocking agent, nine were using 
diuretics and three patients were using a calcium antagonist. 111In-octreotide scintigraphy was 
positive in 33 of 35 patients (94.3 %), whereas 123I-MIBG scintigraphy was positive in 13 of 36 patients 
(36.1 %). 18F-DOPA-PET detected a single head and neck lesion in five evaluated patients and 
multiple lesions in one patient; in five of these patients 111In-octreotide scintigraphy was performed 
and detected the same lesions, whereas in five out of these six patients the 123I-MIBG scintigraphy 
was negative.
Table 1. Clinical characteristics, tumor localization, clinical signs and symptoms of patients with head and neck 
paragangliomas.
All DA excess No DA excess P-value
Number of patients 36 7 29
Male 14 (38.9) 3 (38.9) 11 (37.9) 1.0
Age, years, median (range)  53 (25-85) 62 (38-65) 50 (25-82) 0.13
Tumor localization
  Carotid body tumor PGL 13 (36.1) 4 (57.1) 9 (31.0) 0.23
  Vagal PGL 4 (11.1) 1 (14.3) 3 (10.3) 1.00
  Tympanic PGL 8 (19.4) 0 (0) 8 (27.6) 0.31
  Jugular PGL 10 (27.8) 2 (28.6) 8 (27.6) 1.00
  Temporal PGL 7 (16.7) 2 (28.6) 5 (17.2 ) 0.60
Symptoms and signs
  Tinnitus 19 (52.8) 2 (28.6) 17 (58.6) 0.22
  Hearing loss 17 (47.2) 3 (42.9) 14 (48.3) 1.00
  Dizziness 10 (27.8) 3 (42.9) 7 (24.1) 0.37
  Cranial nerve palsies 10 (27.8) 3 (42.9) 7 (24.1) 0.37
  Diaphoresis 8 (22.2) 3 (42.9) 5 (17.2) 0.17
  Weight loss 7 (19.4) 2 (28.6) 5 (17.2) 0.62
  Palpitations 5 (13.9) 1 (14.3) 4 (13.8) 1.00
  Headache 4 (11.1) 0 (0.0) 4 (13.8) 0.57
  Nausea 1 (2.8) 0 (0.0) 1 (3.4) 1.00
  Systolic BP, mean ± SD (mmHg) 148 (±20) 145 (±17) 148 (±21) 0.73
  Diastolic BP, mean ± SD (mmHg) 80 (±13) 78 (±11) 83 (±13) 0.33
  Hypertension 26 (72.2) 5 (71.4) 21 (72.4) 1.00
  123I-MIBG positive 13 (36.1) 5 (71.4) 8 (27.6) 0.03
  111In-octreotide positive 33 (94.3) 7 (100) 26 (92.9) 0.67
Data in numbers (%) unless stated otherwise. DA: dopamine, PGL: paraganglioma, BP: blood pressure, 123I-MIBG: 




Urinary 3-MT was measured in all patients; median excretion: 120 (range 48-1688) µmol/mol 
creatinine. Urinary 3-MT was elevated in 6 out of 36 patients (16.7%). Plasma dopamine was 
determined in 31 patients. Plasma dopamine was elevated (range 0.06-6.05 nmol/L) in four patients. 
Urinary 3-MT was within the reference range (136 µmol/mol creatinine) in one patient with a plasma 
dopamine of 0.06 nmol/L. Urinary dopamine was within the reference range in all 29 tested patients. 
Dopamine excess was considered to be present in seven patients (19.4%). Plasma dopamine 
and urinary 3-MT levels of these seven patients are provided in table 2. Four out of these seven 
patients were on an antihypertensive regime, including an ACE inhibitor (n=2), a β-blocker (n=2) 
and a diuretic (n=2). Plasma dopamine or urinary 3-MT was not elevated in the patient with the 
pheochromocytoma.   
Epinephrine and norepinephrine excess 
Urinary metanephrine and normetanephrine excretion was measured in all patients; median 
excretion: normetanephrine: 140 (range 61-373) µmol/mol; median metanephrine: 66 (range 30-
118) µmol/mol creatinine. Urinary metanephrine was elevated in four patients (11.1 %); range 101-
118 µmol/mol creatinine. Urinary normetanephrine was elevated in three patients (8.3%); range 
291-373 µmol/mol creatinine, including the patient with pheochromocytoma (normetanephrine 
excretion 373 µmol/mol creatinine). In this patient, urinary normetanephrine normalized after 
removal of the pheochromocytoma. All together, excess epinephrine or norepinephrine, was found 
in six patients (16.7 %). Three of these six patients were using antihypertensive medication, of whom 
two were using a β-blocker. 
A combination of elevated urinary (nor)metanephrine and dopamine excess was present in 
two patients. A total of 12 out of 36 patients (33.3%) had either elevated urinary metanephrine, 
normetanephrine, 3-MT or plasma dopamine levels.
Comparison between patients with and without dopamine excess
 The comparison of patients with and without dopamine excess regarding tumor localization, 
clinical symptoms, blood pressure and nuclear imaging is presented in table 1. A carotid body 
PGL tended to be more frequent in patients with dopamine excess, although this did not reach 
significance. Clinical symptoms, blood pressure and prevalence of hypertension were unrelated to 
dopamine excess. The sensitivity of a 123I-MIBG scintigraphy in patients with dopamine excess was 
71.4% compared to the sensitivity of 27.6% in patients without dopamine excess (P=.030).  
The urinary 3-MT and plasma dopamine in the two patients with dopamine excess and a negative 
123I-MIBG scintigraphy was respectively 234 and 678 µmol/mol creatinine and < 0.0 and 6.05 nmol/L 
(Table 2).
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DISCUSSION
This consecutive series of patients presenting with head and neck PGLs demonstrates that 
dopamine excess is present in approximately 20% of cases. Dopamine excess was associated with 
abnormal 123I-MIBG uptake in the head and neck region, which supports the possibility that these 
PGLs are able to synthesize catecholamines and hence should be considered functional. One of the 
two patients with dopamine excess, who did not have 123I-MIBG uptake, showed only marginally 
elevated urinary 3-MT. Thus, the possibility of false-positive classification of dopamine excess exists 
for only one patient in this series. Furthermore, no relation between dopamine excess and clinical 
signs or symptoms was found. Therefore, it is unlikely that dopamine excess has direct clinical 
consequences, at least in the majority of head and neck PGL patients.
In addition, epinephrine or norepinephrine excess was found in 16.7 % of patients. However, 
elevations of urinary metanephrine and normetanephrine were marginal (< 1.2 times above the 
upper reference limit), except in one patient with a concomitant pheochromocytoma. Of note, 
two of these patients were using β-blocking agents that can elevate urinary (nor)metanephrine 
excretion20,21. Thus, in patients with isolated head and neck PGL, relevant epinephrine or 
norepinephrine excess seems to be infrequent.
For comparison, case reports and patients series obtained from English, German and French 
literature between 1965 and 2009 were reviewed. As shown in table 3, ten case reports were retrieved 
in which dopamine secretion, either demonstrated by dopamine in tissue or elevated dopamine 
concentration in plasma or urine was reported14,22-30. Table 3 also shows the prevalence of dopamine 
excess in five series7-11. Anand et al. found dopamine excess combined with abnormal norepinephrine 
or norepinephrine secretion in 2 of 20 patients (10.0%) and isolated catecholamine excess in another 
patient8. In a series of 14 patients, elevated urinary dopamine excretion was reported in one patient 
(7.1%) with a vagal PGL9. In a selected series of head and neck PGL patients referred for either a 







Patient 1 0.06 136 Positive
Patient 2 0.38 444 Positive
Patient 3 0.00 234 Negative
Patient 4 0.00 581 Positive
Patient 5 6.05 679 Negative
Patient 6 missing 280 Positive
Patient 7 1.71 1688 Positive
3-MT: 3-methoxytyramine, 123I-MIBG: 123I-metaiodobenzylgyuanidine
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positive family history or a mutation in the SDHD gene, elevated urinary catecholamines were 
observed in 17 out of 40 patients10.  In nine of these patients catecholamine excess was attributable 
to head and neck PGLs; urinary dopamine was elevated in one patient (2.5%)10. Erickson et al. 
reported on 204 PGL in 236 patients7. Catecholamine excess was present in nine out of 103 patients 
with a head and neck PGL, but the prevalence of dopamine excess attributable to PGLs of the head 
and neck was not specified7. Finally a recent study of van Duinen et al., which was published while 
the present manuscript was in preparation, shows an increased urinary 3-MT in 23% (31 out of 136) 
patients with a head and neck PGL, consistent with the current findings11. These differences in the 
reported prevalence of dopamine excess, ranging from 2.5 to 23%, are likely to be due, at least in 
part, by referral-based selection of patients and the selected laboratory work-up. In this respect, 
it is important to note that the presently evaluated cases were referred for endocrine work-up by 
the department of otorhinolaryngology from our University Medical Center, although there was 
no selection regarding the co-occurrence of other PGL or pheochromocytoma localizations, nor 
with respect to genetic PGL predisposition. Of the selected work-up in previous reports and the 
current series, urinary 3-MT seems to be the most sensitive11. The inferiority of urinary dopamine 
measurement as diagnostic test6, as confirmed in the current study, has been attributed to the fact 
that dopamine presence in urine originates from renal extraction and decarboxylation of circulating 
of 3,4-dihydroxyphenylalanine.
In support of the contention that there is no well-defined clinical correlation of dopamine 
excess, clinical characteristics and symptoms were not significantly different between patients 
with and without dopamine excess, and the presence of hypertension appeared to be unrelated 
to abnormal dopamine secretion6,12,13. Nevertheless, in clinical practice there are several arguments 
that underscore the necessity for routine assessment of catecholamine excess in the work-up of 
patients with head and neck PGL.
Firstly, catecholamine excess may result in hemodynamic instability during surgery8.14,24. 
However, dopamine excess in these tumors is probably not of major relevance regarding 
hemodynamic instability during surgery, since the amount of dopamine produced, is unlikely to 
affect the cardiovascular system. Secondly, it is important to rule out additional pheochromocytomas, 
especially in patients with a SDHD or SDHB mutation10. This is illustrated by the case of SDHD-
associated pheochromocytoma in the current study. Thirdly, the present findings would suggest 
that measurement of plasma dopamine or 3-MT could be useful in the follow-up of head and neck 
PGLs as a tumor marker. 
A limitation of our study is that results from genetic testing were available in 9 out of 36 patients, 
because they were not routinely followed at our department. Therefore, it is not possible to correlate 
dopamine secretion to a specific mutation. 
Finally, the preliminary findings regarding positive 18F-DOPA-PET imaging in all six tested patients 
raises the possibility that this imaging modality may be sensitive for the detection of head and 
neck PGLs31. Nonetheless, a recent literature survey has demonstrated that the sensitivity of 111In-
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octreotide scintigraphy for head and neck PGL detection amounts to 96 %, whereas the sensitivity 
of 18F-DOPA-PET has not yet been established in large series32. 
In conclusion, dopamine excess is present in a relevant percentage of patients with head and neck 
PGLs. Routine assessment of abnormal secretion of dopamine and other catecholamines in PGL 
management is proposed, and it is suggest that serial measurement of urinary/plasma 3-MT and 
plasma dopamine could be useful in the follow-up of PGL patients. Furthermore, measurement of 
epinephrine and norepinephrine metabolites is required to rule out catecholamine excess resulting 
from a co-existing (adrenal) pheochromocytoma.
Acknowledgements: We appreciate the collaboration with dr. K.P. Koopmans and dr. A.H. Brouwers, 
Department of Nuclear Medicine and Nuclear Imaging, University Medical Centre Groningen.
N Tumor Catecholamine excess
Hirano et al.24 1 Carotic body PGL Elevated plasma and urinary DA
Koch et al.25 1 Carotic body PGL Elevated plasma DA 
Kouzaki et al.26 1 Tympanic PGL Elevated plasma NE, DA and urinary VMA
Levin  et al.27 1 Vagal PGL Elevated plasma DA
Reuland et al.28 1 PGL Elevated urinary NE and DA
Rhigini et al.29 1 Carotic body PGL DA excess
Throughton et al.30 1 Jugular PGL Elevated urinary catecholamines/metabolites, 
elevated plasma DA
Goutcher et al.14 2 Jugular PGL In 1 patient elevated urinary NM, in 1 patient elevated 
urinary DA
Azzarelli et al.22 2 Jugular PGL DA in tissue, in 1 patient elevated urinary VMA
Crowell et al.23 2 Carotic body PGL Both patients tissue catecholamines and DA
Anand et al.8 20 PGL In 2 patients elevated plasma DA, NE and E, in 1 
patient elevated plasma NE
Erickson et al.7 204 PGL In 103 patients urinary DA available, elevated  
catecholamine elevated in 40 patients 
Van Gils et al.9 14 PGL 7 Patients with elevated catecholamines, 1 patient 
with elevated DA in urine
Houten van et al.10 40 PGL 17 patients elevated urinary E, NE, DA or VMA (7 
patients with an additional pheo, 1 patient with an 
additional extra adrenal PGL), 1 patient with elevated 
urinary DA 
Van Duinen et al.11 136 PGL 31 Patients with elevated urinary 3-MT
Table 3. Case reports and series demonstrating dopamine excess in patients with head and neck paraganglioma. 
VMA: Vanillylmandelic acid, HVA: Homovanillic acid, NE: norepinephrine, E: epinephrine, DA: dopamine, M: 
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Background: Plasma 3-methoxytyramine (3-MT), a metabolite of dopamine, is elevated in up to 
28% of patients with head and neck paraganglioma (HNPGLs). As free dopamine is incorporated in 
circulating platelets, we determined dopamine concentration in platelets in patients with a HNPGL.
Methods: A single center cohort study was performed between 2012 and 2014. Thirty-six patients 
with a HNPGL were compared with healthy controls (68 for dopamine in platelets and 120 for 
plasma 3-MT). 
Results: Dopamine concentration in platelets was elevated in HNPGL patients compared with 
healthy controls (median [interquartile ranges] 0.48 [0.32-0.82] pmol/109 platelets vs. 0.31 [0.24-
0.47] pmol/109 platelets; P<.05), whereas plasma 3-MT concentration  between both groups did 
not differ (0.06 [0.06-0.08] nmol/L vs. 0.06 [0.06-0.06] nmol/L; P=.119). Based on 68 healthy controls, 
the reference interval for dopamine concentration in platelets was 0.12-0.97 pmol/109 platelets. Six 
(16.7%) patients with a HNPGL demonstrated an increased dopamine concentration in platelets 
compared to three (8.3%) patients with an increased plasma 3-MT level (P=.053). The sensitivity 
and specificity were 16.7% and 98.5% for platelet dopamine and 8.3% and 97.5% for plasma 3-MT 
concentration (P=.37).
Conclusion: Dopamine concentration in platelets is elevated in patients with a HNPGL compared 
with healthy subjects, and may be a novel biomarker for dopamine producing paraganglioma.
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INTRODUCTION
Paraganglioma of the head and neck (HNPGL) are rare neuroendocrine tumors that arise from 
the parasympathetic nerve system1. HNPGLs may occur sporadically but are also associated with 
germline mutations mainly in genes encoding succinate dehydrogenase (SDH) subunit B and D 
(SDHB, SDHD)2,3. HNPGLs are most often benign tumors with a slow growth rate of about 1-2 mm/
year4,5.
The biochemical diagnosis of sympathetic paraganglioma and pheochromocytoma is based 
on the demonstration of elevated metanephrines in plasma and/or urine6. In contrast, elevated 
metanephrines can be detected only in a minority of patients with a HNPGL7. Therefore, there is a 
need for novel biochemical tests that would be useful for diagnosing HNPGLs, and for the follow-
up of these patients. Ideally, such a test would also facilitate early detection of a HNPGL, especially 
in SDHx mutation carriers. Previous studies have demonstrated that HNPGLs are able to synthesize 
dopamine. Excess dopamine secretion, measured as elevated dopamine and/or its 3-O-methylated 
metabolite 3-methoxytyramine (3-MT) in urine and/or plasma, was reported to be present in 19-
28% of patients with a HNPGL7-9. 
Nearly all circulating dopamine is stored in platelets, whereas reportedly only 1% circulates free 
in plasma10. Free dopamine is rapidly incorporated by circulating platelets through the dopamine 
transporter (DAT)11. As the lifespan of platelets is 8-10 days, the platelet dopamine concentration is 
a reflection of the dopamine secretion in the past 10 days11,12. This offers the theoretical advantage 
that intermittent secretion of dopamine by HNPGLs might be better detected by measurement of 
its concentration in platelets. 
For this report we tested the extent to which measurement of dopamine concentration in 
platelets represents a marker of dopamine overproduction. To this end we compared dopamine 
concentration in platelets with the dopamine metabolite 3-MT in plasma in patients with a HNPGL. 
PATIENTS AND METHODS
Study population
For this single center study, we included consecutive patients older than 18 years of age diagnosed 
with a HNPGL, who visited the outpatient clinic of the Department of Endocrinology and Metabolic 
diseases or the Department of Ear Nose and Throat at the University Medical Center Groningen 
between February 2012 and February 2014. We excluded patients  using selective serotonin 
reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), because these medications might 
decrease the uptake of dopamine in platelets13,14. In addition, dopamine can be depleted from 
platelets by blocking the dopamine uptake through the DAT by use of methylphenidate or illicit 
drugs such as amphetamine and cocaine15,16. We therefore excluded patients reporting the use 
of these substances.  We also excluded patients with concurrent sympathetic paraganglioma or 
pheochromocytoma.
The presence of a HNPGL was based on a combination of anatomical imaging CT and/
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or MRI and/or functional imaging including 111In-octreotide scintigraphy (octreoscan), 
123I-metaiodobenzylguanidine (MIBG scintigraphy) and/or 6-[18F]-fluoro-L-3,4-dihydroxy-
phenylalanine (DOPA) positron emission tomography (PET) (18F-DOPA PET)17.
Patients were seen by a (research) physician (T.E.O., A.N.A.v.H.S., M.N.K., R.P.F.D., T.P.L.), with 
specific attention to symptoms, medication use and family history. Blood pressure and pulse rate 
were manually measured while sitting. Hypertension was defined as a systolic blood pressure 
of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg or the use of anti-hypertensive 
medication. The medical history and results of germline mutation analyses were retrieved from 
patient’s medical files. Blood samples for dopamine in platelets and plasma free metanephrine (MN), 
normetanephrine (NMN) and 3-MT were collected simultaneously from patients in sitting position 
without prior dietary restrictions18. 
The research was conducted in accordance with the Declaration of Helsinki Principles and the 
study protocol was approved by the Medical Ethics committee of the University Medical Center of 
Groningen. Both patients and healthy controls gave written informed consent.
Reference Population
Reference values for plasma free 3-MT concentrations were determined in 120 healthy controls (63 
men and 57 women, 36-81 years of age) participating in the Prevention of Renal and Vascular End 
Stage Disease (PREVEND) study in sitting position without prior dietary restrictions19. 
Reference values for dopamine in blood platelets were established in a group of 68 healthy 
controls (35 men and 33 woman, 35-56 years of age). These healthy volunteers were recruited via 
the Department of Medical Oncology at the University Medical Center of Groningen.
Analytical methods
Blood samples were collected by venipuncture in two 10 mL Vacutainer Tubes (Becton Dickinson) 
containing K2EDTA solution as anticoagulant. To determine the dopamine concentration in blood 
platelets, plasma blood samples were centrifuged at 120 g for 30 minutes at an ambient temperature 
to get platelet rich plasma (PRP) within one hour after sample collection. In addition, a platelet count 
of PRP was determined before storing the samples at -80 °C until processing at the department of 
laboratory medicine. Glutathion was added as an antioxidant. PRP was transferred to storage tubes 
using plastic pipettes. 
After thawing, deuterium labeled dopamine was added as internal standard to PRP. Samples 
were subsequently derivatized, essentially as described by van de Merbel et al.20. After derivatization, 
samples were extracted and analyzed using solid phase extraction in combination with isotope 
dilution tandem mass spectrometry, essentially as described by van de Merbel et al.20. Plasma free 
serotonin was measured as an internal control for the integrity of the platelets. Results of platelet 
dopamine were obtained by dividing PRP dopamine concentration by the previously obtained 
platelet count. The intra-assay and inter-assay analytical variation coefficients were <5% and 12%, 
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respectively. The lower limit of quantification was 15 pmol/L. 
Plasma free MN, NMN and 3-MT assays were performed with a High-Performance Liquid 
Chromatography tandem mass spectrometric technique (LC-MS/MS) with automated solid phase 
extraction sample preparation, as previously described by de Jong et al.19;  the only modification 
was that the chromatography was optimized, so 3-MT was chromatographically separated from MN 
to prevent ionic cross talk as described by Twentyman et al.21,22. Established reference intervals for 
plasma free metanephrines were: MN 0.07-0.33 nmol/L, NMN 0.23-1.07 nmol/L, 3-MT <0.17 nmol/
L19. The lower limit of quantification of plasma 3-MT was 0.06 nmol/L. The intra-assay and inter-assay 
analytical variation coefficients were 2.5%-4.8% and 3.4%-5.6% for free plasma MN, 5.1%-6.2% and 
4.2%-7.1% for free plasma NMN, and 4.4%-8.0% and 4.5% -11.1% for free plasma 3-MT, respectively. 
Sample size calculation
Urinary or plasma 3-MT is increased in 19-28% of patients with a HNPGL7-9. Assuming that an 
additional 16.6% of HNPGL patients would have an abnormal test result when measuring dopamine 
concentration in blood platelets instead of plasma 3-MT (i.e. one in every 6 patients, which was 
deemed clinically relevant), the sample size that would be required to provide more than 80% 
power with a two-sided alpha-level of 0.05 was calculated to be 30 HNPGL patients (McNemar test).
Statistical analysis 
Data are presented as mean ±standard deviation (SD) or as median with interquartile ranges [IQR] 
where appropriate. Relationships between dopamine in platelet concentration and plasma free 
3-MT were evaluated by Spearman’s rank correlation analysis (Spearmans ρ). Reference intervals 
for platelet dopamine concentrations were calculated using EP EvaluatorTM software. Differences 
between HNPGL patients and healthy controls for dopamine concentration in platelets and plasma 
free 3-MT were evaluated using the Mann-Whitney U test. Based on the calculated reference values 
we calculated the sensitivity and specificity of both markers. With these reference values we also 
calculated the number of patients who had an elevated dopamine concentration in platelets and 
plasma free 3-MT and used a chi-square test for comparison. To test for a difference in sensitivity 
and specificity between dopamine concentration in platelets and plasma 3-MT, we used a McNemar 
test. Statistical analyses were performed with PASW statistics (version 22; IBM/SPSS, Armonk, New 
York). A two sided P value <.05 was considered statistically significant. 
RESULTS
Patient characteristics
Between February 2012 and February 2014, 36 HNPGL patients were included. Table 1 shows the 
characteristics of the participants included in the study. Free plasma MN and NMN concentrations 
were in the normal range for both patients with a HNPGL and healthy controls. Plasma free NMN 





Age, y (mean ±SD) 56±18
Tumor size [cm3 ±IQR] 2.1 [0.20-21]
Tumor location




Germline mutations, n (%)
None (sporadic) 14 (39)
Unknown 5 (14)
Familiar Syndrome 17 (47)
   VHL 1 (3)
   SDHA 1 (3)
   SDHB 10 (28)
   SDHD 4 (11)
   SDHAF2 1 (3)
Complaints, n (%)
   Headache 12 (33)
   Palpitations 12 (33)
   Perspiration 10 (28)
   Pallor 3 (8)
   Nausea 8 (22)
   Flushes 8 (22)
   Tiredness 14 (39)
   Anxiety attacks 3 (8)
   Tinnitus 18 (49)
   Impaired hearing  19 (52)
   Vertigo 12 (33)
   Dysphagia 8 (22)
   Hoarseness 7 (19)
Hemodynamic control
Mean BP (±SD, mmHg) 142 (±22)/83 (±8)
Mean pulse (±SD, beats/min) 71 (±12)
Hypertension, n (%) 24 (58)
Table 1. Patient characteristics
HNPGL, head and neck paraganglioma; y year; SD, standard deviation; IQR, interquartile range; VHL, von Hippel 
Lindau; SDHB, succinate dehydrogenase subunit B; SDHD, succinate dehydrogenase subunit D; SDHAF2, 
succinate dehydrogenase assembly factor 2; BP, blood pressure.
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with healthy controls 0.53 [0.41-0.70] nmol/L (P<.001) (Table 2). 
Dopamine in platelets and plasma free 3-MT in HNPGL patients 
The median value of dopamine in blood platelets was significantly higher in patients with a HNPGL, 
0.48 [0.32-0.82] pmol/109 platelets, compared with healthy controls 0.31 [0.24-0.47] pmol/109 
platelets (P<.05) (Table 2, Figure 1). Plasma free 3-MT concentrations in patients with a HNPGL, 0.06 
[0.06-0.08] nmol/L, were not significantly different from concentrations in healthy controls 0.06 
[0.06-0.06] nmol/L (P=.12) (Table 2, Figure 1). The median free plasma dopamine concentrations 
were not significantly different between patients with a HNPGL and healthy controls (P=.09) (Table 
2, Figure 1).
Based on 68 healthy controls, the calculated reference interval for dopamine concentration in 
platelets was 0.12-0.97 pmol/109 platelets. When using this reference interval, 6 (16.7%) patients 
HNPGL (N=36) Controls
Plasma free 3-MT (nmol/l) 0.06 [0.06-0.08] 0.06 [0.06-0.06]a
Plasma free NMN (nmol/l) 0.77 [0.59-1.02]c 0.53 [0.41-0.70]a
Plasma free MN (nmol/l) 0.21 [0.12-0.27] 0.18 [0.13-0.23] a
Dopamine in platelets (pmol/109 
platelets)
0.48 [0.32-0.82]d 0.31 [0.24-0.47]b
Plasma free dopamine (nmol/l) 55.6 [44.9-68.1] 51.1 [39.0-59.4]b
Table 2. Dopamine levels in platelets compared with plasma free metanephrine, normetanephrine and 3-me-
thoxytyramine (3-MT) 
Figure 1. Box plots whiskers representing 5 and 95 percentiles and outliers. Concentrations of platelet dopamine 
(A) and plasma free 3-methoxytyramine (3-MT) (B) in patients with a head and neck paraganglioma (HNPGL) and 
healthy controls. 
a Plasma free metanephrine, normetanephrine and 3-methoxytyramine levels of the reference population 
(n=120). b Dopamine concentrations in platelets and plasma free dopamine concentrations determined in 
healthy controls (n=68). Values are reported as median [interquartile range]. c P<.001 and d P<.05 compared with 
patients with a HNPGL. NMN, normetanephrine; MN, metanephrine; 3-MT, 3-methoxytyramine. 
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with a HNPGL had an increased dopamine concentration in platelets. In contrast, only three 
(8.3%) HNPGL patients showed an elevated plasma free 3-MT level (i.e.≥0.17 nmol/L) (P=.053). The 
calculated sensitivity and specificity were 16.7% and 98.5% for platelet dopamine concentration and 
8.3% and 97.5% for plasma 3-MT concentration (P=.37). For patients with a HNPGL, the Spearman’s 
correlation coefficient between dopamine levels in platelets and plasma free 3-MT was 0.19 (P= .29). 
Moreover, there was no relation between tumor size and dopamine concentration in platelets (ρs= 
0.05, P=.79).
DISCUSSION
In the present study, we show for the first time that dopamine concentration in blood platelets is 
significantly higher in patients with HNPGL than in healthy controls. 
Dopamine concentration in platelets has been measured previously only in patients with 
schizophrenia and in patients with migraine. Dopamine concentration in platelets is higher in 
patients with migraine compared with healthy controls12,23-25. The platelet dopamine concentration 
decreases during a migraine attack, which is accompanied by an increase of the plasma dopamine 
concentration25,26. In patients with schizophrenia, dopamine uptake in platelets did not differ from 
healthy controls23. 
Theoretically, measurement of platelet dopamine may represent a more sensitive method for 
detection of dopamine overproduction, because it is presumed to reflect the average exposure 
to plasma free dopamine during the preceding 8-10 days27. The transport of dopamine into the 
platelet is facilitated by the DAT11. Depending on the orientation of DAT (inward- or outward-
facing), dopamine can be transported either into or out of the platelet. After transportation into 
the cytoplasm, dopamine is taken up into dense granules by the vesicular monoamine transporter 
(VMAT) 2 until it is released by exocytosis (Figure 2)28-30. In this way platelets can take up circulating 
dopamine and serotonin released from the autonomic nerve endings and from dopamine secreting 
organs11. 
We demonstrate for the first time in patients with HNPGLs that dopamine in human blood 
platelets can be measured with sufficient accuracy, as the applied measurement has sufficient 
analytical sensitivity and specificity to reproducibly measure the analyte both in healthy controls 
and patients. Our report shows an elevated dopamine concentration in platelets from a relevant 
proportion of HNPGL patients and should be regarded as a proof of concept study. Increased 
plasma free 3-MT concentrations were already demonstrated in previous studies. In our population, 
the dopamine concentration in platelets was more often increased, compared with the plasma 
free 3-MT concentration, 16.7% vs. 8.3% respectively. This seems at variance with the study by van 
Duinen et al.9, who found an increase of plasma free 3-MT in 28% of their patients with a HNPGL. 
This difference is probably explained by a difference in study population, as the study by van Duinen 
et al.9 consisted predominantly of SDHx associated mutation carriers (95 out of 124; 77%), while 
in our study only 16 out of 36 had a SDHx associated mutation (44%). Dopamine production has 
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been shown to be particularly prevalent among SDHB and SDHD mutation carriers, compared with 
SDHx negative patients31. This could be the result of an indirect stimulatory effect of SDHx mutations 
on the tyrosine hydroxylase enzyme activity, which is the rate-limiting enzyme in the dopamine 
synthesis pathway32,33.
Although dopamine concentrations in platelets were significantly higher in HNPGL patients 
than in healthy controls, their diagnostic sensitivity was not significantly different from plasma free 
3-MT. This could also be the consequence of our power analysis, as the percentage of patients with 
an increased plasma free 3-MT concentration was found to be lower than we expected. It should, 
therefore, be emphasized that further studies are needed to evaluate whether the combined 
measurement of dopamine in platelets and free 3-MT in plasma, both with high diagnostic specificity 
but with apparently low sensitivity, would improve biochemical characterization of patients with a 
suspected HNPGL. Specifically, the usefulness of measurement of dopamine in platelets in the (post-
treatment) follow-up of HNPGL patients, as well as in the characterization of SDHx mutation carriers, 
must still  be established. Moreover, dopamine in platelets might also be used as a tumor marker for 
postsurgical follow-up in patients with a HNPGL or pheochromocytoma.
In addition, we did not find any differences in free plasma dopamine levels between patients and 
healthy controls. In our study we noticed a higher percentage of plasma free dopamine (31±21%) 
Figure 2. Uptake and exocytosis of dopamine in platelets. 
The transport of dopamine into the platelet is facilitated by the dopamine transporter (DAT). After transportation 
into the cytoplasm, dopamine is taken up by dense granules through the vesicular monoamine transporter 




compared with the previously described 1% by in the study by Da Prada and Picotti10. The difference 
in distribution of dopamine between platelets and plasma between the two studies could be 
explained by the use of different analytical methods, as we used mass spectrometric detection 
whereas Da Prada used a radioenzymatic assay. The suitability of our pre-analytical procedure has 
previously been established for serotonin34.
In conclusion, platelet dopamine concentrations are increased in patients with HNPGL 
compared with healthy controls. Further studies are warranted in order to determine the diagnostic 
value of the measurement of dopamine concentration in platelets in patients with a HNPGL, 
pheochromocytoma, sympathetic PGL and in SDHx mutation carriers.
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Pheochromocytoma (PCCs) and sympathetic paraganglioma (PGLs) are rare neuroendocrine 
tumors that derive from chromaffin cells in the adrenal medulla and sympathetic paraganglia. 
These often benign tumors are characterized by the secretion of catecholamines, i.e. epinephrine, 
norepinephrine and dopamine. Parasympathetic PGLs are located in the head and neck region, and 
are called head and neck paraganglioma (HNPGLs). In HNPGLs the secretion of catecholamines has 
only been described in a minority of up to 28% of patients1,2. The diagnosis of a PCC/PGL can be 
made by measuring an increased level of the metabolites of metanephrine (MN), normetanephrine 
(NMN) and 3-methoxytyramine (3-MT) in plasma and/or urine. The measurement of the plasma free 
metanephrines are the most accurate method to diagnose PCCs/PGLs, however, the measurement 
can be influenced by several pre-analytical factors, such as position, certain drugs and previous 
adrenalectomy. To eliminate falsely positive results, the Endocrine Society recommends that 
patients rest for 20-30 minutes in a supine position before blood sampling. For the determination of 
plasma 3-MT overnight fasting is recommended3. 
In approximately 40% of patients diagnosed with a PCC/PGL an underlying gene mutation 
has been established4,5. Especially gene mutations in the succinate dehydrogenase (SDH) subunit 
B (SDHB) and subunit D (SDHD) are frequently found. The penetrance of a PCC in SDHB mutation 
carriers ranges from 8-55%6-9. Therefore, the Dutch national guidelines recommend to screen SDHB, 
SDHC and paternally inherited SDHD and SDHAF2 mutation carriers from the age of 18 for the 
development of PCCs/PGLs, starting from the age of 1810. The screening of SDHB mutation carriers 
includes ENT-investigations, yearly measurements of plasma and/or urine metanephrines, once 
every three years conventional imaging with MRI scans of the head and neck region and biennial 
MRI scans of the thorax, abdomen and pelvis. The screening of SDHD mutation carriers includes ENT-
investigations, biennial measurements of metanephrines in plasma and/or urine and imaging with 
MRI scans in case of excess catecholamine secretion. 
Resection of the tumor is the only option for curative treatment of patients with a PCC/PGL. 
Both during the anesthetic induction and the operation an excessive release of catecholamines can 
be evoked by the tumor, resulting in a hypertensive crisis, cardiac arrhythmia, respiratory edema, 
and ischemic heart disease. To prevent these complications, perioperative blockade with α- and 
β-receptor blockers before surgery is advised. After operation, long-term follow-up is recommended. 
Recurrence rates of 17% within 10 years after surgery have been described. 
The aim of this thesis was to improve the current diagnostic procedure of patients with PCCs/
PGLs and to explore new biochemical markers and methods. 
In chapter 1 a general introduction and the aims and outlines of the thesis are presented. 
In chapter 2 we retrospectively describe the results of plasma MN and NMN in 70 patients who 
underwent unilateral adrenalectomy and 24 patients who underwent bilateral adrenalectomy 
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because of a PCC. Urinary and plasma MN concentrations 3 to 6 months after unilateral 
adrenalectomy were lower compared to the reference population with two adrenal glands. Urinary 
MN concentrations were even lower after bilateral adrenalectomy compared to healthy controls. 
Urinary and plasma NMN were both higher after unilateral and bilateral adrenalectomy. From this 
study we concluded that concentrations of MN are lower, whereas NMN concentrations are higher 
after unilateral and bilateral adrenalectomy. Therefore, we recommend that adjusted reference 
values for plasma and urine MN and NMN are needed in the postsurgical follow-up of patients with 
resected PCC.
In chapter 3, we prospectively studied the influence of frequently prescribed antihypertensive 
drugs (i.e. β-blockers, thiazide diuretics and angiotensin-converting enzyme (ACE) inhibitors) on 
the plasma MN and NMN concentration. Thirty-nine patients with recently diagnosed hypertension 
that had not yet started with antihypertensive therapy were included. The plasma MN and NMN 
concentrations were determined with liquid chromatography with tandem mass spectrometry (LC-
MS/MS) before and one month after the start of the antihypertensive medication. No physiological 
or analytical interference was found on the plasma free MN and NMN concentrations. Our results 
show that, contrary to current assumptions, it is not necessary to stop antihypertensive medication 
before determining plasma MN and NMN in patients suspected with PCCs/PGLs when determined 
with LC-MS/MS. 
In chapter 4 we aimed to determine whether SDHB and SDHD gene mutations in patients with 
PCCs/PGLs could be determined using a saliva sample. Paired blood and saliva samples were 
collected from 30 patients. Total yields from blood DNA were similar to those obtained from 
saliva DNA. The purity of the saliva DNA samples was lower than that of blood, indicating more 
protein contamination in the saliva-extracted DNA. The results of this study show that salivary DNA 
collected from patients with PCCs/PGLs is a good alternative for extraction of genomic DNA for its 
high concentration and acceptable purity. Moreover, saliva collection is less expensive, noninvasive 
and easy to obtain which is particular important in children, and can even be collected from home. 
We propose the use of DNA extracted from saliva in the screening for children with a risk of a SDHB 
and SDHD mutation.
In chapter 5 we describe a patient with an intestinal pseudo-obstruction caused by excessive 
catecholamine production from a malignant PGL. We provide a literature overview of 34 cases. 
Intravenous administration of phentolamine is the most frequently described treatment when 
surgical resection of the tumor is not feasible. We conclude that intestinal pseudo-obstruction is a 
rare but potential life-threatening complication of PCCs/PGLs.
In chapter 6 we describe a pilot study in which we determined MN, NMN and 3-MT in saliva of 
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healthy controls and compared the results to the simultaneously measured plasma levels analyzed 
with LC-MS/MS. In addition, we looked at the possible influence of pre-analytical conditions such as 
use of a collection device (with or without the use of a salivette), posture (supine or seated position), 
and eating (fasting or 30 minutes after eating) on the salivary metanephrine levels. Metanephrines 
were detectable in saliva from all participants both in seated and supine position. We found no 
difference between MN, NMN and 3-MT samples collected with or without a collection device and 
no significant correlation between the MN, NMN and 3-MT concentrations in saliva and plasma in 
seated or supine position. The MN and NMN concentrations in saliva after eating were lower than the 
fasting levels, probably due to dilution caused by increased saliva production. From this study we 
concluded that metanephrines can be detected in saliva with LC-MS/MS with sufficient sensitivity 
and precision. Our findings warrant evaluation of salivary metanephrine measurement in the work-
up of patients suspected of having a PCC. 
In chapter 7 we discuss the role of dopamine in the angiogenesis pathway and the contradicting 
relation between neuroendocrine tumor dopamine production and tumor behavior. On the one 
hand dopamine inhibits angiogenesis and on the other hand an increased dopamine concentration 
is found in patients with malignant PCCs/PGLs. Dopamine acts both as a neurotransmitter and 
as a hormone, exerting its function via dopamine receptors that are present in a broad variety of 
organs and systems. Circulating dopamine is primarily stored in and transported by blood platelets. 
Recently, the important contribution of dopamine in the regulation of angiogenesis has been 
recognized. Dopamine mediated activation of the D2-receptor inhibits endothelial cell proliferation, 
vascularization and tumor growth. In vitro and in vivo studies have shown that dopamine counteracts 
the actions of HIF-α and VEGF by blocking the phosphorylation of the vascular endothelial factor 
(VEGF)-2 receptor through activation of the dopamine D2-receptor. These effects seem to be lost in 
PCCs/PGL. In these tumors, the production of dopamine is an independent predictor for malignancy. 
Neoplasms may circumvent the actions of dopamine by reducing sympathetic nervous activity or 
by lowering the concentration of dopamine D2-receptor binding sites. Remarkably, little is known 
about the role of dopamine in the development and progression of catecholamine secreting PCCs/
PGLs. Although there is an increased dopamine synthesis and secretion in patients with SDHB- and 
SDHD-related PCCs/PGLs, these tumors are more often multiple and more aggressive. SDHx-related 
gene mutations in PCCs/PGLs might be associated with a decreased concentration of D2-receptors. 
This is most likely caused by DNA hypermethylation of the D2-receptor genes due to succinate 
accumulation. This could be an explanation for the multiple and more malignant tumors in patients 
with SDHB-related genotypes, despite the dopamine overproduction in these tumor types.
In chapter 8 we describe the immunohistochemical staining of 19 HNPGLs tissues for the presence 
of catecholamine-synthesizing enzymes, i.e. tyrosine hydroxylase (TH), aromatic L-amino acid 
decarboxylase (AADC) and dopamine β-hydroxylase (DBH). All tumors stained positive for AADC, 
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six (32%) for TH and two (11%) for DBH. Catecholamine excess was only present in one patient. The 
tissue of this single patient showed only positive staining for AADC. From this study we concluded 
that catecholamine synthesizing enzymes, in particular AADC, are expressed in the majority of 
HNPGL tissues. The immunohistochemical staining pattern of AADC, DBH and TH in HNPGL tissues is 
compatible with the biochemical catecholamine secretion profile, i.e. predominantly hypersecretion 
of dopamine, whereas hypersecretion of norepinephrine only occurs in rare instances.
In chapter 9 we demonstrated dopamine excess measured as elevated 3-MT concentrations and/or 
dopamine concentrations in urine or plasma in seven out of 36 patients (19.4%). Dopamine excess 
was unrelated to clinical signs and symptoms. 123I-MIBG uptake was associated with dopamine 
excess. 
As free dopamine is incorporated in circulating platelets, in chapter 10 we determined the 
dopamine concentration in platelets and the plasma 3-MT concentrations in 36 patients with 
HNPGL. The concentration of dopamine in blood platelets of these patients was compared with 
healthy controls (68 for dopamine in platelets and 120 for plasma 3-MT). In literature, plasma 3-MT 
has described to be elevated in up to 28% of patient with HNPGL. The dopamine concentration in 
platelets was elevated in patients with HNPGL compared to healthy controls, whereas plasma 3-MT 
did not differ between both groups. Six (16.7%) patients with HNPGLs demonstrated an increased 
dopamine concentration in platelets compared to three (8.3%) patients with an increased plasma 
3-MT level. In this study, we demonstrated that dopamine in platelets is elevated in patients with 
HNPGL compared to healthy subjects and that this could be a novel biomarker for dopamine 
producing PGL. 
DISCUSSION AND FUTURE PERSPECTIVES
Optimizing current diagnostics for HNPGLs
In this thesis, we explored several biochemical strategies in the diagnosis of PCC/PGL with a focus on 
dopamine. Improvement of biochemical tools could lead to earlier detection of HNPGLs. Currently, 
there is no optimal biochemical test to diagnose these tumors, since elevated catecholamine and/or 
metanephrine concentrations are only found in a minority of the patients. One approach to enhance 
the potential of biochemical methods is to increase the sensitivity and specificity of analytical 
methods. Improvements in the LC-MS/MS assay enable simultaneous specific quantification of 
metabolically related compound at pmol level. In addition, better knowledge about pre-analytical 
factors such as use of medication, position during blood sampling and diet, will lead to more 
accurate interpretation of biomarker values. The improvement of the analytical sensitivity, however, 
has a limit as only signals that exceed the background biological variation can be reliably quantified. 
Therefore, a challenging and alternative approach is to more broadly scan the aberrant biological 
background of malignant neuroendocrine cells. This approach can lead to the development of more 
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accurate biochemical marker panels. We have shown that all HNPGL tissues stained positive for 
AADC, the enzyme converting L-DOPA to dopamine. In addition, one third of these tissues showed 
combined positive staining of both TH and AADC, although an increased plasma MN concentration 
was only present in one patient. The disparity between the tissue staining and the dopamine 
production could be a result of the relative insensitivity of the plasma 3-MT assay. It could also be 
that only a limited percentage of the HNPGLs are endocrine active, or a slightly elevated dopamine 
production in all patients with HNPGLs could be present, too small for the current assay to detect. 
Then it would be difficult to detect tumor derived dopamine overproduction against a background 
of normal dopamine production.  
The immunohistochemical results showed that HNPGLs could be capable of synthesizing 
dopamine. This let to the idea that dopamine in platelets could be a promising marker for patients 
with HNPGLs. In our study population, there was a 2-fold increase of dopamine concentration 
in platelets in patients with HNPGLs compared to plasma 3-MT (16.7% vs. 8.3%). These results 
underscore that measuring the dopamine concentration in platelets can be of complementary value 
in the biochemical diagnosis of a HNPGL. Due to the high specificities, the combined measurement 
of dopamine in platelets and free 3-MT in plasma could have particular additional value for patients 
in which a HNPGL has to be ruled out. 
In contrast to dopamine synthesis, the positive staining for AADC in 100% of HNPGL tissues 
could also imply that HNPGLs secrete serotonin. Tryptophan is converted to 5-hydroxytryptophan 
(5-HTP) by tryptophan hydroxylase, the rate limiting step in serotonin synthesis, thereafter, AADC 
converts to 5-hydroxytryptamine (5-HT, also called serotonin). If both tryptophan hydroxylase and 
AADC could be detected in HNPGL tissue, serotonin could be elevated in patients with HNPGL. 
Although, increased serotonin production, measured as its metabolite 5-hydroxyindolacetic acid (5-
HIAA) in urine, was not detectable in patients with HNPGLs11, platelet serotonin content, however, is 
a more sensitive marker for the detection of serotonin overproduction12. It would be of interest both 
from pathophysiological and clinical point of view to evaluate tryptophan hydroxylase staining in 
HNPGL tissue, serotonin related symptoms and platelet serotonin concentration in patients with 
HNPGLs13. However comparable to dopamine overproduction, it will be difficult to detect tumor 
derived serotonin overproduction against a background of normal serotonin production.
Increasing knowledge of genetics is another field to expect and find promising new biomarkers. 
Identification of a molecular fingerprint by measuring the transcript levels of mRNA from plasma 
using PCR-amplification, has successfully been undertaken in other cancers such as breast, colon 
and gastroenteropancreatic neuroendocrine tumors (GEP-NETs)14,15. In GEP-NETs this molecular 
signature test is based on 51 genes and identifies GEP-NETs with a high specificity and sensitivity16. 
Furthermore, tissue microarrays might be used for genetic tumor profiling and could be used as a 
predictor of malignancy in PGLs17. Identification of relevant tumor specific target genes is needed to 
identify mRNA transcripts that could be used for genetic based diagnosis of patients with PCC/PGLs. 
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Optimizing screening for HNPGLs in SDHx mutation carriers 
Since 2000 the discovery of new genetic mutations, there has been a large increase of mostly 
asymptomatic SDHx mutation carriers coming to the outpatient clinic to be screened for HNPGLs, 
PCC and sympathetic PGLs. Inclusion of index patients has most likely led to overestimation of the 
penetrance of disease8,9. This could have led to an ‘over’ extensive screening program. Observations 
from our clinic show that in 83 SDHB mutation carriers only 5 new manifestations were detected 
after a screening period of 1.9 years, all HNPGLs. Thirty-five percent of SHDB mutation carriers 
developed a manifestation of disease at the age of 60, while other studies describe a percentage 
of 8-55% of SDHB mutation carriers that develop a manifestation of disease at the age of 406-8,18. 
All new manifestations in our patient group were HNPGLs, which are most often slowly growing, 
hormonal inactive tumors. In addition, our study suggest that the screening for HNPGLs in SDHB 
mutation carriers could start at an older age (24 years instead of 18 years of age), which would result 
in a significant decrease in financial costs and hospital visits for the patient19. 
Depending on the mutation status of the patient, most HNPGLs are slow growing (1-2 mm/y) 
or do not show any growth at all20,21. Since the majority of the HNPGLs are apparently nonsecreting, 
they are often only revealed by the presence of a mass and/or specific local symptom (e.g., hearing 
loss, tinnitus, cervical mass, dysphagia, cranial nerve palsies) or detected on imaging studies. 
Therefore, a ‘wait-and-scan’ policy with MRI is suggested as a primary option when a HNPGL is 
diagnosed, to establish the growth pattern22. Based on this, the question rises if intensive screening 
and early detection of the tumor is really in the patient’s best interest. The Dutch Health Council has 
published a report about the principles for responsible screening. First of all, the disease should be 
a significant health problem and the early detection of the disease should be of important benefit. 
Second, the screening should be based on free choice of the individual and respect for autonomy 
is important. Finally, the use of healthcare resources should be cost-effective and appropriate23. 
With regard to screening for HNPGLs, screening criteria could be fulfilled. Waiting until patients 
suffer from symptoms of a HNPGL will lead to the detection of the tumors at a late stage with no or 
limited treatment options. A ‘wait-and-scan’ policy can help to define the optimal timeframe for the 
surgical removal of the tumor balanced with the minimal chance of complications and irreversible 
damage to the surrounding tissues. Determining the mutation status and growth rate of the tumor 
is a cumbersome way to distinguish between aggressive and nonaggressive tumors. Making the 
difference between aggressive and nonaggressive tumors could benefit from a very sensitive 
biochemical marker. An elevated plasma 3-MT has been identified as an independent risk factor 
for malignancy, but does not have a high enough diagnostic accuracy24. Future studies will need 
to evaluate the current screening for SDHx mutation carriers, especially the age to start screening, 
identify markers to distinguish aggressive and nonaggressive tumors, the imaging method used for 
the screening (e.g. anatomical vs. functional) and the interval of screening.
156
Chapter 11
Genotype-specific imaging phenotypes for patients with PCC/PGLs 
Currently, in 40% of patients with a PCC/PGL a mutation is found. The increasing knowledge of the 
genetic background of PCC/PGLs has directed the use of specific imaging tracers13. An example is 
the 18F-FDG PET scan in SDHx related PCC/PGLs. Several studies have shown that 18F-FDG PET/CT has 
a very high sensitivity for SDHx germline and VHL mutations in comparison to multiple endocrine 
neoplasia (MEN) type 2 related PCCs, regardless of tumor location25-28. Decreased SDH and VHL 
protein activity results in a decreased degradation of the hypoxic angiogenesis pathway via HIFs-1α 
and HIF-2α. As a result increased transcription in HIF-1α and HIF-2α genes occurs, which are involved 
in glucose metabolism (glucose transporters (GLUTs) and hexokinases (HK)). Similar to glucose, 
18F-FDG is taken up by tumor cells mostly via facilitative transport by GLUTs and phosphorylated 
by HKs into 18F-FDG-6-P, which accumulates in the cell. A significantly higher HK-2 gene expression 
was observed in SDHx-related PCC/PGLs, compared to NF1- and RET-related PCC/PGLs29,30. From all 
these data, it can be concluded that 18F-FDG is the best tracer to use in patients with SDHx-related 
PCC/PGLs. 
Recently, utility of [68GA]-DOTATATE PET/CT also showed a very high detection rate in SDHB-
related metastatic PCC/PGLs. This imaging modality could lead to earlier detection of metastatic 
disease, and could also be useful for peptide receptor radionuclide therapy for malignant PCC/
PGLs31.
New treatment options for malignant PGLs
The treatment options of malignant PCC/PGLs are limited. Currently, there is no effective treatment 
for malignant PCC. Extensive surgical debulking of the tumor tissue is the first approach of 
malignant PGLs to improve symptoms and survival32. In addition, treatment with chemotherapy 
(cyclophosphamide, vincristine and doxorubicin (CVD)) and radionuclide therapy with either 
131I-MIBG or radiolabelled somatostatin analogues can be considered. Peptide receptor radionuclide 
therapy with radiolabelled somatostatin analogues offers new treatment options. Response rates 
of these therapeutic approaches vary. A (partial) tumor response of approximately 24-45% can be 
achieved by 131I-MIBG33,34. The improvement of the uptake of 123I-MIBG in the tumor cells could lead to 
an increase in tumor response and more successful 131I-MIBG treatment. Treatment with the histone 
deacetylase inhibitor romidepsin has shown some promising results on the uptake of 123I-MIBG in 
mouse PCC cells35. The possible benefit of romidepsin pretreatment on the uptake of 123I-MIBG in 
patients with metastatic PGLs still needs to be investigated. However, 131I-MIBG and 111In-octreotide 
treatment is only possible in patients with uptake of 123I-MIBG or radiolabelled somatostatin 
analogues. In addition, treatment with 131I-MIBG and 111In-octreotide is limited due to a maximum 
radiation dose, because of long term complications that can occur such as hypothyroidism and 
secondary leukemia or myelodysplasia36. A pilot study using a combined treatment protocol with 
[90Y]DOTA-TATE and [177LU]DOTA-TATE showed that this is a feasible and well tolerated therapeutic 
option for patients with metastatic neuroendocrine tumors with progressive disease that were 
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refractory to conventional therapy37. 
Other examples of new therapies are inhibitors of vascular endothelial growth factor (VEGF), 
mammalian Target of Rapamycin (mTOR), heat shock protein 90 (Hsp90) inhibitors, agents that 
restore of activated PHD enzyme activity38,39. Most of these new treatment options are currently 
evaluated in phase 1 and phase 2 clinical trials, and will also need to be examined in patients with 
PCCs/PGL. Theoretically, HIF-2α inhibitors and hypomethylating agents could also play a role in the 
treatment of malignant PCCs/PGLs, but currently no such agents are known.
Optimizing patient comfort
The effect of screening and diagnostic procedures on mutation carriers and PCC/PGL patients is 
generally underexposed. Although there is still limited data about the effect on screening for the 
mutation carriers, the quality of life in asymptomatic SDHx mutation carriers and asymptomatic 
patients with HNPGLs seems not the be decreased compared to the general population40. However, 
there is still need to reduce the amount of diagnostic procedures or and to make them as comfortable 
as possible. This should be something to strive for. First of all, the increase of the accessibility of 
diagnostic procedures will support its use and may contribute to the patients comfort. We showed 
that measurement of MN, NMN and 3-MT, as well as SDHx genetic testing can be performed using 
saliva instead of plasma, with high quality promising results. This approach offers several advantages 
for clinical practice. It is noninvasive and free of venipuncture related side effects such as pain or 
hematoma formation. In addition, metanephrine measurements can be readily repeated at various 
intervals and samples can be collected at home, which is likely to be more cost-effective compared 
to in-hospital venipuncture41. Furthermore, measurement of saliva would be particular suitable for 
children as well as for periodic screening in patients with a hereditary PCC/PGL. Future studies with a 
large amount of patients with PCCs/PGLs and healthy subjects will need to be conducted to further 
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Feochromocytomen en sympathische paragangliomen zijn zeldzame neuroendocrine tumoren 
die ontstaan uit chromafine cellen in het bijniermerg en in de sympathische paraganglia. 
Deze voornamelijk goedaardige tumoren worden gekarakteriseerd door het uitscheiden van 
catecholamines. Parasympathische paragangliomen ontstaan in parasympathische paraganglia die 
voornamelijk in de hoofd-hals regio aanwezig zijn, en worden hoofd-hals paragangliomen genoemd. 
Bij hoofd-hals paragangliomen is maar bij 28% van de patiënten secretie van catecholamines 
beschreven1,2. De diagnose feochromocytoom of sympathisch paraganglioom daarentegen wordt 
primair gesteld door het vaststellen van een verhoogde concentratie van metanefrine, normetanefrine 
en 3-methoxytyramine (3-MT) in het plasma en/of de urine. Dit zijn de metabole eindproducten 
van adrenaline, noradrenaline en dopamine. Het meten van de vrije metanefrine concentratie in 
plasma is op dit moment de meest gevoelige methode om een feochromocytoom of sympathisch 
paraganglioom aan te tonen. Echter, deze plasma metanefrine meting kan beïnvloed worden door 
pre-analytische factoren, zoals de houding tijdens bloedafname, bepaalde medicamenten en het 
reeds hebben ondergaan van een adrenalectomie. Om de kans op fout-positieve resultaten zo 
klein mogelijk te maken, wordt door de Endocrine Society, de wetenschappelijke vereniging voor 
endocrinologen in Amerika, aanbevolen om patiënten voorafgaand aan de bloedafname 20-30 
minuten te laten rusten en bloed af te nemen in een liggende houding. Voor de bepaling van het 
plasma 3-MT wordt een nuchtere bloedafname geadviseerd3. 
In ongeveer 40% van de patiënten bij wie een feochromocytoom of paraganglioom wordt 
vastgesteld, blijkt er sprake te zijn van een erfelijke aanleg op basis van DNA veranderingen; een 
zogenaamde genmutatie in het erfelijk materiaal4,5. Mutaties in het gen coderend voor succinate 
dehydrogenase (SDH) subunit B (SDHB) en subunit D (SDHD) zijn het meest voorkomend. Andersom 
hebben mensen die drager zijn van een SDHB mutatie een kans tussen de 8-55% op het ontwikkelen 
van een feochromocytoom6-9. Daarom adviseert de Nederlandse Stichting Opsporing Erfelijke 
Tumoren (StOET) om SDHB, SDHC en paternaal overgeërfde SDHD en SDHAF2 mutatiedragers vanaf 
18 jarige leeftijd te screenen op de aanwezigheid van een feochromocytoom of paraganglioom10. 
De screening van SDHB mutatiedragers omvat KNO-onderzoek, jaarlijks meten van de plasma en/
of urine metanefrines en één keer per drie jaar conventionele beeldvorming middels MRI scans van 
het hoofd-hals gebied, en tweejaarlijks een MRI van de thorax, het abdomen en het bekken. De 
screening van SDHD mutatiedragers omvat KNO-onderzoek, tweejaarlijks meten van  metanefrines 
in plasma en/of urine en beeldvormend onderzoek indien een verhoogde catecholamine 
concentratie gemeten wordt.
Chirurgische verwijdering van de tumor is de enige curatieve behandel mogelijkheid voor 
patiënten met een feochromocytoom of paraganglioom. Zowel tijdens de inleiding van de 
anesthesie alsook tijdens de operatie, kan er een overmatige afgifte van catecholamines door 
de tumor plaatsvinden, hetgeen kan leiden tot een hypertensieve crisis, hartritme stoornissen, 
longoedeem of myocard ischemie. Om deze complicaties te voorkomen wordt in Nederland 
163
Nederlandse samenvatting
standaard gestart met α-blokkers en β-blokkers voor de operatie. Na chirurgische verwijdering van 
de tumor wordt langdurige poliklinische controle aangeraden, omdat bij 17% van de patiënten een 
tumorrecidief kan optreden.
Dit proefschrift heeft als doel de huidige diagnostische procedures voor patiënten met een 
feochromocytoom of paraganglioom te optimaliseren en nieuwe biochemische markers en 
methoden te onderzoeken.
In hoofdstuk 1 wordt een algemene introductie van het onderwerp gegeven en het doel en de 
opzet van het proefschrift gepresenteerd. 
In hoofdstuk 2 beschrijven we in een retrospectieve studie de plasma metanefrine en normetanefrine 
concentraties in patiënten die vanwege een feochromocytoom een adrenalectomie hebben 
ondergaan (70 patiënten een enkelzijdige en 24 patiënten een dubbelzijdige bijnierverwijdering). 
Drie tot zes maanden na enkelzijdige (unilaterale) adrenalectomie waren urine en plasma metanefrine 
concentraties lager in vergelijking met de referentie populatie met gezonde controles met twee 
normale bijnieren. De metanefrine concentratie in de urine van patiënten na een dubbelzijdige 
(bilaterale) adrenalectomie was nog lager in vergelijking met de gezonde controles. De urine en 
plasma normetanefrine concentraties waren hoger zowel na enkelzijdige adrenalectomie als na 
dubbelzijdige adrenalectomie. Uit de resultaten van deze studie concludeerden we dat metanefrine 
concentraties dalen, terwijl normetanefrine concentraties stijgen na enkelzijdige en dubbelzijdige 
adrenalectomie. Het is daarom belangrijk aangepaste referentie waarden op te stellen voor plasma 
en urine metanefrine en normetanefrine concentraties voor de postoperatieve controle van 
patiënten van een feochromocytoom.
In hoofdstuk 3 hebben we prospectief onderzocht wat de invloed van frequent voorgeschreven 
antihypertensiva (β-blokkers, thiazide diuretica en angiotensine-omzettend enzym (ACE) remmers) 
op de plasma metanefrine en normetanefrine concentraties is. Negenendertig patiënten werden 
geïncludeerd bij wie recent hypertensie was vastgesteld en bij wie de behandeling nog niet 
was gestart. De plasma metanefrine en normetanefrine concentraties werden bepaald met de 
vloeistofchromatografie met tandem massaspectrometrie (LC-MS/MS techniek) voorafgaand 
en één maand na de start van het antihypertensieve medicatie. Er werd geen fysiologische of 
analytische interferentie gevonden op de plasma metanefrine en normetanefrine concentratie. 
Onze resultaten tonen aan dat het niet nodig is om de antihypertensive medicatie te stoppen 
voor de bepaling van plasma metanefrine en normetanefrine bij patiënten tijdens de diagnostiek 
naar een feochromocytoom of paraganglioom, als deze bepaling gedaan wordt met de LC-MS/MS 
methode.
In hoofdstuk 4 was het doel om te bepalen of SDHB en SDHD gen mutaties kunnen worden 
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vastgesteld in het speeksel van patiënten met een feochromocytoom of paraganglioom. Bij 30 
patiënten werden tegelijkertijd bloed- en speekselmonsters verzameld. De totale DNA opbrengst 
uit het bloed was vergelijkbaar met de DNA opbrengst uit speeksel. De zuiverheid van DNA monster 
uit speeksel was lager dan het DNA monster uit bloed. Dit wijst er op dat er in het speeksel monster 
meer vervuiling door eiwit optreedt, maar uiteindelijk beïnvloedde dit niet de mutatieanalyse. De 
resultaten van deze studie laten zien dat speeksel DNA in patiënten met een feochromocytoom 
of paragangliomen een goed alternatief is voor de extractie van DNA vanwege de hoge DNA 
concentratie en acceptabele zuiverheid. Daarnaast is een speeksel monster minder duur, niet 
invasief en makkelijker af te nemen, wat met name van belang is bij kinderen. Eventueel kan het 
monster zelfs thuis worden verzameld. We stellen voor om DNA geëxtraheerd uit speeksel te 
gebruiken in de screening van kinderen met een risico op een SDHB of SDHD mutatie.
In hoofdstuk 5 beschrijven we een patiënt met een intestinale pseudo-obstructie veroorzaakt door 
overmatige catecholamine productie door een maligne paraganglioom en geven we een overzicht 
van de 34 casus die in de literatuur zijn beschreven. Intraveneuze toediening van fentolamine 
wordt het meest toegepast bij een pseudo-obstructie als een chirurgische resectie van de tumor 
niet mogelijk is. We concluderen dat intestinale pseudo-obstructie een zeldzame maar potentieel 
levensbedreigende complicatie is van een feochromocytoom of paraganglioom.
In hoofdstuk 6 beschrijven we een pilot studie waarin in gelijktijdig afgenomen speeksel en 
plasma monsters van gezonde controles de metanefrine, normetanefrine en 3-MT concentraties 
worden vergeleken. De metanefrine, normetanefrine en 3-MT concentraties in speeksel werden 
geanalyseerd met de LC-MS/MS methode. Daarnaast hebben we gekeken naar de mogelijke 
invloed van pre-analytische factoren op de speeksel metanefrine concentraties, zoals het gebruik 
van een hulpmiddel (een wattenstaafje) voor het verzamelen van het speeksel, de houding 
(liggende of zittend) en eten (nuchter of 30 minuten na voedsel inname). Metanefrines konden 
worden aangetoond in het speeksel van alle deelnemers, in zowel zittende als liggende houding. 
We vonden geen verschil tussen metanefrine, normetanefrine en 3-MT concentraties in speeksel 
afgenomen met of zonder hulpmiddel en geen significante correlatie tussen de metanefrine, 
normetanefrine en 3-MT concentraties in speeksel en plasma in zittende of liggende houding. De 
metanefrine en normetanefrine concentraties in speeksel na eten waren lager dan de nuchtere 
waarden, waarschijnlijk door verdunning bij verhoogde speekselproductie. In deze studie hebben 
we geconcludeerd dat speeksel metanefrines met voldoende sensitiviteit en precisie gemeten 
kunnen worden met LC-MS/MS. Deze resultaten onderschrijven dat verder onderzoek naar waarde 
van speeksel metanefrine metingen in de diagnostische work-up voor een feochromocytoom 
zinvol is.
In hoofdstuk 7 worden van de verschillende werkingsmechanismen van dopamine besproken. 
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Enerzijds remt dopamine de vaatnieuwvorming (angiogenese) en anderzijds wordt een verhoogde 
dopamine concentratie gevonden bij maligne feochromocytomen en paragangliomen. Dopamine 
werkt zowel als een neurotransmitter en een hormoon. Het oefent zijn functie uit via dopamine 
receptoren die aanwezig zijn in een groot aantal organen en weefsels. Circulerend dopamine wordt 
primair opgeslagen in en getransporteerd door bloedplaatjes. Onlangs is vastgesteld dat dopamine 
een belangrijke rol speelt in de regulatie van de angiogenese. Dopamine gemedieerde activatie 
van D2-receptoren remt de endotheelcel proliferatie, vascularisatie en tumorgroei. In vitro en in 
vivo onderzoek toont dat dopamine de acties van hypoxie-inducerende factor (HIF)-α en vasculaire 
endotheliale groeifactor (VEGF) remt door via de dopamine D2-receptor de fosforylatie van de VEGF-
2 receptor te blokkeren. Dit heeft een negatief effect op de tumor groei. Deze remmende invloed op 
tumorgroei lijkt afwezig bij feochromocytomen en paragangliomen. Bij deze tumoren is de productie 
van dopamine juist een onafhankelijke risicofactor voor maligne ontaarding. Tumoren kunnen de 
acties van dopamine omzeilen door het verlagen van de sympathische zenuwactiviteit of door het 
verlagen van de concentratie van dopamine D2-receptor. Het is opmerkelijk dat er weinig bekend 
is over de rol van dopamine als biomarker in de ontwikkeling en progressie van catecholamine 
producerende feochromocytomen en paragangliomen. Hoewel er een verhoogde synthese en 
secretie is van dopamine bij patiënten met SDHB- en SDHD-gerelateerde feochromocytomen en 
paragangliomen, zijn de tumoren bij deze patiënten groepen vaak multipel en agressiever. Mogelijk 
is er een verband tussen SDHx-gerelateerde gen mutaties in feochromocytomen en paragangliomen 
enerzijds en een verminderde concentratie van D2-receptoren anderzijds. Dit zou veroorzaakt kunnen 
worden door hypermethylatie van het D2-receptorgen, waardoor het gen verminderd afgelezen kan 
worden. Dit zou mogelijk kunnen verklaren waarom er meer maligne tumoren gevonden worden bij 
patiënten met een SDHB gen mutatie, ondanks de dopamine overproductie. In dit overzichtsartikel 
pleiten we er dan ook voor om dopamine als epifenomeen, een niet-veroorzakende biomarker, van 
maligniteit te beschouwen bij patiënten met een feochromocytoom of een paraganglioom.
In hoofdstuk 8 beschrijven we de immunohistochemische kleuring van 19 hoofd-hals 
paraganglioom weefsels op de aanwezigheid van catecholamine-synthetiserende enzymen, 
zoals tyrosine hydroxylase (TH), aromatische L-amino zuur decarboxylase (AADC) en dopamine 
β-hydroxylase (DBH). Alle tumoren kleurden positief voor AADC, zes (32%) voor TH en twee (11%) 
voor DBH. Catecholamine overproductie werd maar in één patiënt aangetoond. De histologische 
kleuringen in het weefsel van deze patiënt waren alleen positief voor AADC. Deze studie laat zien 
dat catecholamine synthetiserende enzymen, vooral AADC, aangetoond kunnen worden in het 
grootste deel van de onderzochte hoofd-hals paraganglioom weefsels. Het immunohistochemische 
kleuringspatroon van AADC, DBH en TH in hoofd-hals paraganglioom weefsel is vergelijkbaar 
met het biochemische catecholamine secretie profiel, namelijk hoofdzakelijk uitscheiding van 




In hoofdstuk 9 laten we zien dat in zeven van de 36 (19.4%) patiënten die gediagnosticeerd 
zijn met een hoofd-hals paraganglioom dopamine overproductie voorkomt, gemeten als een 
verhoogde 3-MT en/of dopamine concentratie in urine of plasma. Dopamine overproductie was 
niet gerelateerd aan klinische klachten of symptomen. De opname van 123I-MIBG was geassocieerd 
met dopamine overproductie.
Omdat bekend is dat vrij dopamine opgenomen wordt in circulerende bloedplaatjes hebben we 
in hoofdstuk 10 de concentraties van dopamine in bloedplaatjes en het plasma 3-MT bepaald bij 
36 patiënten met een hoofd-hals paraganglioom. De concentratie van dopamine in bloedplaatjes 
van deze patiënten werd vergeleken met gezonde controles (68 gezonde controles voor dopamine 
in plaatjes en 120 gezonde controles voor plasma 3-MT). In de literatuur wordt beschreven dat 
plasma 3-MT verhoogd is bij ongeveer 28% van de patiënten met een hoofd-hals paraganglioom. 
Bij patiënten met een hoofd-hals paraganglioom was de dopamine concentratie in bloedplaatjes 
hoger bij gezonde controles. De plasma 3-MT concentratie was niet verschillend tussen beide 
groepen. Zes (16.7%) patiënten met een hoofd-hals paraganglioom hadden een verhoogde 
dopamine concentratie in bloedplaatjes terwijl maar bij drie patiënten (8.3%) een verhoogde plasma 
3-MT concentratie werd vastgesteld. Met dit onderzoek hebben we aangetoond dat de dopamine 
concentratie in bloedplaatjes verhoogd is bij patiënten met een hoofd-hals paraganglioom 
vergeleken met gezonde controles. Mogelijk is de dopamine concentratie in bloedplaatjes een 
nieuwe biomarker voor dopamine producerende paragangliomen.
DISCUSSIE EN TOEKOMST PERSPECTIEVEN
Optimaliseren van de huidige diagnostiek naar hoofd-hals paragangliomen
In dit proefschrift hebben we een aantal nieuwe ontwikkelingen op het gebied van de biochemie 
beschreven in de diagnostiek naar feochromocytomen en (hoofd-hals) paragangliomen met 
name gericht op dopamine. Verbetering van biochemische diagnostiek zou kunnen leiden tot het 
eerder vaststellen van een hoofd-hals paraganglioom. Op dit moment bestaat er geen optimale 
biochemische test om deze tumoren op te sporen, aangezien een verhoogde catecholamine en/
of metanefrine concentratie maar in een klein deel van patiënten met hoofd-hals paragangliomen 
wordt gevonden. Een mogelijkheid om de biochemische diagnostiek te verbeteren is het 
verhogen van de sensitiviteit en specificiteit van de gebruikte analysemethode, de LC-MS/MS. 
De verbeteringen tot nu toe hebben geleid tot een meer specifieke kwantificatie van plasma 
metanefrines en hebben een de gelijktijdige bepaling van metabool gerelateerde componenten 
zoals 3-MT tot op de pmol nauwkeurig mogelijk gemaakt. Verder is door toename van de kennis over 
het effect van pre-analytische factoren zoals medicatie, houding tijdens de bloedafname en dieet, 
een betere interpretatie van de resultaten mogelijk. De verbetering van de analytische sensitiviteit 
is echter beperkt omdat alleen signalen die boven de biologische achtergrond variatie uitkomen 
betrouwbaar gekwantificeerd kunnen worden. Een meer uitdagend alternatief is om te achterhalen 
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wat de oorzaak is van het afwijkende celmetabolisme van kwaadaardige neuroendocriene 
cellen. Dit kan het ontwikkelen van nieuwe nauwkeurigere panels met biochemische markers 
ondersteunen. In een van onze studies hebben wij aangetoond dat alle onderzochte weefsels 
van hoofd-hals paragangliomen bij immunohistochemisch onderzoek aankleuren voor AADC, 
het enzym dat L-DOPA omzet in dopamine. Daarnaast was er bij een derde van de weefsels ook 
nog een positieve kleuring voor TH en AADC, de enzymen die tyrosine omzetten in dopamine. 
In tegenstelling tot deze immunohistochemische bevindingen werd maar bij één patiënt een 
verhoogde plasma metanefrine concentratie gevonden. Het verschil tussen de beperkte waarde 
van biochemie en de duidelijke immunohistochemische aankleuring zou een illustratie kunnen zijn 
van de relatieve ongevoeligheid van de plasma 3-MT analyse. Er zou een licht verhoogde dopamine 
productie aanwezig kunnen zijn in alle patiënten met een hoofd-hals paraganglioom, maar deze 
zou te klein kunnen zijn om met de huidige analyse methoden te kunnen aantonen. In dat geval zou 
het moeilijk zijn om dopamine productie door de tumor aan te tonen tegen een achtergrond van 
normale dopamine productie. Een andere mogelijkheid is toch dat maar een beperkt percentage 
van de hoofd-hals paragangliomen endocrien actief is. 
De resultaten van ons immunohistochemische onderzoek ondersteunen de hypothese 
dat hoofd-hals paragangliomen in staat zijn om dopamine te synthetiseren. Dit leidde tot de 
onderzoeksvraag of de dopamine concentratie in bloedplaatjes een marker zou kunnen zijn voor 
patiënten met een hoofd-hals paraganglioom. Dit werd bevestigd in ons onderzoek waarbij bij 
patiënten met een hoofd-hals paraganglioom de concentratie van dopamine in bloedplaatjes twee 
keer zo hoog was als de plasma 3-MT concentratie (16.7% versus 8.3%). Deze resultaten illustreren 
dat het meten van de dopamine concentratie in plaatjes een toegevoegde waarde zou kunnen 
hebben bij de biochemische diagnose van het hoofd-hals paraganglioom. Door de hoge specificiteit 
van deze beide bepalingen zou de gecombineerde meting van de dopamine concentratie in 
bloedplaatjes en de vrije 3-MT concentratie in plasma mogelijk van toegevoegde waarde kunnen 
zijn bij patiënten bij wie een hoofd-hals paraganglioom moet worden uitgesloten. 
Het feit dat we AADC aantoonden in hoofd-hals paraganglioom weefsels zou kunnen betekenen 
dat er ook sprake is van serotonine synthese in de hoofd-hals paragangliomen. Tryptofaan wordt 
omgezet in 5-hydroxytryptofaan (5-HTP) door het tryptofaan hydroxylase, de snelheidsbepalende 
stap in de serotonine synthese. Daarna zet het enzym AADC 5-HTP om in 5-hydroxytryptamine (5-
HT, ook wel serotonine genoemd). Als zowel tryptofaan hydroxylase als AADC aanwezig is in hoofd-
hals paragangliomen, dan zou de serotonine concentratie in bloedplaatjes verhoogd kunnen zijn 
bij patiënten met een hoofd-hals paraganglioom. Eerder werd geen verhoging aangetoond van de 
metaboliet van serotonine, 5-hydroxyindolaat zuur (5-HIAA), in urine bij patiënten met een hoofd-
hals paraganglioom11. Echter de concentratie van serotonine in bloedplaatjes is een veel gevoeligere 
methode om een eventuele serotonine overproductie te meten12. Zowel vanuit pathofysiologisch 
als klinisch oogpunt zou het interessant zijn om tryptofaan hydroxylase kleuringen te doen in hoofd-
hals paraganglioom weefsel en serotonine gerelateerde symptomen en de serotonine concentratie 
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in bloedplaatjes te evalueren in patiënten met een hoofd-hals paraganglioom13. Het zal echter lastig 
kunnen zijn om serotonine productie door de tumor te onderscheiden van de normale biologische 
serotonine productie. 
Een ander veelbelovend gebied voor nieuwe biomarkers is de genetica. Door middel van PCR-
amplificatie kan het meten van mRNA transcriptie levels in plasma leiden tot het vaststellen van een 
genetisch profiel. Dit wordt al gebruikt voor de typering van verschillende soorten tumoren zoals 
borstkanker, darmkanker en gastroentropancreatische neuroendocrine tumoren (GEP-NETs)14,15. Bij 
GEP-NETs is het genetische profiel gebaseerd op een pakket van 51 genen die GEP-NETs kunnen 
identificeren met een hoge specificiteit en sensitiviteit16. Daarnaast zouden ook weefsel microassays 
gebruikt kunnen worden voor genetische tumor profilering en mogelijk ook als voorspeller 
kunnen worden toegepast voor het maligne karakter van paragangliomen17. Om specifieke mRNA 
transcriptie factoren te vinden die gebruikt kunnen worden voor genetische profilering van 
feochromocytomen en paragangliomen zal verder onderzoek gedaan moeten worden. Identificatie 
van relevante tumor specifieke genen is nodig om mRNA transcriptie factoren te vinden die 
gebruikt zouden kunnen worden voor op genetica gebaseerde diagnostiek bij patiënten met een 
feochromocytoom of paraganglioom. 
Het verbeteren van screeningsmethoden voor hoofd-hals paragangliomen bij SDHx 
mutatiedragers  
Het vaststellen van nieuwe genetische mutaties bij patiënten met een hoofd-hals paraganglioom 
heeft geleid tot een toename van screening van meestal asymptomatische SDHx mutatiedragers op 
hoofd-hals paragangliomen, feochromocytomen en sympathisch paraganglioom. Doordat in het 
verleden ook de indexpatiënten, dit zijn de patiënten bij wie de mutatie is als eerste in de familie 
werd vastgesteld, werden meegenomen in de analyse is de penetrantie van de ziekte overschat8,9 
en wordt een (te) uitgebreid screeningsprogramma aanbevolen. Evaluatie van onze patiëntengroep 
toont aan dat er tijdens de screening van 83 SDHB mutatiedragers slechts vijf nieuwe uitingen van 
ziekte werden gezien na een gemiddelde screeningsperiode van 1.9 jaar. Vijfendertig procent van 
de mutatie dragers had een uiting van de ziekte ontwikkeld op 60-jarige leeftijd, terwijl in eerder 
onderzoek werd beschreven dat 8-55% van de SDHB mutatie dragers op 40-jarige leeftijd een uiting 
van de ziekte had6-8,18. Alle nieuw gevonden manifestaties in onze patiëntengroep waren hoofd-hals 
paragangliomen, dit zijn over het algemeen langzaam groeiende, niet hormonaal actieve, tumoren. 
Daarnaast laat ons onderzoek zien dat de screening op hoofd-hals paragangliomen in SDHB 
mutatiedragers op een latere leeftijd zou kunnen starten (24 jaar in plaats van 18 jaar). Dit zou leiden 
tot een significante verlaging van de kosten en vermindering van het aantal ziekenhuisbezoeken 
voor de patiënt19. 
De meeste hoofd-hals paragangliomen groeien langzaam (1-2 mm/jaar) tot niet, afhankelijk 
van de onderliggende mutatie20,21. Omdat de meerderheid van de hoofd-hals paragangliomen niet 
endocrien actief zijn, worden ze meestal gevonden bij palpatie van een massa in de hals, specifieke 
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lokale symptomen (zoals gehoorverlies, oorsuizen, massa in de nek, moeite met slikken en paralyse 
van aangezichtszenuwen) of gevonden op beeldvorming die gemaakt wordt tijdens de screening. 
Volgens de internationale richtlijnen wordt bij patiënten met een hoofd-hals paraganglioom een 
‘wacht-en-scan’ beleid aanbevolen met MRI, om het groeipatroon te observeren22. De vraag blijft of 
het in het belang van de patiënt is om intensief te screenen en hoofd-hals paragangliomen vroeg 
vast te stellen. De Nederlandse gezondheidsraad stelt in een in 2008 gepubliceerd rapport over 
verantwoorde screening in de eerste plaats dat de ziekte een significant gezondheidsprobleem 
is en dat een vroegtijdige opsporing hiervan een belangrijk voordeel oplevert. Ten tweede wordt 
aangegeven dat de screening gebaseerd moet op de vrije keus van de patiënt en dat diens 
autonomie gerespecteerd moet worden. Tot slot moet ook het gebruik van de gezondheidszorg 
kosteneffectief zijn en in verhouding staan met de behaalde gezondheidswinst23. Voor wat de 
screening van hoofd-hals paragangliomen betreft wordt aan deze criteria voldaan. Immers, het 
uitstellen van de screening tot een patiënten zich presenteert met klachten van een hoofd-hals 
paraganglioom zal leiden tot het vaststellen van tumoren in een laat stadium waarin er geen of 
beperkte behandelingsopties zijn. Een ‘wacht-en-scan’ beleid kan dan helpen om het optimale 
behandeltijdstip vast te stellen voor chirurgische verwijdering van de tumor met in acht neming 
van een minimale kans op complicaties of onherstelbare schade aan de omliggende weefsels. 
Een gevoeliger biomarker zou het verschil te kunnen maken tussen agressieve en niet-agressieve 
tumoren, echter deze is nog niet beschikbaar. Een verhoogd plasma 3-MT is geïdentificeerd als een 
onafhankelijke risicofactor voor kwaadaardige ontaarding, maar de diagnostische gevoeligheid is 
beperkt gebleken24. Verdere studies zijn nodig om screeningsmethoden voor SDHx mutatiedragers 
te optimaliseren, zowel wat betreft de leeftijd van de start van screening, het identificeren van 
markers om onderscheid te maken tussen agressieve en niet-agressieve tumoren, de optimale 
(anatomische of functionele) beeldvorming en het interval van beeldvorming. 
Genotype-specifieke beeldvorming voor verschillende fenotypes van patiënten met 
feochromocytomen en paragangliomen
Het aantal patiënten feochromocytoom of paraganglioom als gevolg van een onderliggende stamcel 
mutatie is momenteel 40%. Dit hoge percentage heeft geleid tot een toename van kennis over de 
achtergrond van tumoren en het gebruik van specifieke tracers op het gebied van beeldvorming. 
Een voorbeeld is het gebruik van de 18F-FDG PET scan in SDHx-gerelateerde feochromocytomen 
en paragangliomen. Meerdere studies hebben aangetoond dat 18F-FDG PET/CT een zeer gevoelige 
diagnostische methode is bij patiënten met SDHx en VHL mutaties in vergelijking met patiënten met 
een multiple endocriene neoplasie (MEN) type 2 gerelateerde feochromocytomen, onafhankelijk 
van tumor locatie25-28. Verminderde SDH en VHL eiwit activiteit leidt tot een verminderde 
degeneratie van de hypoxie en vaatnieuwvormingsmechanismen via HIF-1α en HIF-2α. Hierdoor 
vindt er een verhoogde transcriptie van HIF-1α en HIF-2α plaats, die beiden betrokken zijn bij het 
glucose metabolisme. Door stimulatie van glucosetransporters (GLUTs) en hexokinases (HK) wordt 
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18F-FDG PET, net als glucose, opgenomen via GLUT en daarna gefosforyleerd door HKs in 18F-FDG-
6-P, dat zich ophoopt in de cel. Een significant hogere HK-3 gen expressie wordt gevonden in SDHx-
gerelateerde feochromocytomen en paragangliomen in vergelijking met NF1- en RET-gerelateerde 
feochromocytomen en paragangliomen. Dit bevestigt dat 18F-FDG op dit moment de beste tracer 
is voor het opsporen van feochromocytomen en paragangliomen bij patiënten met een SDHx 
mutatie29,30. 
Recent is aangetoond dat [68GA]-DOTATATE PET/CT een heel gevoelig diagnosticum is bij het 
opsporen van SDHB-gerelateerde gemetastaseerde feochromocytomen en paragangliomen. 
Deze beeldvormende techniek kan leiden tot het eerder opsporen van metastasen bij SDHB 
mutatiedragers en zou ook gebruikt kunnen worden voor eiwit receptor radioactief nucleotide 
therapie bij maligne feochromocytomen en paragangliomen31. 
Nieuwe behandelopties voor maligne paragangliomen
Er zijn geen effectieve behandelingen voor gemetastaseerde feochromocytomen en 
paragangliomen. Uitgebreide chirurgische debulking is de eerste behandeloptie met als doel de 
klachten te verminderen en de overlevingskans van de patiënt te verbeteren32. Daarnaast kan 
een behandeling met chemotherapie (cyclofosfaminde, vincristine en doxorubicine (CVD)) of 
behandeling met een radioactief gelabeled nucleotide zoals 131I-MIBG of een radioactief gelabelde 
somatostatine analoog overwogen worden. De responspercentages van deze therapieën variëren. 
Een behandeling met 131I-MIBG kan een (gedeeltelijke) tumorrespons geven die varieert tussen de 
24-45%33,34. Een toename van de opname van 131I-MIBG in de tumorcellen zou de tumorrespons 
kunnen vergroten. Behandeling met de histon deacetylase remmer romidepsine is in dit opzicht 
veelbelovend te noemen omdat het de opname van 123I-MIBG in feochromocytoom cellen van 
muizen verhoogt35. Het mogelijke voordeel van voorbehandeling met romidepsine in het verhogen 
van de opname van 123I-MIBG bij patiënten met een gemetastaseerd paraganglioom moet nog 
verder onderzocht worden. 131I-MIBG en 111In-octreotide behandeling is echter alleen mogelijk bij 
patiënten met aanwezige opname van 123I-MIBG of radioactief gelabelde somatostatine analogen 
in de tumor. Daarnaast is behandeling met 131I-MIBG en 111In-octreotide gelimiteerd omdat na een 
hoge stralingsdosis op langere termijn complicaties kunnen ontstaan zoals hypothyreoïdie en 
secundaire leukemie of myelodysplasie36. Daarom is er behoefte aan nieuwe effectieve therapieën, 
een voorbeeld is de behandeling met radioactief gelabelde somatostatine analogen. In een pilot 
studie met een gecombineerde behandeling met [90Y]DOTA-TATE en [177LU]DOTA-TATE werd deze 
behandeling beschreven als een goed getolereerde en haalbare therapeutische alternatief voor 
patiënten met gemetastaseerde neuroendocrine tumoren, waaronder paragangliomen, met 
progressieve ziekte die niet reageerde op conventionele therapie37. 
Andere voorbeelden van nieuwe therapieën zijn VEGF remmers, mammalian target of rapamycin 
(mTOR) remmers, heat stroke eiwit (Hsp90) remmers en middelen die de prolyl hydroxylase (PHD) 
enzym activiteit herstellen38,39. De meeste van deze nieuwe behandelingsmethoden worden op dit 
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moment geëvalueerd in fase 1 en fase 2 klinische onderzoeken en de toegevoegde waarde voor 
patiënten met feochromocytomen en paragangliomen moet nog worden afgewacht. In theorie 
zouden HIF-2α-remmers en methylatieremmende middelen ook een rol kunnen spelen in de 
behandeling van maligne feochromocytomen en paragangliomen, maar zulke middelen zijn op dit 
moment nog niet ontwikkeld.
Optimaliseren van patiëntcomfort
Over het effect van alle diagnostiek die tijdens de screening wordt gebruikt op het welzijn van 
mutatiedragers en patiënten met een feochromocytoom of paraganglioom is weinig bekend. Er 
is een onderzoek beschikbaar dat laat zien dat de kwaliteit van leven van asymptomatische SDHx 
mutatiedragers en asymptomatische patiënten met een hoofd-hals paraganglioom niet lager is 
vergeleken met de algemene populatie40. Het is echter zeker belangrijk om te streven het aantal 
diagnostische procedures zoveel mogelijk te beperken en zo comfortabel mogelijk te laten 
verlopen. Het vergroten van de toegankelijkheid van de diagnostische procedures zal het gebruik 
ervan stimuleren en dit kan bijdragen aan het comfort van de patiënt. We hebben laten zien dat 
zowel het bepalen van metanefrine, normetanefrine en 3-MT als het testen van SDHx mutaties 
gedaan kan worden in speeksel in plaats van in plasma, met behoud van een goede kwaliteit. Deze 
benadering heeft voordelen voor de klinische praktijk. De afname van speekselmonsters is niet-
invasief en er zijn geen aan venapunctie gerelateerde effecten zoals pijn of hematoomvorming. 
Daarnaast kunnen metanefrine metingen snel herhaald worden en kunnen monsters ook thuis 
afgenomen worden, wat waarschijnlijk kosteneffectiever is dan de bloedafname in het ziekenhuis41. 
Afname van speekselmonsters zou met name geschikt zijn voor kinderen en voor periodieke 
screening van patiënten met een SDHx mutatie. In de nabije toekomst zullen studies met grotere 
aantallen patiënten met een feochromocytoom of paraganglioom en gezonde controles uitgevoerd 
moeten worden om de plaats van de metanefrine in speeksel bepaling in de diagnostiek van 
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Het succesvol afronden van een proefschrift is bij uitstek een gezamenlijke prestatie, waaraan zowel 
patiënten, begeleiders, collega’s, vrienden en familie elk hun eigen belangrijke rol spelen. Ik ben 
dan ook zeer dankbaar voor alle hulp die ik de afgelopen jaren ontvangen heb. Daarnaast ben ik 
ook de Junior Scientific Master Class en GUIDE zeer dankbaar voor de financiële mogelijkheid om 
dit onderzoek uit te voeren. 
Allereerst wil ik de patiënten bedanken die deel hebben genomen aan de verschillende studies. 
Zonder patiënten die bereid zijn deel te nemen aan onderzoek, waren veel van mijn studies niet 
mogelijk geweest. 
Veel dank gaat uit naar mijn 2 promotoren prof. dr. T.P. Links en prof. dr. I.P. Kema. 
Beste Thera, we hebben elkaar voor het eerst ontmoet bij een bespreking voor de aanvraag van 
een MD/PhD traject. Ik had toen nog niet kunnen denken hoe groot jouw rol zou zijn in mijn 
promotie. Je wist altijd praktische oplossingen aan te dragen voor de problemen die we onderweg 
tegen kwamen. Daarnaast was je ook altijd bereid om te helpen, door bijvoorbeeld samen een 
huisartsenpraktijk te bezoeken. Ik heb bewondering voor het feit dat je naast alle drukte in de 
kliniek en alles wat er van je gevraagd wordt, ook altijd oog houdt voor de mensen met wie je werkt 
en hun persoonlijke zaken.
Beste Ido, jouw biochemische kennis is ongeëvenaard en ik ben dan ook zeer dankbaar dat jij mijn 
tweede promotor wilt zijn. Jouw rustige en analytische manier van denken heeft mij meerdere 
malen teruggekregen op de goede weg als ik er even niet meer uitkwam. Daarnaast heeft de 
bepaling van metanefrines in speeksel een mooie samenwerking met de NIH opgeleverd, wat een 
super mooie ervaring was!
Veel dank gaat ook uit naar mijn copromotoren dr. A.N.A. van der Horst-Schrivers en dr. M.N. Kerstens.
Beste Anouk, bij jou is het allemaal begonnen. Als onwetende student was ik nog bijna de kant van 
de oncologie op gegaan. Na afloop van een bespreking, met de deurklink in de hand, vroeg je mij 
of een promotietraject niet iets voor mij zou kunnen zijn. Toen had ik niet kunnen denken waar ik 
aan begon, maar ik heb er absoluut geen spijt van gekregen. Ook zal ik de besprekingen bij jou en 
Iwan thuis nooit vergeten, waar we op een avond besloten om samen een bezoek aan prof. Pacak 
te brengen. Ik wil je heel erg bedanken voor de ontzettend lieve en motiverende gesprekken als ik 
dacht dat we totaal vastgelopen waren (‘het komt goed’ is tot nu toe altijd uitgekomen). Ik hoop dat 
het einde van dit promotietraject niet het einde zal zijn van onze samenwerking. 
Beste Michiel, met jou heb ik de PRESCRIPT studie opgezet. Tijdens onze eerste ontmoeting vertelde 
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je over je reis door India, waar ik op het punt stond om naar toe te gaan. Samen hebben we heel 
Nederland doorgereisd om PRESCRIPT in zo veel mogelijk centra van de grond te krijgen. Je kritische 
blik op mijn manuscripten heeft altijd tot significante verbeteringen geleid. En tussen alle drukte in 
de kliniek had je altijd tijd om iets voor het onderzoek te bespreken en voelde ik me nooit te veel. 
Leuk om te zien dat Edward doorgaat met PRESCRIPT.
Ook wil ik dr. R.P.F. Dullaart bedanken voor zijn hulp bij mijn onderzoek.
Beste Robin, bedankt voor je hulp bij het uitdenken van mijn onderzoeken en met name met 
de statistiek. Je snelheid in nakijken van manuscripten is ongeëvenaard. Je zorgt vaak voor een 
humoristische noot die ik erg kan waarderen.
And of course I would like to thank prof. dr. K. Pacak of the National Institutes of Health in Bethesda, 
Maryland.
Dear prof. Pacak, thank you for providing me with the opportunity to conduct my research in your 
research group. During my time at the NIH, you and your research group were as a family for me. 
I really had a very good time with lots of good memories. It is a real honor to me that you will be 
present at my thesis defense. I hope we can continue our collaboration in the future!
In addition, I would like to thank all my friends and colleagues that I met at the NIH. Special thanks 
to Joan, Petra, Tamara (the other T), Ingo, Roland, Matt, Evi, Maria, Anna, April, Ruby, Henrique, 
Barbora, Ivana, Thanh, Steffi and Karen. Joan, I hope we can meet in Marseille when you come to 
Europe! Petra, Tamara and Maria, I really liked our Sunday brunches together! Ingo, thank you for 
spending so much time with me reviewing scans. I promise I will finish the article. Matt, I would like 
to thank you and Clara for taking me and Roland to the Air and Space museum the first weekend I 
was alone in Washington, and for treating me on my birthday! Evi, after spending some late nights 
in the lab, our article is published. I hope I can visit you once in London. Thanh, thank you for helping 
me processing all the plasma and samples. Karen, thank you for helping me recruit patients for 
my research. Furthermore, I would like to thank prof. Stratakis and his team for teaching me DNA 
extraction techniques and sequencing. 
Aan alle co-auteurs veel dank voor jullie bijdrage. In het bijzonder wil ik prof. dr. B.F.A.M. van der 
Laan bedanken voor het aandragen van patiënten via de polikliniek van de KNO. Ook wil ik prof. dr. 
R.R. de Krijger en dr. Esther Korpershoek bedanken voor het kleuren en beoordelen van de hoofd-
hals paraganglioom weefsels. Prof. dr. G.H. de Bock wil ik bedanken voor de statistische hulp bij de 
dopamine in bloedplaatjes studie. Drs. Marloes A.M. Peters wil ik graag bedanken voor het delen 
van de database met gezonde controles voor de dopamine in bloedplaatjes studie.
Veel dank gaat uit naar het personeel van het laboratorium bijzondere chemie die altijd klaar 
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stonden om mijn monsters aan te nemen en te verwerken, vooral Margreet, Jasper, Hillie en Herman. 
Beste Herman, je bent een bijzonder persoon. Bedankt voor alle gesprekken over suikerziekte, 
Surinaams eten en pelgrimage. Ook Martijn en Helma bedankt voor het helpen met het opzetten 
van onderzoek en de analyse van alle monsters.
Alle collega’s van de afdeling Endocrinologie, kamergenoten (in het bijzonder Jorien, Sandra, Sarah, 
Dieneke en Robert) en ex-kamergenoten wil ik graag bedanken voor de gezelligheid, het samen 
lunchen/thee drinken en het kunnen delen van tegenslagen en triomfen. Edward, Karin en Janneke, 
leuk om te zien hoe een promotietraject leidt tot vele nieuwe onderzoekspaden en dat jullie verder 
gaan met onderzoek naar feochromocytomen en paragangliomen. 
Lieve Carlijn en Mariëlle, wij zijn samen ‘gegroeid’ in ons onderzoek, en daarom konden we 
voorspoed en tegenslagen samen delen. De dingen die we delen zijn herkenbaar. Ik hoop dat we in 
de toekomst contact blijven houden. Ook wil ik Lammie en Gillian op deze plaats bedanken voor de 
gezelligheid en praatjes. Gillian, bijzonder was de rondleiding in het Twente van jouw jeugd. Ik hoop 
jullie hier nog eens te ontvangen.
Mijn nieuwe collega’s in het ZGT in Almelo wil ik bedanken voor de hartelijke ontvangst en het 
wegwijs maken in de kliniek. De Raad van Bestuur van het ZGT wil ik bedanken voor de financiële 
bijdrage aan het drukken van dit proefschrift.
Lieve Ineke, Anita, Karin, Sylvia nu we niet meer samen in hetzelfde huis en ook niet meer in dezelfde 
stad wonen, wordt het afspreken iets moeilijker. Toch vinden we altijd wel een weekendje waarin we 
gezellig kunnen bijkletsen. Ook de gezamenlijke vakanties zijn altijd een hoogtepunt! Lieve Ineke, 
ik vind het super leuk dat jij mijn paranimf wilt zijn. Lieve Hillie, je bent al vele jaren een dierbare 
vriendin. Gelukkig spreken we nog regelmatig een weekendje af om te lunchen en te shoppen. 
Lieve Nienke, Jan Pieter, Sanne en Chris Peter, bedankt voor alle gezelligheid! 
Lieve familie, lieve Stephan, Alexander, papa, mama, lieve stief oom Henk en Wilma, heel erg bedankt 
dat jullie mij hebben gesteund deze jaren en af en toe een van mijn stukken wilde doorlezen, ook 
al snapte jullie er zelf soms helemaal niets van. Ook de familie van Freek heel erg bedankt voor alle 
steun, de liefde, de warmte en de gesprekken over het leven.
En dan tot slot, lieve Freek, wat fijn dat je naast me wil staan als paranimf. We zijn al negen jaar 
samen, en hebben samen de hele wereld over gereisd. Het leven met jou is één groot avontuur 
en vaak zitten we samen in hetzelfde schuitje. Lief en leed kan ik met je delen zowel tijdens mijn 
onderzoek als tijdens mijn eerste stappen in de kliniek. Je geeft me de ruimte die ik nodig heb, maar 









Figure 1. Schematic representation of the adrenal gland. (see 
page 10)
Example of chromatogram of forward and reverse DNA sequence from saliva (A) and blood (B) results of a patient 
with a mutation in exon 4 of the SDHB gene. (see  page 54)
Chapter 4, figure 1.
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Figure 1. Biosynthesis and metabolism of dopamine.
Dopamine is deaminated by monoamine oxidase (MAO) to dihydrophenylacetaldehyde (DOPAL). DOPAL 
is metabolized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (AD), and to 
3,4-dihydroxyphenylglycol (DOPET) by aldehyde reductase (AR). DOPET is metabolized by catechol-O-methyl 
transferase (COMT) to 4-hydroxy-3-methoxyphenylethanol (MOPET). DOPAC and MOPET are metabolized to 
homovanillic acid (HVA), the end product of dopamine metabolism.
Abbreviations: PAH, phenylalanine hydroxylase; TYR, tyrosinase; TH, tyrosine hydroxylase; L-DOPA, L-3,4-
dihydroxyphenylalanine; AADC, aromatic L-amino acid decarboxylase; DBH, dopamine β-hydroxylase; PNMT, 
phenylethanolamine-N-methyltransferase; SULT1A3, sulfotransferase type 1A3; ARS, arylsulfatases; MAO, 
monoamine oxidase; COMT, catechol-O-methyl transferase; DOPAL, dihydrophenylacetaldehyde; 3-MT, 
3-methoxytyramine; AR, aldehyde reductase; AD, aldehyde dehydrogenase; DOPET, 3,4-dihydroxyphenylglycol; 
DOPAC, 3,4-dihydroxyphenylacetic acid; MOPET, 4-hydroxy-3-methoxyphenylethanol; ADH, alcohol 




Figure 2 Uptake and storage of dopamine from the extracellular milieu into the vesicle of neuronal and non-
neuronal cells 
The dopamine transporter (DAT) transports dopamine (DA) into the neuronal or non-neuronal cell. In the 
cytoplasm, dopamine is taken up into storage vesicles via the vesicular monoamine transporter (VMAT). 
It is presumed that, when dopamine binds to DAT, together with Na+ and Cl-, they promote a change in the 
conformation of DAT from a primarily outward-facing to a predominantly inward-facing transporter. In 




Figure 4 Schematic representation of hypoxia inducible factor (HIF)-α under normoxic and hypoxic conditions
When tissue oxygen concentration is normal, HIF-α is hydroxylated by the oxygen sensitive prolyl hydroxylase 
domain proteins (PHD) or factor inhibiting HIF-1 (FIH-1), promoting the interaction with von Hippel Lindau 
protein (pVHL). This targets HIF-α for ubiquitin-mediated proteolysis, resulting in proteolytic degredation. 
When tissue oxygen concentration is low, the activity of PHD and FIH is reduced and degradation of HIF-α is 
impaired. The ensuing elevation of HIF-α levels allow the formation of an active transcription complex with 
HIF-β. This HIF-α/β complex binds to the hypoxia responsive element (HRE) on the promoter region of certain 
genes of target cells, e.g. those encoding vascular endothelial growth factor (VEGF), vascular permeability factor 
(VPF) and tyrosine hydroxylase (TH). In patients with a VHL gene mutation, the interaction between pVHL and 
hydroxylated HIF-α is disrupted, which reduces the ubiquitin-mediated proteolysis of HIF-α. This causes HIF-α 




Figure 5 Schematic representation of dopamine (DA) release and proposed actions of DA and vascular 
endothelial growth factor (VEGF) in various tissues
DA and VEGF are released from activated platelets and neuroendocrine cells (NECs)/ hypoxic endothelial 
cells (ECs). Dopamine can  also be released by sympathetic nerves after excitation. Dopamine inhibits the 
phosphorylation (i.e. activation) of the VEGF-2 receptor through activation of the D2- receptor. As a result, 
proliferation and migration of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) from the 
bone marrow is inhibited (60-63).
Abbreviations: VMAT, vesicular monoamine transporter; DAT, dopamine transporter; L-DOPA, L-3,4-




Figure 6 Proposed mechanism of the interplay between the mitochondrial complex II and fumarate hydratase 
in the stabilization of the hypoxia-inducible factor (HIF)-α signalling pathway.
The mitochondrial complex II, located on the inner mitochondrial membrane, consists of succinate 
dehydrogenase (SDH)-proteins and catalyzes the conversion of succinate to fumarate. Fumarate hydratase (FH), 
another mitochondrial enzyme, converts succinate to malate. In case of a mutation in one of the SDH subunits 
(SDHA, SDHB, SDHC or SDHD gene mutations) or FH genes, the intracellular concentration of succinate and 
fumarate rise, resulting in inhibition of 2-oxyglutarate-dependent dioxygenases, including prolyl hydroxylase 
domain proteins (PHD), histone lysine demethylases (KDMs) and the ten-eleven translocation (TET) enzymes. 
This leads to  HIF stimulated increase of transcription of the gene encoding tyrosine hydroxylase (TH), and to 
hypermethylation of the dopamine D2-receptor gene




Figure 2. Immunohistochemical staining for catecholamine-synthesizing enzymes in HNPGL of case 1 (see table 
2). HE staining (A). Positive TH staining, 1-25% positive cells (B). Positive AADC staining, 26-50% positive cells (C). 




Figure 2. Uptake and exocytosis of dopamine in platelets. 
The transport of dopamine into the platelet is facilitated by the dopamine transporter (DAT). After transportation 
into the cytoplasm, dopamine is taken up by dense granules through the vesicular monoamine transporter 
(VMAT) 2 until it is released by exocytosis. (Image constructed using Servier Medical Art) (see page 145)
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